<SEC-DOCUMENT>0001193125-17-217594.txt : 20170629
<SEC-HEADER>0001193125-17-217594.hdr.sgml : 20170629
<ACCEPTANCE-DATETIME>20170629094330
ACCESSION NUMBER:		0001193125-17-217594
CONFORMED SUBMISSION TYPE:	424B5
PUBLIC DOCUMENT COUNT:		3
FILED AS OF DATE:		20170629
DATE AS OF CHANGE:		20170629

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			Minerva Neurosciences, Inc.
		CENTRAL INDEX KEY:			0001598646
		STANDARD INDUSTRIAL CLASSIFICATION:	PHARMACEUTICAL PREPARATIONS [2834]
		IRS NUMBER:				260784194
		STATE OF INCORPORATION:			DE
		FISCAL YEAR END:			1231

	FILING VALUES:
		FORM TYPE:		424B5
		SEC ACT:		1933 Act
		SEC FILE NUMBER:	333-205764
		FILM NUMBER:		17936954

	BUSINESS ADDRESS:	
		STREET 1:		1601 TRAPELO ROAD
		STREET 2:		SUITE 284
		CITY:			WALTHAM
		STATE:			MA
		ZIP:			02451
		BUSINESS PHONE:		617-600-7373

	MAIL ADDRESS:	
		STREET 1:		1601 TRAPELO ROAD
		STREET 2:		SUITE 284
		CITY:			WALTHAM
		STATE:			MA
		ZIP:			02451
</SEC-HEADER>
<DOCUMENT>
<TYPE>424B5
<SEQUENCE>1
<FILENAME>d382980d424b5.htm
<DESCRIPTION>424B5
<TEXT>
<HTML><HEAD>
<TITLE>424B5</TITLE>
</HEAD>
 <BODY BGCOLOR="WHITE">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="right"><B>Filed Pursuant to Rule 424(b)(5)<BR>Registration No. 333-205764 </B></P>
<p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>PROSPECTUS SUPPLEMENT </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>(to Prospectus dated July&nbsp;27, 2015) </B></P>
<P STYLE="margin-top:14pt; margin-bottom:0pt; font-size:18pt; font-family:Times New Roman" ALIGN="center"><B>5,000,000 Shares </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<P STYLE="font-size:0pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="margin-top:0pt;margin-bottom:0pt" ALIGN="center">


<IMG SRC="g382980g82i05.jpg" ALT="LOGO">
 </P> <P STYLE="margin-top:14pt; margin-bottom:0pt; font-size:14pt; font-family:Times New Roman" ALIGN="center"><B>Common Stock </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><center>
<P STYLE="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000;width:21%">&nbsp;</P></center> <P STYLE="margin-top:14pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">We are
offering&nbsp;5,000,000&nbsp;shares of our common stock. Our common stock is listed on The NASDAQ Global Market under the symbol &#147;NERV.&#148; The closing sale price of our common stock on June&nbsp;28, 2017 was $7.95 per share. </P>
<P STYLE="margin-top:14pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">We are an &#147;emerging growth company&#148; as defined by the Jumpstart Our Business Startups Act of 2012 and, as such, we have elected to comply with
certain reduced public company reporting requirements for this prospectus and future filings. Please see &#147;Summary&#151;Implications of Being an Emerging Growth Company.&#148; </P>
<P STYLE="font-size:14pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><center> <P STYLE="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000;width:21%">&nbsp;</P></center>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman"><B>Investing in our common stock involves a high degree of risk. Please read the &#147;<A HREF="#suptoc382980_3">Risk Factors</A>&#148; beginning on page S-9
of this prospectus supplement and found in the documents incorporated by reference into this prospectus supplement. </B></P> <P STYLE="margin-top:14pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Neither the Securities and
Exchange Commission nor any state securities commission has approved or disapproved of these securities, or determined if this prospectus supplement or the accompanying prospectus is truthful or complete. Any representation to the contrary is a
criminal offense. </B></P> <P STYLE="font-size:14pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><center> <P STYLE="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000;width:21%">&nbsp;</P></center>
<P STYLE="font-size:14pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="76%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>
<TD WIDTH="70%"></TD>
<TD VALIGN="bottom" WIDTH="6%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="6%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>PER</B><br><B>SHARE</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>TOTAL</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Public offering price</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">7.75</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">38,750,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Underwriting discounts and
commissions<SUP STYLE="font-size:85%; vertical-align:top">(1)</SUP></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">0.465</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">2,325,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Proceeds to us, before expenses</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">7.285</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">36,425,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
</TABLE> <P STYLE="line-height:8.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000;width:10%">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(1)</TD>
<TD ALIGN="left" VALIGN="top">The underwriters will be reimbursed for certain expenses incurred in this offering. See &#147;Underwriting&#148; for details. </TD></TR></TABLE>
<P STYLE="font-size:14pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><center> <P STYLE="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000;width:21%">&nbsp;</P></center>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Delivery of the shares of common stock is expected to be made on or about July&nbsp;5, 2017. We have granted the underwriters an option for a period of
30&nbsp;days to purchase up to&nbsp;750,000 additional&nbsp;shares of our common stock. If the underwriters exercise this option in full, the total underwriting discounts and commissions payable by us will be $2,673,750 and the total proceeds to us,
before expenses, will be $41,888,750. </P> <P STYLE="font-size:14pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><center> <P STYLE="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000;width:21%">&nbsp;</P></center>
<P STYLE="margin-top:14pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><I>Joint Book-Running Managers </I></B></P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:16pt" ALIGN="center">


<TR>
<TD WIDTH="51%"></TD>
<TD VALIGN="bottom" WIDTH="37%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:16pt">
<TD VALIGN="top"><B>Citigroup</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>Jefferies</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD></TR>
</TABLE> <P STYLE="margin-top:14pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><I>Lead Manager </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:14pt; font-family:Times New Roman" ALIGN="center"><B>JMP Securities </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Prospectus Supplement dated&nbsp;June&nbsp;29, 2017 </B></P>

<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="toc"></A>TABLE OF CONTENTS </B></P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>
<TD WIDTH="94%"></TD>
<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>Prospectus Supplement</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#suptoc382980_1">About this Prospectus Supplement</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">i</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#suptoc382980_2">Prospectus Supplement Summary</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="white-space:nowrap">S-1</FONT></TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#suptoc382980_3">Risk Factors</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="white-space:nowrap">S-9</FONT></TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#suptoc382980_4">Special Note Regarding Forward-Looking Statements</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="white-space:nowrap">S-11</FONT></TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#suptoc382980_7">Use of Proceeds</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="white-space:nowrap">S-12</FONT></TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#suptoc382980_5">Price Range of our Common Stock</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="white-space:nowrap">S-13</FONT></TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#suptoc382980_6">Dividend Policy</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="white-space:nowrap">S-14</FONT></TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#suptoc382980_8">Capitalization</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="white-space:nowrap">S-15</FONT></TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#suptoc382980_9">Dilution</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="white-space:nowrap">S-16</FONT></TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#suptoc382980_10">Material U.S. Federal Income Tax Consequences to <FONT
STYLE="white-space:nowrap">Non-U.S.</FONT> Holders</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="white-space:nowrap">S-17</FONT></TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#suptoc382980_11">Underwriting</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="white-space:nowrap">S-21</FONT></TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#suptoc382980_11a">Notice to Investors</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">S-25</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#suptoc382980_12">Legal Matters</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="white-space:nowrap">S-30</FONT></TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#suptoc382980_13">Experts</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="white-space:nowrap">S-30</FONT></TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#suptoc382980_14">Where You Can Find More Information</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="white-space:nowrap">S-31</FONT></TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#suptoc382980_15">Incorporation of Certain Information by Reference</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="white-space:nowrap">S-32</FONT></TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>Prospectus</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#rom382980_1">About this Prospectus</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">i</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#rom382980_2">Prospectus Summary</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#rom382980_3">Risk Factors</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">5</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#rom382980_4">Special Note Regarding Forward-Looking Statements</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">5</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#rom382980_5">Use of Proceeds</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">6</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#rom382980_6">Description of Capital Stock</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">7</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#rom382980_7">Description of Debt Securities</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">12</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#rom382980_8">Description of Warrants</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">19</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#rom382980_9">Legal Ownership of Securities</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">22</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#rom382980_10">Plan of Distribution</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">26</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#rom382980_11">Legal Matters</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">28</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#rom382980_12">Experts</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">28</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#rom382980_13">Where You Can Find More Information</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">28</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#rom382980_14">Incorporation of Certain Information by Reference</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">28</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
</TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>You should rely only on the information contained or incorporated by reference in this prospectus supplement, the
accompanying prospectus or any free writing prospectus that we have authorized for use in connection with this offering. Neither we nor the underwriters have authorized anyone to provide you with information different from that contained in this
prospectus supplement, the accompanying prospectus or any accompanying free writing prospectus. We are offering to sell, and seeking offers to buy, common stock only in jurisdictions where offers and sales are permitted. If anyone provides you with
different or inconsistent information, you should not rely on it. We and the underwriters take no responsibility for, and can provide no assurance as to the reliability of, any other information that others may give you. The information contained in
this prospectus supplement, the accompanying prospectus and any accompanying free writing prospectus is accurate only as of the date of this prospectus supplement, the accompanying prospectus and any such accompanying free writing prospectus,
regardless of the time of delivery of this prospectus supplement, the accompanying prospectus, any such accompanying free writing prospectus or of any sale of our common stock. Our business, financial condition, results of operations and prospects
may have changed since those dates. You should read this prospectus supplement, the accompanying prospectus, the documents incorporated by reference in this prospectus supplement and the accompanying prospectus, and any free writing prospectus that
we have authorized for use in connection with this offering, in their entirety before making an investment decision. You should also read and consider the information in the documents to which we have referred you in the sections of this prospectus
supplement entitled &#147;Where You Can Find More Information&#148; and &#147;Incorporation of Documents by Reference.&#148; </B></P>

<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="suptoc382980_1"></A>ABOUT THIS PROSPECTUS SUPPLEMENT </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">This prospectus supplement and the accompanying prospectus form part of a registration statement on Form <FONT STYLE="white-space:nowrap">S-3</FONT> that we
filed with the Securities and Exchange Commission, or SEC, utilizing a &#147;shelf&#148; registration process. This document contains two parts. The first part consists of this prospectus supplement, which provides you with specific information
about this offering. The second part, the accompanying prospectus, provides more general information, some of which may not apply to this offering. Generally, when we refer only to the &#147;prospectus,&#148; we are referring to both parts combined.
This prospectus supplement may add, update or change information contained in the accompanying prospectus. To the extent that any statement we make in this prospectus supplement is inconsistent with statements made in the accompanying prospectus or
any documents incorporated by reference herein or therein, the statements made in this prospectus supplement will be deemed to modify or supersede those made in the accompanying prospectus and such documents incorporated by reference herein and
therein. You should read this prospectus supplement and the accompanying prospectus, including the information incorporated by reference herein and therein, and any related free writing prospectus that we have authorized for use in connection with
this offering. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">You should rely only on the information that we have included or incorporated by reference in this prospectus supplement, the accompanying
prospectus and any related free writing prospectus that we may authorize to be provided to you. We have not authorized any dealer, salesman or other person to give any information or to make any representation other than those contained or
incorporated by reference in this prospectus supplement, the accompanying prospectus or any related free writing prospectus that we may authorize to be provided to you. You must not rely upon any information or representation not contained or
incorporated by reference in this prospectus supplement, the accompanying prospectus or any related free writing prospectus. This prospectus supplement, the accompanying prospectus and any related free writing prospectus do not constitute an offer
to sell or the solicitation of an offer to buy any securities other than the registered securities to which they relate, nor do this prospectus supplement, the accompanying prospectus or any related free writing prospectus constitute an offer to
sell or the solicitation of an offer to buy securities in any jurisdiction to any person to whom it is unlawful to make such offer or solicitation in such jurisdiction. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">You should not assume that the information contained in this prospectus supplement, the accompanying prospectus or any related free writing prospectus is
accurate on any date subsequent to the date set forth on the front of the document or that any information we have incorporated by reference herein or therein is correct on any date subsequent to the date of the document incorporated by reference,
even though this prospectus supplement, the accompanying prospectus or any related free writing prospectus is delivered, or securities are sold, on a later date. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">This prospectus supplement contains or incorporates by reference summaries of certain provisions contained in some of the documents described herein, but
reference is made to the actual documents for complete information. All of the summaries are qualified in their entirety by the actual documents. Copies of some of the documents referred to herein have been or will be filed or have been or will be
incorporated by reference as exhibits to the registration statement of which this prospectus supplement forms a part, and you may obtain copies of those documents as described in this prospectus supplement under the heading &#147;Where You Can Find
More Information.&#148; </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">i </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<div style ="BORDER-BOTTOM:1.00pt solid #000000;BORDER-LEFT:1.00pt solid #000000;BORDER-RIGHT:1.00pt solid #000000;BORDER-TOP:1.00pt solid #000000;MARGIN-LEFT:0px;MARGIN-RIGHT:0px;max-width:100%"><div style="width:97%; margin-top:1.5%; margin-left:1.5%; margin-right:-1.25%">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="suptoc382980_2"></A>PROSPECTUS SUPPLEMENT SUMMARY </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>This summary highlights information contained in other parts of this prospectus supplement. Because it is only a summary, it does not contain all of the
information that you should consider before investing in shares of our common stock and it is qualified in its entirety by, and should be read in conjunction with, the more detailed information appearing elsewhere in this prospectus supplement, the
accompanying prospectus, any applicable free writing prospectus and the documents incorporated by reference herein and therein. You should read all such documents carefully, especially the risk factors and our financial statements and the related
notes included or incorporated by reference herein or therein, before deciding to buy shares of our common stock. Unless the context requires otherwise, references in this prospectus supplement to &#147;Minerva,&#148; &#147;we,&#148; &#147;us&#148;
and &#147;our&#148; refer to Minerva Neurosciences, Inc. and our subsidiaries. </I></P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Company Overview </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">We are a clinical-stage biopharmaceutical company focused on the development and commercialization of a portfolio of product candidates to treat patients
suffering from central nervous system, or CNS, diseases. Leveraging our scientific insights and clinical experience, we have acquired or <FONT STYLE="white-space:nowrap">in-licensed</FONT> four development-stage proprietary compounds that we believe
have innovative mechanisms of action and therapeutic profiles that can potentially address the unmet needs of patients with these diseases. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Our product
portfolio and potential indications include: <FONT STYLE="white-space:nowrap">MIN-101</FONT> for the treatment of schizophrenia; <FONT STYLE="white-space:nowrap">MIN-202</FONT> (also known as <FONT STYLE="white-space:nowrap">JNJ-42847922),</FONT>
which we are <FONT STYLE="white-space:nowrap">co-developing</FONT> with Janssen Pharmaceutica NV, one of the Janssen Pharmaceutical Companies of Johnson&nbsp;&amp; Johnson, or Janssen, for the treatment of insomnia disorder and adjunctive major
depressive disorder, or MDD; <FONT STYLE="white-space:nowrap">MIN-117</FONT> for the treatment of MDD; and <FONT STYLE="white-space:nowrap">MIN-301</FONT> for the treatment of Parkinson&#146;s disease. We believe our product candidates have
significant potential to improve the lives of a large number of affected patients and their families who are currently not well-served by available therapies. According to Datamonitor, an independent market research firm, in 2016 approximately
3.3&nbsp;million people suffered from schizophrenia, 28.9&nbsp;million suffered from MDD and 1.9&nbsp;million suffered from Parkinson&#146;s disease in the United States, Japan and the five major European Union markets of France, Germany, Italy,
Spain and the United Kingdom. Insomnia is believed to affect approximately 30 to 35&nbsp;percent of the global population as estimated by American Academy of Sleep Medicine. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Our management team has extensive experience in the pharmaceutical industry, in particular with respect to CNS products. Dr.&nbsp;Remy Luthringer, our
President and Chief Executive Officer, has participated in numerous clinical trials in the CNS area, including trials for many products approved by the U.S. Food and Drug Administration, or the FDA. Our Executive Vice President, Chief Financial
Officer and Chief Business Officer, Geoffrey Race, has worked in the biotechnology industry since 1997 and has served as a chief executive officer or chief financial officer in seven early stage development companies, including Funxional
Therapeutics Ltd and PanGenetics BV. </P>
 <P STYLE="margin-top:0pt;margin-bottom:0pt; font-size:8pt">&nbsp;</P></div><br clear="All"></div><br clear="All">

 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">S-1 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<div style ="BORDER-BOTTOM:1.00pt solid #000000;BORDER-LEFT:1.00pt solid #000000;BORDER-RIGHT:1.00pt solid #000000;BORDER-TOP:1.00pt solid #000000;MARGIN-LEFT:0px;MARGIN-RIGHT:0px;max-width:100%"><div style="width:97%; margin-top:1.5%; margin-left:1.5%; margin-right:-1.25%">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Our Pipeline </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<P STYLE="margin-top:0pt;margin-bottom:0pt" ALIGN="center">


<IMG SRC="g382980g60u25.jpg" ALT="LOGO">
 </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><FONT STYLE="white-space:nowrap">MIN-101</FONT> </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><FONT STYLE="white-space:nowrap">MIN-101</FONT> is a compound that has been shown to block serotonin receptors and sigma receptors, two receptors in the brain
that are involved in the regulation of mood, cognition, sleep and anxiety. We are developing <FONT STYLE="white-space:nowrap">MIN-101</FONT> to treat patients with schizophrenia. <FONT STYLE="white-space:nowrap">MIN-101</FONT> has been designed to
block a specific subtype of serotonin receptor called <FONT STYLE="white-space:nowrap">5-HT2A.</FONT> When <FONT STYLE="white-space:nowrap">5-HT2A</FONT> is blocked, certain symptoms of schizophrenia, such as hallucinations, delusions, agitation and
thought and movement disorders, as well as the side effects associated with antipsychotic treatments, can be minimized. Additionally, blocking <FONT STYLE="white-space:nowrap">5-HT2A</FONT> promotes slow wave sleep, a sleep stage often disrupted in
patients with schizophrenia. <FONT STYLE="white-space:nowrap">MIN-101</FONT> has also been designed to block a specific subtype of sigma receptor called sigma2, which is involved in movement control, psychotic symptom control and learning and
memory. Blocking sigma2 also increases calcium levels in neurons in the brain, which can improve memory. Recent literature has also indicated that a <FONT STYLE="white-space:nowrap">sub-type</FONT> of progesterone protein complex might also be a
putative binding site for sigma2 receptors and might explain the effects on cognition of <FONT STYLE="white-space:nowrap">MIN-101.</FONT> </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">We believe the
scientifically supported and innovative mechanisms of action of <FONT STYLE="white-space:nowrap">MIN-101</FONT> may potentially address the unmet needs of schizophrenic patients, which include negative symptoms and cognitive impairment, as well as
the side effects of existing therapies. We plan to seek approval of <FONT STYLE="white-space:nowrap">MIN-101</FONT> initially as a first line therapy to treat negative symptoms in patients diagnosed with schizophrenia, and we also may study its use
in combination with approved atypical antipsychotic agents. We believe that <FONT STYLE="white-space:nowrap">MIN-101,</FONT> if approved, could treat the majority of patients diagnosed with schizophrenia. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">In May 2016, we announced top line results from a prospective Phase IIb, <FONT STYLE="white-space:nowrap">12-week,</FONT> randomized, double-blind,
placebo-controlled parallel clinical trial evaluating the efficacy, safety and tolerability of <FONT STYLE="white-space:nowrap">MIN-101</FONT> in patients with negative symptoms of schizophrenia. The study achieved its primary endpoint,
demonstrating the </P>
 <P STYLE="margin-top:0pt;margin-bottom:0pt; font-size:8pt">&nbsp;</P></div><br clear="All"></div><br clear="All">

 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:1pt" ALIGN="center">

<TR>
<TD WIDTH="33%"></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="33%"></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="32%"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"><FONT STYLE="font-size:0.5pt" COLOR="#FFFFFF">Program Origin Primary Indications Mechanisms of Action Pre-clinical Phase I Phase II Status Next Steps</FONT><br><FONT STYLE="font-size:0.5pt" COLOR="#FFFFFF">MIN-101 Mitsubishi Tanabe
Schizophrenia 5-HT2A antagonist Sigma2 antagonist Phase IIb completed Results announced May &amp; October 2016 End of Phase II meeting with FDA held early in Q2 2017 Initiation of pivotal Phase III trial expected in H2 2017</FONT><br><FONT
STYLE="font-size:0.5pt" COLOR="#FFFFFF">MIN-202 Janssen (under co-development) Primary Insomnia Major Depressive Disorder Selective Orexin2 antagonist Phase IIa completed Phase Ib completed Results Announced January 2016 Results announced March 2016
Phase II trial preparation underway Next trials in insomnia disorder and MDD planned for second half of 2017</FONT><br><FONT STYLE="font-size:0.5pt" COLOR="#FFFFFF">MIN-117 Mitsubishi Tanabe Major Depressive Disorder 5-HT1A 5HT transporter Alpha-1a,
b Dopamine transporter 5-HT2A antagonist Phase IIa completed Results announced May 2016 Planning underway for next phase of clinical trials expected to begin in late 2017</FONT><br><FONT STYLE="font-size:0.5pt" COLOR="#FFFFFF">MIN-301 Mind-NRG
Parkinson&#146;s Disease Neuregulin 1&#226;1 activating ErbB4 Pre-clinical Pre-clinical activities ongoing Filing of IND or IMPD, with Phase I expected to initiate thereafter</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top" ALIGN="center">S-2</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"></TD></TR></TABLE>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<div style ="BORDER-BOTTOM:1.00pt solid #000000;BORDER-LEFT:1.00pt solid #000000;BORDER-RIGHT:1.00pt solid #000000;BORDER-TOP:1.00pt solid #000000;MARGIN-LEFT:0px;MARGIN-RIGHT:0px;max-width:100%"><div style="width:97%; margin-top:1.5%; margin-left:1.5%; margin-right:-1.25%">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
statistically significant benefit of <FONT STYLE="white-space:nowrap">MIN-101</FONT> over placebo in improving negative symptoms as measured by the pentagonal structure model, or PSM, of the
PANSS. The consistency and robustness of the effect was also supported by the demonstrated statistically significant benefit of <FONT STYLE="white-space:nowrap">MIN-101</FONT> over placebo in at least one dose size in multiple secondary endpoints as
measured by the following: the Positive and Negative Syndrome Scale (PANSS) general psychopathology subscale, Brief Negative Symptoms Scale total score, Clinical Global Impression of Improvement, Personal and Social Performance total score and Brief
Assessment of Cognition in Schizophrenia. <FONT STYLE="white-space:nowrap">MIN-101</FONT> was generally reported to be well tolerated, and the incidence and types of side effects did not differ significantly between the <FONT
STYLE="white-space:nowrap">MIN-101</FONT> group and the placebo group. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">We have exclusively licensed <FONT STYLE="white-space:nowrap">MIN-101</FONT> and a
number of <FONT STYLE="white-space:nowrap">back-up</FONT> compounds from Mitsubishi Tanabe Pharma Corporation, or MTPC. MTPC has retained commercialization rights to <FONT STYLE="white-space:nowrap">MIN-101</FONT> in most of Asia. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>Recent Developments </I></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">In April 2017, we applied for
Breakthrough Therapy designation for <FONT STYLE="white-space:nowrap">MIN-101</FONT> for the treatment of negative symptoms of schizophrenia. In recent correspondence, although denying our request, the FDA confirmed that treatment of negative
symptoms of schizophrenia meets the criteria for a serious or life threatening disease and consequently for Breakthrough Therapy designation. The FDA also advised that they were not able to grant designation as a Breakthrough Therapy at this time
pending receipt of additional analyses of certain data from the Phase IIb study. The Company is currently in dialogue with the FDA to clarify why it believes the Phase IIb data provides the analyses the FDA is seeking and expects a further review of
our request in the near future. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">On June&nbsp;22, 2017, we announced the completion of a bridging trial to select an improved, gastric-resistant (GR)
formulation of <FONT STYLE="white-space:nowrap">MIN-101</FONT> that we plan to use in the Phase III clinical trial with <FONT STYLE="white-space:nowrap">MIN-101</FONT> and to include in the potential future submission of a New Drug Application
(NDA). </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Data from the bridging trial of the selected new formulation demonstrated: bioequivalent exposure of
<FONT STYLE="white-space:nowrap">MIN-101</FONT> based on area under the curve shown in the Phase IIb study; reduction of an inactive metabolite of <FONT STYLE="white-space:nowrap">MIN-101</FONT> known as
<FONT STYLE="white-space:nowrap">BFB-520</FONT> by approximately 30% in the improved formulation, thereby reducing the potential for transient QTc increases observed in the Phase IIb study at the higher dose but not the lower dose; no observations
of QTc prolongations throughout the bridging trial; no observable food effect, thus allowing administration of the drug with or without food without changing its pharmacokinetic properties; confirmation of the overall safety and tolerability profile
of <FONT STYLE="white-space:nowrap">MIN-101.</FONT> </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">We plan to immediately initiate CMC <FONT STYLE="white-space:nowrap">scale-up</FONT> processes. As
exposures of <FONT STYLE="white-space:nowrap">MIN-101</FONT> in the Phase IIb study and the GR formulation to be used in the Phase III trial are comparable, we believe data from both studies can be aggregated for the purposes of evaluating efficacy.
We have also filed a patent application for the GR formulation, which is in addition to an already granted patent in the U.S. that provides protection until 2035. If granted, the additional patent could potentially extend exclusivity beyond 2035.
</P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">In May 2017, we announced the outcome of an &#147;end of Phase 2&#148; meeting with the FDA and announced our plans to initiate Phase III development of <FONT
STYLE="white-space:nowrap">MIN-101.</FONT> We expect that a pivotal Phase III trial with <FONT STYLE="white-space:nowrap">MIN-101</FONT> will be initiated in the second half of 2017. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The Phase III trial design will be a <FONT STYLE="white-space:nowrap">12-week,</FONT> double-blind, randomized, placebo-controlled, monotherapy study testing
two doses of <FONT STYLE="white-space:nowrap">MIN-101</FONT> in patients with negative symptoms and a diagnosis of schizophrenia. To be eligible for the study, patients will be required to have stable negative and positive symptoms over several
months prior to enrollment, with a specified minimum threshold baseline score on the PANSS negative <FONT STYLE="white-space:nowrap">sub-scale.</FONT> After the double-blind phase, patients may enter a <FONT STYLE="white-space:nowrap">36-week</FONT>
open label extension phase in which all patients will receive active treatment. This multi-center, international trial is expected to enroll approximately 500 patients at approximately 60 clinical sites across the U.S. and Europe. </P>
 <P STYLE="margin-top:0pt;margin-bottom:0pt; font-size:8pt">&nbsp;</P></div><br clear="All"></div><br clear="All">

 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">S-3 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<div style ="BORDER-BOTTOM:1.00pt solid #000000;BORDER-LEFT:1.00pt solid #000000;BORDER-RIGHT:1.00pt solid #000000;BORDER-TOP:1.00pt solid #000000;MARGIN-LEFT:0px;MARGIN-RIGHT:0px;max-width:100%"><div style="width:97%; margin-top:1.5%; margin-left:1.5%; margin-right:-1.25%">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><FONT STYLE="white-space:nowrap">MIN-202</FONT> </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><FONT STYLE="white-space:nowrap">MIN-202</FONT> is an innovative selective orexin 2 receptor antagonist we are
<FONT STYLE="white-space:nowrap">co-developing</FONT> with Janssen for the treatment of insomnia and as adjunctive therapy for major depressive disorder, or MDD. Insomnia is the repeated difficulty with sleep initiation, maintenance or quality that
occurs despite adequate time and opportunity for sleep, resulting in daytime impairment. Insomnia can be the primary condition for patients or a secondary symptom of, and contributor to, another medical or psychiatric condition, such as MDD or
schizophrenia. Pending the effectiveness of an amendment to our <FONT STYLE="white-space:nowrap">co-development</FONT> agreement with Janssen, we will gain global strategic control of the decision-making regarding the use <FONT
STYLE="white-space:nowrap">of&nbsp;MIN-202&nbsp;to</FONT> treat insomnia. We and Janssen will retain development and commercial rights to <FONT STYLE="white-space:nowrap">MIN-202</FONT> to treat insomnia and as adjunctive therapy for MDD. For
additional information regarding the pending amendment, please see &#147;Recent Developments&#148; below. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">In the brain, the orexin system is involved in
the control of several key functions, including metabolism and wakefulness. <FONT STYLE="white-space:nowrap">MIN-202</FONT> seeks to inhibit the activity of the neurons that promote wakefulness by selectively blocking the orexin 2 receptor. Rather
than making an individual sleepier, blocking the orexin 2 receptor reduces the level of the neurotransmitters that signal the brain to maintain vigilance and wakefulness, which can be helpful for patients with insomnia. Janssen completed a Phase I
single ascending dose study of <FONT STYLE="white-space:nowrap">MIN-202</FONT> in 2011 that suggested a relationship which supports a rapid induction and promotion of sleepiness. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">In January 2016, we announced top line results from a Phase IIa clinical trial of <FONT STYLE="white-space:nowrap">MIN-202</FONT> for the treatment of
insomnia disorder. Patients treated with <FONT STYLE="white-space:nowrap">MIN-202</FONT> in the trial were observed to have statistically significant improvements in key sleep parameters, compared to patients treated with placebo. These parameters
include sleep efficiency as measured by objective polysomnography, the primary endpoint of the trial, for which a positive efficacy signal was observed with a 40 milligram dose of <FONT STYLE="white-space:nowrap">MIN-202</FONT> versus placebo
(p&lt;0.001). No serious adverse events were observed in this trial, and preliminary data indicate that <FONT STYLE="white-space:nowrap">MIN-202</FONT> was well tolerated by patients. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">In March 2016, we announced top line results from a Phase Ib clinical trial in MDD with <FONT STYLE="white-space:nowrap">MIN-202.</FONT> <FONT
STYLE="white-space:nowrap">MIN-202</FONT> was observed to result in consistent improvements in the symptoms of depression in MDD patients in this trial. <FONT STYLE="white-space:nowrap">MIN-202</FONT> was observed to be well tolerated by study
participants over a <FONT STYLE="white-space:nowrap">one-month</FONT> treatment duration, with no serious adverse events. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">We are <FONT
STYLE="white-space:nowrap">co-developing</FONT> <FONT STYLE="white-space:nowrap">MIN-202</FONT> with Janssen and own the exclusive rights to develop and commercialize the compound in the Minerva Territory and we have the right to receive royalties
on any sales outside the Minerva Territory. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>Recent Developments </I></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">In June 2017, we entered into an Amendment to our <FONT STYLE="white-space:nowrap">Co-Development</FONT> and License Agreement with Janssen, pursuant to which
Janssen agreed to forgo its right to royalties on <FONT STYLE="white-space:nowrap">MIN-202</FONT> insomnia sales in Minerva territories. We retained our rights to <FONT STYLE="white-space:nowrap">MIN-202&nbsp;as</FONT> adjunctive therapy for MDD,
which include an exclusive license in the European Union, Switzerland, Liechtenstein, Iceland and Norway, with royalties payable by Minerva to Janssen, and royalties on sales payable by Janssen to Minerva elsewhere worldwide. Janssen also agreed to
make an upfront payment to us of $30&nbsp;million upon the effectiveness of the Amendment, a $20&nbsp;million payment at the start of a Phase III insomnia trial <FONT STYLE="white-space:nowrap">for&nbsp;MIN-202,&nbsp;a</FONT> $20&nbsp;million
payment when 50% of the patients are enrolled in this trial, and further agreed to waive the remaining payments due from Minerva for Phase II development <FONT STYLE="white-space:nowrap">of&nbsp;MIN-202,&nbsp;which</FONT> total approximately
$13&nbsp;million. Upon the effectiveness of the Amendment, we will assume all financial responsibility for Phase III development costs <FONT STYLE="white-space:nowrap">for&nbsp;MIN-202&nbsp;in</FONT> insomnia. The effectiveness of the Amendment is
contingent upon approval by the European Commission. </P>
 <P STYLE="margin-top:0pt;margin-bottom:0pt; font-size:8pt">&nbsp;</P></div><br clear="All"></div><br clear="All">

 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">S-4 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<div style ="BORDER-BOTTOM:1.00pt solid #000000;BORDER-LEFT:1.00pt solid #000000;BORDER-RIGHT:1.00pt solid #000000;BORDER-TOP:1.00pt solid #000000;MARGIN-LEFT:0px;MARGIN-RIGHT:0px;max-width:100%"><div style="width:97%; margin-top:1.5%; margin-left:1.5%; margin-right:-1.25%">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><FONT STYLE="white-space:nowrap">MIN-117</FONT> </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><FONT STYLE="white-space:nowrap">MIN-117</FONT> is a compound we are developing to treat patients suffering from MDD, the most prominent subtype of depression.
Patients suffering from MDD experience feelings of sadness, loss, anger or frustration that interfere with their ability to carry out and enjoy once-pleasurable activities. While suicide is the leading cause of death in those with MDD, other
factors, such as changes in immune function and susceptibility to disease, can also lead to early mortality. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">We believe
<FONT STYLE="white-space:nowrap">MIN-117</FONT> has the potential to address limitations of existing therapies, such as slow onset of action and poor safety and tolerability, without many of the typical side effects associated with currently
approved therapies. The pharmacological effects of <FONT STYLE="white-space:nowrap">MIN-117</FONT> are related to serotonin and dopamine, two neurotransmitters in the brain. <FONT STYLE="white-space:nowrap">MIN-117</FONT> is meant to block a
specific subtype of serotonin receptor called <FONT STYLE="white-space:nowrap">5-HT1A.</FONT> When <FONT STYLE="white-space:nowrap">5-HT1A</FONT> is blocked, anxiety and mood can be regulated. In addition,
<FONT STYLE="white-space:nowrap">MIN-117</FONT> is meant to prevent the reuptake of serotonin and dopamine, which increases the amount of serotonin and dopamine in the brain, which is tied to an improvement in mood in individuals suffering from MDD.
<FONT STYLE="white-space:nowrap">MIN-117</FONT> is also meant to modulate the levels of <FONT STYLE="white-space:nowrap">Alpha-1a</FONT> and 1b, which further modulates serotonin and dopamine. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">In May 2016, we announced top line results from a Phase IIa clinical trial in MDD with <FONT STYLE="white-space:nowrap">MIN-117.</FONT> Data from this trial
were subsequently presented at the 55<SUP STYLE="font-size:85%; vertical-align:top">th</SUP>&nbsp;Annual Meeting of the American College of Neuropsychopharmacology in December 2016. We observed dose-dependent superiority of <FONT
STYLE="white-space:nowrap">MIN-117</FONT> over placebo as measured by change in the Montgomery-Asberg Depression Rating Scale, or MADRS. Both doses of <FONT STYLE="white-space:nowrap">MIN-117</FONT> demonstrated a favorable tolerability profile, and
the incidence and types of side effects did not differ significantly between the <FONT STYLE="white-space:nowrap">MIN-117</FONT> group and the placebo group. No unexpected adverse events were reported. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Based upon clinical and <FONT STYLE="white-space:nowrap">pre-clinical</FONT> studies completed to date, we believe
<FONT STYLE="white-space:nowrap">MIN-117</FONT> may demonstrate a safety profile comparable to placebo without many of the typical side effects of current MDD treatments, including cognitive impairment, sexual dysfunction, sleep disorders and weight
gain. As part of our license agreement with MTPC, we may develop, sell, and import products related to the <FONT STYLE="white-space:nowrap">MIN-117</FONT> compound globally, excluding most of Asia. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><FONT STYLE="white-space:nowrap">MIN-301</FONT> </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">We are
developing <FONT STYLE="white-space:nowrap">MIN-301,</FONT> a soluble recombinant form of the <FONT STYLE="white-space:nowrap">Neuregulin-1b1,</FONT> or <FONT STYLE="white-space:nowrap">NRG-1b1,</FONT> protein, for the treatment of Parkinson&#146;s
disease. We believe <FONT STYLE="white-space:nowrap">MIN-301</FONT> has the potential to slow the onset of, and restore the brain tissue damage caused by, the disease. <FONT STYLE="white-space:nowrap">MIN-301</FONT> is produced by recombinant
technology, which is a type of process that modifies the genetics of a biological organism to cause it to produce a particular product. <FONT STYLE="white-space:nowrap">MIN-301</FONT> is a peptide that contains the extracellular domain of the human <FONT
STYLE="white-space:nowrap">neuregulin-1</FONT> beta 1 protein and is produced using an Escherichia coli organism that is genetically engineered to express this peptide. Once administrated, this peptide binds to a particular receptor, ErbB4, which
produces certain biological effects. For instance, binding to ErbB4 modulates the levels of certain neurotransmitters such as GABA and glutamate in the brain, which are often unbalanced in individuals with Parkinson&#146;s disease. Further, ErbB4
promotes oxygenation and metabolism of neurons, which could indicate <FONT STYLE="white-space:nowrap">MIN-301</FONT> could reverse the damage caused by Parkinson&#146;s disease. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Parkinson&#146;s disease is a progressive and incurable disease that leads to disability and lower quality of life. Current treatments for Parkinson&#146;s
disease improve the symptoms of patients, but none have been proven to delay the onset of the disease, slow or prevent the progression of the disease or reverse its effects. Due to <FONT STYLE="white-space:nowrap">MIN-301&#146;s</FONT> novel
mechanism of action that targets neurological deficits, we believe <FONT STYLE="white-space:nowrap">MIN-301</FONT> has the potential to address these unmet needs of patients and, if approved, may be used as an early-stage monotherapy as well as a
complementary therapy to existing treatments. </P>
 <P STYLE="margin-top:0pt;margin-bottom:0pt; font-size:8pt">&nbsp;</P></div><br clear="All"></div><br clear="All">

 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">S-5 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<div style ="BORDER-BOTTOM:1.00pt solid #000000;BORDER-LEFT:1.00pt solid #000000;BORDER-RIGHT:1.00pt solid #000000;BORDER-TOP:1.00pt solid #000000;MARGIN-LEFT:0px;MARGIN-RIGHT:0px;max-width:100%"><div style="width:97%; margin-top:1.5%; margin-left:1.5%; margin-right:-1.25%">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">In January 2015, we announced results from a <FONT STYLE="white-space:nowrap">non-human</FONT> primate study
showing that treatment with an analog of <FONT STYLE="white-space:nowrap">MIN-301</FONT> resulted in improvements in a range of symptoms associated with a Parkinson&#146;s disease model in primates. The results confirmed the beneficial effects of <FONT
STYLE="white-space:nowrap">MIN-301</FONT> in <FONT STYLE="white-space:nowrap">non-primate</FONT> preclinical models. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The mechanism of action of <FONT
STYLE="white-space:nowrap">MIN-301</FONT> is still under further investigation, but we believe this peptide has important characteristics, such as effects on oxidative stress reversal, effects on cell metabolism particularly adenosine triphosphate,
or ATP, and effects on GABA and glutamate. Taken together, we believe the effects described above could protect dopaminergic neurons, the dysfunction of which is a key element in the cause of Parkinson&#146;s disease, and possibly other <FONT
STYLE="white-space:nowrap">sub-types</FONT> of neurons and other brain cells such as glial cells. These potential effects indicate that <FONT STYLE="white-space:nowrap">MIN-301</FONT> may have a novel neuro-protecting and neuro-restorative profile.
In view of this <FONT STYLE="white-space:nowrap">MIN-301</FONT> mechanism of action and based on a number of other studies performed by other research labs on neuregulin, we believe several other indications of the molecule may be pursued, such as
for Alzheimer&#146;s disease and other neuro-degenerative disorders, such as multiple sclerosis, and for other psychological disorders, such as schizophrenia, stroke and traumatic brain injury. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Our next steps for the development for <FONT STYLE="white-space:nowrap">MIN-301</FONT> include continuing to conduct preclinical studies in preparation for an
Investigational New Drug, or IND, or Investigational Medicinal Product Dossier, or IMPD filing, with a Phase I study expected to commence thereafter. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Financial Information </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">As of March&nbsp;31, 2017, we had
approximately $85.4&nbsp;million of cash, cash equivalents and marketable securities and an accumulated deficit of $143.5&nbsp;million. In addition, in June 2017, we signed an amendment to our <FONT STYLE="white-space:nowrap">Co-Development</FONT>
and License Agreement with Janssen, pursuant to which Janssen agreed to forgo its right to royalties on <FONT STYLE="white-space:nowrap">MIN-202</FONT> insomnia sales in Minerva territories and agreed to make an upfront payment to us of
$30&nbsp;million upon effectiveness of the amendment. As of the date of this prospectus, the effectiveness of the amendment is still pending approval by the European Commission. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Corporate Information </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Information concerning the Company
is contained in the documents that we file with the SEC as a reporting company under the Securities Exchange Act of 1934, which are accessible at <I>www.sec.gov</I>.<I> </I>Our website address is <I>www.minervaneurosciences.com</I>. The information
contained on, or that can be accessed through, our website is not a part of this prospectus. Investors should not rely on any such information in deciding whether to purchase our common stock. We have included our website address in this prospectus
solely as an inactive textual reference. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Our mailing address is 1601 Trapelo Road, Suite 284, Waltham, Massachusetts 02451. Our telephone number is (617)
<FONT STYLE="white-space:nowrap">600-7373.</FONT> </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Implications of Being an Emerging Growth Company </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">As a company with less than $1&nbsp;billion in revenue during our last fiscal year, we qualify as an &#147;emerging growth company&#148; as defined in the
Jumpstart Our Business Startups Act of 2012, or the JOBS Act. For so long as we remain an emerging growth company, we are permitted and intend to rely on exemptions from specified disclosure requirements that are applicable to other public companies
that are not emerging growth companies. These exemptions include: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">being permitted to provide only two years of audited financial statements, in addition to any required unaudited interim financial statements, with correspondingly reduced &#147;Management&#146;s Discussion and Analysis
of Financial Condition and Results of Operations&#148; disclosure; </TD></TR></TABLE>
 <P STYLE="margin-top:0pt;margin-bottom:0pt; font-size:8pt">&nbsp;</P></div><br clear="All"></div><br clear="All">

 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">S-6 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<div style ="BORDER-BOTTOM:1.00pt solid #000000;BORDER-LEFT:1.00pt solid #000000;BORDER-RIGHT:1.00pt solid #000000;BORDER-TOP:1.00pt solid #000000;MARGIN-LEFT:0px;MARGIN-RIGHT:0px;max-width:100%"><div style="width:97%; margin-top:1.5%; margin-left:1.5%; margin-right:-1.25%">


<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">not being required to comply with the auditor attestation requirements in the assessment of our internal control over financial reporting; </TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">not being required to comply with any requirement that may be adopted by the Public Company Accounting Oversight Board regarding mandatory audit firm rotation or a supplement to the auditor&#146;s report providing
additional information about the audit and the financial statements; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">reduced disclosure obligations regarding executive compensation; and </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">exemptions from the requirements of holding a nonbinding advisory vote on executive compensation and shareholder approval of any golden parachute payments not previously approved. </TD></TR></TABLE>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">We may take advantage of these provisions until December&nbsp;31, 2019, or until such earlier time that we are no longer an emerging growth company. We would
cease to be an emerging growth company if we have more than $1&nbsp;billion in annual revenues, have more than $700&nbsp;million in market value of our capital stock held by <FONT STYLE="white-space:nowrap">non-affiliates</FONT> or issue more than
$1&nbsp;billion of <FONT STYLE="white-space:nowrap">non-convertible</FONT> debt over a three-year period. We may choose to take advantage of some, but not all, of the available exemptions. We have taken advantage of some reduced reporting burdens in
this prospectus supplement, the accompanying prospectus and the documents incorporated by reference herein and therein. Accordingly, such information may be different than the information you receive from other public companies in which you hold
stock. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">In addition, the JOBS Act provides that an emerging growth company can take advantage of an extended transition period for complying with new or
revised accounting standards. This provision allows an emerging growth company to delay the adoption of some accounting standards until those standards would otherwise apply to private companies. We have irrevocably elected not to avail ourselves of
this exemption from new or revised accounting standards and, therefore, we will be subject to the same new or revised accounting standards as other public companies that are not emerging growth companies. </P>
 <P STYLE="margin-top:0pt;margin-bottom:0pt; font-size:8pt">&nbsp;</P></div><br clear="All"></div><br clear="All">

 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">S-7 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<div style ="BORDER-BOTTOM:1.00pt solid #000000;BORDER-LEFT:1.00pt solid #000000;BORDER-RIGHT:1.00pt solid #000000;BORDER-TOP:1.00pt solid #000000;MARGIN-LEFT:0px;MARGIN-RIGHT:0px;max-width:100%"><div style="width:97%; margin-top:1.5%; margin-left:1.5%; margin-right:-1.25%">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>THE OFFERING </B></P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR VALIGN="TOP">
<TD WIDTH="38%"> <P STYLE=" margin-top:0pt; margin-bottom:1pt; margin-left:2%; text-indent:-2%; font-size:10pt; font-family:Times New Roman">Common stock offered by us </P></TD>
<TD>5,000,000&nbsp;shares </TD></TR></TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="38%">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"></TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR VALIGN="TOP">
<TD WIDTH="38%"> <P STYLE=" margin-top:0pt; margin-bottom:1pt; margin-left:2%; text-indent:-2%; font-size:10pt; font-family:Times New Roman">Option to purchase additional shares </P></TD>
<TD>We have granted the underwriters an option to purchase up to 750,000 additional shares of our common stock. This option is exercisable, in whole or in part, for a period of 30 days from the date of this prospectus supplement. </TD></TR></TABLE>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR VALIGN="TOP">
<TD WIDTH="38%"> <P STYLE=" margin-top:0pt; margin-bottom:1pt; margin-left:2%; text-indent:-2%; font-size:10pt; font-family:Times New Roman">Common stock to be outstanding after this offering </P></TD>
<TD>41,704,872&nbsp;shares (42,454,872&nbsp;shares if the underwriters elect to exercise in full their option to purchase additional shares from us). </TD></TR></TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="38%">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"></TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR VALIGN="TOP">
<TD WIDTH="38%"> <P STYLE=" margin-top:0pt; margin-bottom:1pt; margin-left:2%; text-indent:-2%; font-size:10pt; font-family:Times New Roman">Use of proceeds </P></TD>
<TD>We intend to use the net proceeds of this offering to fund part of the continued clinical development of <FONT STYLE="white-space:nowrap">MIN-101,</FONT> <FONT STYLE="white-space:nowrap">MIN-117,</FONT>
<FONT STYLE="white-space:nowrap">MIN-202</FONT> and <FONT STYLE="white-space:nowrap">MIN-301,</FONT> and for working capital and other general corporate purposes. See &#147;Use of Proceeds.&#148; </TD></TR></TABLE>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR VALIGN="TOP">
<TD WIDTH="38%"> <P STYLE=" margin-top:0pt; margin-bottom:1pt; margin-left:2%; text-indent:-2%; font-size:10pt; font-family:Times New Roman">Risk factors </P></TD>
<TD>An investment in our common stock involves a high degree of risk. See &#147;Risk Factors&#148; beginning on page <FONT STYLE="white-space:nowrap">S-9</FONT> of this prospectus supplement and the similarly titled sections in the documents
incorporated by reference into this prospectus supplement. </TD></TR></TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR VALIGN="TOP">
<TD WIDTH="38%"> <P STYLE=" margin-top:0pt; margin-bottom:1pt; margin-left:2%; text-indent:-2%; font-size:10pt; font-family:Times New Roman">Nasdaq Global Market symbol </P></TD>
<TD>NERV </TD></TR></TABLE> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Outstanding Shares </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The
number of shares of our common stock to be outstanding after this offering is based on 36,704,872 shares of our common stock outstanding as of March&nbsp;31, 2017, and excludes: </P>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">warrants to purchase 40,790 shares of common stock; and </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">5,485,881 shares of common stock reserved for issuance under our Amended and Restated 2013 Equity Incentive Plan as of March&nbsp;31, 2017, consisting of 4,059,346 shares of common stock subject to outstanding awards
and 1,426,535 shares of common stock that remain available under our Amended and Restated 2013 Equity Incentive Plan for future grants. </TD></TR></TABLE>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Except as otherwise indicated herein, all information in this prospectus supplement, including the number of shares that will be outstanding after this
offering, does not assume or give effect to the exercise of options or warrants outstanding as of March&nbsp;31, 2017 or the exercise of the underwriters&#146; option to purchase additional shares in this offering. </P>
 <P STYLE="margin-top:0pt;margin-bottom:0pt; font-size:8pt">&nbsp;</P></div><br clear="All"></div><br clear="All">

 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">S-8 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="suptoc382980_3"></A>RISK FACTORS </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>An investment in our common stock involves a high degree of risk. Before deciding whether to invest in our common stock, you should carefully consider the
risks described below and those discussed under the Section captioned &#147;Risk Factors&#148; contained in our Quarterly Report on Form <FONT STYLE="white-space:nowrap">10-Q</FONT> for the quarter ended March&nbsp;31, 2017, which is incorporated by
reference in this prospectus supplement and the accompanying prospectus, together with other information in this prospectus supplement, the accompanying prospectus, the information and documents incorporated by reference herein and therein, and in
any free writing prospectus that we have authorized for use in connection with this offering. If any of these risks actually occurs, our business, financial condition, results of operations or cash flow could be seriously harmed. This could cause
the trading price of our common stock to decline, resulting in a loss of all or part of your investment. </I></P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Risks Related to our Business </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>The effectiveness of the amendment to our <FONT STYLE="white-space:nowrap">Co-Development</FONT> Agreement with Janssen Pharmaceutica NV and the closing of
the related Stock Repurchase Agreement is subject to certain conditions that are outside our control and there can be no assurance that the conditions will be met in a timely fashion, or at all. </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">In June 2017, we signed an amendment to our <FONT STYLE="white-space:nowrap">Co-Development</FONT> and License Agreement with Janssen, pursuant to which
Janssen agreed to forgo its right to royalties on <FONT STYLE="white-space:nowrap">MIN-202</FONT> insomnia sales in Minerva territories and agreed to make an upfront payment to us of $30&nbsp;million upon effectiveness, in addition to other
payments. In connection with this amendment, we also entered into a stock repurchase agreement with Johnson&nbsp;&amp; Johnson Innovation-JJDC Inc. to repurchase all of the approximately 3.9&nbsp;million shares of our stock held by
Johnson&nbsp;&amp; Johnson Innovation-JJDC Inc. at a per share price of $0.0001, for an aggregate purchase price of approximately $389. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The effectiveness
of both the amendment and the stock repurchase agreement are contingent upon approval of the transaction by the European Commission. While custom dictates an approval within thirty (30)&nbsp;days, as of the date of this prospectus, the European
Commission has not yet approved the transaction. If the European Commission does not approve the transaction and our amendment is not effective and the repurchase does not close, it could have a material adverse effect on our business and cause the
price of our common stock to decline. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>If we are able to achieve Breakthrough Therapy designation with the FDA for our product candidates, it may not
lead to a faster development or regulatory review or approval process, and it does not increase the likelihood that our product candidates will receive marketing approval. </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Our <FONT STYLE="white-space:nowrap">MIN-101</FONT> product candidate was initially denied Breakthrough Therapy designation by the FDA in June 2017, but we may
in the future <FONT STYLE="white-space:nowrap">re-submit</FONT> our request or seek Breakthrough Therapy designation for one or more of our other product candidates. A Breakthrough Therapy is defined as a drug that is intended, alone or in
combination with one or more other drugs, to treat a serious or life-threatening disease or condition, and preliminary clinical evidence indicates that the drug may demonstrate substantial improvement over existing therapies on one or more
clinically significant endpoints. For drugs that have been designated as Breakthrough Therapies, interaction and communication between the FDA and the sponsor of the trial can help to identify the most efficient path for clinical development while
minimizing the number of patients placed in ineffective control regimens. Drugs designated as breakthrough therapies by the FDA are also eligible for accelerated approval. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Designation as a&nbsp;Breakthrough Therapy&nbsp;is within the discretion of the FDA. Accordingly, even if we believe one of our product candidates meets the
criteria for designation as a&nbsp;Breakthrough Therapy, the FDA may disagree and instead determine not to make such designation. The availability of&nbsp;Breakthrough Therapy&nbsp;designation was established recently with the passage of the Food
and Drug Administration Safety and Innovation Act of 2012. We cannot be sure that any evaluation we may make of our product candidates as qualifying for&nbsp;Breakthrough </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">S-9 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
Therapy designation will meet the FDA&#146;s expectations. In any event, the receipt of a&nbsp;Breakthrough Therapy&nbsp;designation for a product candidate may not result in a faster development
process, review or approval compared to drugs considered for approval under conventional FDA procedures and does not assure ultimate approval by the FDA. In addition, even if one or more of our product candidates qualify as Breakthrough Therapies,
the FDA may later decide that such product candidates no longer meet the conditions for qualification or decide that the time period for FDA review or approval will not be shortened. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Additional Risks Related to This Offering </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Management
will have broad discretion as to the use of the proceeds from this offering, and we may not use the proceeds effectively. </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Our management will have
broad discretion with respect to the use of proceeds of this offering, including for any of the purposes described in the section of this prospectus supplement entitled &#147;Use of Proceeds.&#148; You will be relying on the judgment of our
management regarding the application of the proceeds of this offering. The results and effectiveness of the use of proceeds are uncertain, and we could spend the proceeds in ways that you do not agree with or that do not improve our results of
operations or enhance the value of our common stock. Our failure to apply these funds effectively could have a material adverse effect on our business, delay the development of our product candidates and cause the price of our common stock to
decline. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>You will experience immediate and substantial dilution in the net tangible book value per share of the common stock you purchase. </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Since the public offering price for our common stock in this offering is substantially higher than the net tangible book value per share of our common stock
outstanding prior to this offering, you will suffer immediate and substantial dilution in the net tangible book value of the common stock you purchase in this offering. If the underwriters exercise their option to purchase additional shares, you
will experience additional dilution. See the section entitled &#147;Dilution&#148; below for a more detailed discussion of the dilution you will incur if you purchase shares in this offering. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The issuance of additional shares of our common stock could be dilutive to stockholders if they do not invest in future offerings. In addition, we have a
significant number of options and warrants to purchase shares or our common stock outstanding. If these securities are exercised, you may incur further dilution. Moreover, to the extent that we issue additional options or warrants to purchase, or
securities convertible into or exchangeable for, shares of our common stock in the future and those options, warrants or other securities are exercised, converted or exchanged, stockholders may experience further dilution. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">S-10 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="suptoc382980_4"></A>SPECIAL NOTE REGARDING FORWARD-LOOKING STATEMENTS </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">This prospectus supplement and the information incorporated by reference in this prospectus supplement, contains forward-looking statements within the meaning
of the Private Securities Litigation Reform Act of 1995, as amended, that involve substantial risks and uncertainties. All statements other than statements of historical facts contained in this prospectus supplement, including statements regarding
our future operating results and financial position, business strategy, and plans and objectives of management for future operations, are forward-looking statements. In many cases, you can identify forward-looking statements by terms such as
&#147;may,&#148; &#147;should,&#148; &#147;expects,&#148; &#147;plans,&#148; &#147;anticipates,&#148; &#147;could,&#148; &#147;intends,&#148; &#147;target,&#148; &#147;projects,&#148; &#147;contemplates,&#148; &#147;believes,&#148;
&#147;estimates,&#148; &#147;predicts,&#148; &#147;potential,&#148; or &#147;continue&#148; or the negative of these terms or other similar expressions. Forward looking statements include statements herein with respect to our ability to successfully
develop and <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">commercialize&nbsp;MIN-101,&nbsp;MIN-202,</FONT></FONT> <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">MIN-117&nbsp;and&nbsp;MIN-301;</FONT></FONT> the
approval by the European Commission of matters related to the acquisition of Actelion Ltd. by affiliates of Janssen; the improved formulation of <FONT STYLE="white-space:nowrap">MIN-101</FONT> to be used in the planned Phase III trial; our
expectations regarding approval of <FONT STYLE="white-space:nowrap">MIN-101</FONT> for Breakthrough Therapy designation by the U.S. Food and Drug Administration; and future performance </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The forward-looking statements contained in this prospectus supplement reflect our views as of the date of this prospectus supplement about future events and
are subject to risks, uncertainties, assumptions, and changes in circumstances that may cause our actual results, performance, or achievements to differ significantly from those expressed or implied in any forward-looking statement. Although we
believe that the expectations reflected in the forward-looking statements are reasonable, we cannot guarantee future events, results, performance, or achievements. A number of important factors could cause actual results to differ materially from
those indicated by the forward-looking statements, including, without limitation, those factors described or referenced in &#147;Risk Factors.&#148; In addition, those &#147;Risk Factors&#148; may be updated from time to time by our filings under
the Securities Exchange Act of 1934, as amended. Except as required by law, after the date of this prospectus supplement, we are under no duty to update or revise any of the forward-looking statements contained or incorporated by reference herein,
whether as a result of new information, future events or otherwise. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">You should read this prospectus supplement, the accompanying prospectus and the
information that we incorporate by reference, completely and with the understanding that our actual future results may be materially different from what we expect. We qualify all of our forward-looking statements by these cautionary statements. </P>

 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">S-11 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="suptoc382980_7"></A>USE OF PROCEEDS </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">We estimate that the net proceeds from our issuance and sale of 5,000,000&nbsp;shares of common stock in this offering will be approximately $36.0 million, or
approximately $41.5 million if the underwriters exercise their option to purchase additional shares in full, in each case after deducting the underwriting discounts and commissions and the estimated offering expenses payable by us. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">We intend to use the net proceeds of this offering to fund part of the continued clinical development of <FONT STYLE="white-space:nowrap">MIN-101,</FONT> <FONT
STYLE="white-space:nowrap">MIN-117,</FONT> <FONT STYLE="white-space:nowrap">MIN-202</FONT> and <FONT STYLE="white-space:nowrap">MIN-301,</FONT> and<B> </B>for working capital and general corporate purposes. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">We have not determined the amounts we plan to spend on any of the areas listed above or the timing of these expenditures. As a result, our management will
have broad discretion in allocating the net proceeds from this offering. Pending application of the net proceeds as described above, we intend to invest the net proceeds of this offering in short-term, investment-grade, interest-bearing securities.
</P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">These expected uses represent our intentions based upon our current plans and business conditions, which could change in the future as our plans and
business conditions evolve. The amounts and timing of our actual expenditures may vary significantly depending on numerous factors, including the progress of our development, the status of and results from clinical trials, as well as any new
collaborations that we may enter into with third parties for our product candidates, and any unforeseen cash needs. As a result, our management will have broad discretion in the application of the net proceeds from this offering, and investors will
be relying on the judgment of our management regarding the application of the net proceeds from this offering. The timing and amount of our actual expenditures will be based on many factors, including cash flows from operations and the anticipated
growth of our business. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">S-12 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="suptoc382980_5"></A>PRICE RANGE OF OUR COMMON STOCK </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Our common stock has been traded on the NASDAQ Global Market under the symbol &#147;NERV&#148; since our initial public offering on July&nbsp;1, 2014. Prior
to that time, there was no public market for our common stock. The following table sets forth the high and low sale prices per share for our common stock on the NASDAQ Global Market for the periods indicated: </P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="76%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>
<TD WIDTH="78%"></TD>
<TD VALIGN="bottom" WIDTH="6%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="6%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>High</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Low</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>2017</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">First Quarter</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">12.60</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">7.40</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Second Quarter (through June&nbsp;26, 2017)</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">11.15</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">6.50</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>2016</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">First Quarter</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">6.30</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">4.38</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Second Quarter</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">15.84</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">3.45</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Third Quarter</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">14.92</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">9.99</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Fourth Quarter</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">14.83</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">8.80</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>2015</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Third Quarter</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">6.50</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">5.01</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Fourth Quarter</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">6.24</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">4.27</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
</TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">On June&nbsp;26, 2017, the closing price of our common stock as reported by the NASDAQ Global Market was $9.30 per share. As
of June&nbsp;26, 2017, there were approximately 24 holders of record of our common stock. We believe that the number of beneficial owners of our common stock at that date was substantially greater. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">S-13 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="suptoc382980_6"></A>DIVIDEND POLICY </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">We have never declared or paid any cash dividends on our common stock and our ability to pay cash dividends is currently prohibited by the terms of our debt
financing arrangements. We do not anticipate paying cash dividends on our common stock in the foreseeable future. Payment of future dividends, if any, on our common stock will be at the discretion of our board of directors after taking into account
various factors, including our financial condition, operating results, anticipated cash needs and plans for expansion. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">S-14 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="suptoc382980_8"></A>CAPITALIZATION </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The following table sets forth our cash, cash equivalents and marketable securities and our capitalization as of March&nbsp;31, 2017: </P>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">on an actual basis; and </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">on an as adjusted basis to reflect our issuance and sale of 5,000,000&nbsp;shares of common stock in this offering at the public offering price of $7.75 per share, after deducting underwriting discounts and commissions
and estimated offering expenses payable by us. </TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">You should read this table together with our financial statements and the related notes
incorporated by reference in this prospectus supplement and the sections entitled &#147;Management&#146;s Discussion and Analysis of Financial Condition and Results of Operations&#148; included in our most recent Annual Report on Form <FONT
STYLE="white-space:nowrap">10-K</FONT> and Quarterly Report on Form <FONT STYLE="white-space:nowrap">10-Q,</FONT> each as incorporated by reference herein. </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>
<TD WIDTH="72%"></TD>
<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>As of March&nbsp;31, 2017,</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Actual</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>As&nbsp;Adjusted</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>(unaudited)</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Cash, cash equivalents and marketable securities</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">85,359,363</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">121,359,363</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Notes payable</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">7,559,524</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">7,559,524</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Stockholders&#146; equity:</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Preferred stock, $0.0001 par value; 100,000,000 shares authorized, no shares issued or
outstanding, actual or as adjusted</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Common stock, $0.0001 par value; 125,000,000 shares authorized, 36,704,872 shares issued and
outstanding, actual;&nbsp;41,704,842&nbsp;shares issued and outstanding, as adjusted</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">3,671</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">4,171</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Additional <FONT STYLE="white-space:nowrap">paid-in</FONT> capital</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">249,785,412</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">285,784,912</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Accumulated deficit</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(143,502,830</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(143,502,830</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:5.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Total stockholders&#146; equity</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">106,286,253</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">142,286,253</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:7.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Total capitalization</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">113,845,777</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">149,845,777</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The foregoing table and calculations are based on 36,704,872 shares of our common stock outstanding as of March&nbsp;31, 2017,
and excludes: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">warrants to purchase 40,790 shares of common stock; and </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">5,485,881 shares of common stock reserved for issuance under our Amended and Restated 2013 Equity Incentive Plan as of March&nbsp;31, 2017, consisting of 4,059,346 shares of common stock subject to outstanding awards
and 1,426,535 shares of common stock that remain available under our Amended and Restated 2013 Equity Incentive Plan for future grants. </TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">S-15 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="suptoc382980_9"></A>DILUTION </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">If you invest in our common stock, your interest will be diluted immediately to the extent of the difference between the public offering price per share you
will pay in this offering and the as adjusted net tangible book value per share of our common stock after this offering. Net tangible book value per share represents our total tangible assets less total liabilities, divided by the number of shares
of our common stock outstanding. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">As of March&nbsp;31, 2017, our net tangible book value was $57.2&nbsp;million, or $1.56 per share of common stock. After
giving effect to our issuance and sale of 5,000,000&nbsp;shares of common stock in this offering at the public offering price of $7.75 per share, after deducting underwriting discounts and commissions and estimated offering expenses payable by us,
the as adjusted net tangible book value as of March&nbsp;31, 2017 would have been $93.2&nbsp;million, or $2.24 per share. This represents an immediate increase in as adjusted net tangible book value to existing stockholders of $0.68 per share and an
immediate dilution to new investors purchasing common stock in this offering of $5.51 per share. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The following table illustrates this per share dilution
to the new investors purchasing shares of common stock in this offering: </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>
<TD WIDTH="88%"></TD>
<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Public offering price per share</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">7.75</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Net tangible book value per share at March&nbsp;31, 2017</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">1.56</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Increase in net tangible book value per share attributable to new investors purchasing shares in
this offering</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">0.68</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">As adjusted net tangible book value per share after this offering</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">2.24</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Dilution per share to new investors in this offering</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">5.51</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">If the underwriters exercise their option to purchase additional shares in full, at the public offering price of $7.75 per
share, the as adjusted net tangible book value will increase to $2.32 per share, representing an immediate increase in net tangible book value to existing stockholders of $0.76 per share and immediate dilution in net tangible book value of $5.43 per
share to new investors. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The foregoing table and calculations are based on 36,704,872 shares of our common stock outstanding as of March&nbsp;31, 2017,
and excludes: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">warrants to purchase 40,790 shares of common stock; and </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">5,485,881 shares of common stock reserved for issuance under our Amended and Restated 2013 Equity Incentive Plan as of March&nbsp;31, 2017, consisting of 4,059,346 shares of common stock subject to outstanding awards
and 1,426,535 shares of common stock that remain available under our Amended and Restated 2013 Equity Incentive Plan for future grants. </TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">S-16 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="suptoc382980_10"></A>MATERIAL U.S. FEDERAL INCOME TAX CONSEQUENCES TO <FONT
STYLE="white-space:nowrap">NON-U.S.</FONT> HOLDERS </B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The following is a general discussion of the material U.S. federal income tax consequences of the
acquisition, ownership and disposition of our common stock by <FONT STYLE="white-space:nowrap">&#147;Non-U.S.</FONT> Holders&#148; (as defined below). This discussion is a summary for general information purposes only and does not consider all
aspects of U.S. federal income taxation that may be relevant to particular <FONT STYLE="white-space:nowrap">Non-U.S.</FONT> Holders in light of their individual circumstances or to certain types of <FONT STYLE="white-space:nowrap">Non-U.S.</FONT>
Holders subject to special tax rules under the Internal Revenue Code of 1986, as amended, or the Code, including partnerships or other pass-through entities for U.S. federal income tax purposes, banks, financial institutions or other financial
services entities, broker-dealers, insurance companies, <FONT STYLE="white-space:nowrap">tax-exempt</FONT> organizations, real estate investment trusts, controlled foreign corporations, passive foreign investment companies, corporations that
accumulate earnings to avoid U.S. federal income tax, persons who use or are required to use <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">mark-to-market</FONT></FONT> accounting, persons that hold our shares as part of a
&#147;straddle,&#148; a &#147;hedge&#148; or a &#147;conversion transaction,&#148; certain former citizens or permanent residents of the U.S., investors in pass-through entities, or persons subject to the alternative minimum tax. In addition, this
summary does not address the effects of any applicable gift or estate tax, and this summary does not address the potential application of the Medicare contribution tax or any tax considerations that may apply to
<FONT STYLE="white-space:nowrap">Non-U.S.</FONT> Holders of our common stock under state, local or <FONT STYLE="white-space:nowrap">non-U.S.</FONT> tax laws and any other U.S. federal tax laws. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">This summary is based on the Code and applicable Treasury Regulations, rulings, administrative pronouncements and judicial decisions as of the date of this
registration statement, all of which are subject to change or differing interpretations at any time with possible retroactive effect. We have not sought, and will not seek, any ruling from the Internal Revenue Service, or the IRS, with respect to
the tax consequences discussed herein, and there can be no assurance that the IRS will not take a position contrary to the tax consequences discussed below or that any position taken by the IRS would not be sustained. This discussion assumes that a <FONT
STYLE="white-space:nowrap">Non-U.S.</FONT> Holder will hold our common stock as a &#147;capital asset&#148; within the meaning of Section&nbsp;1221 of the Code (generally, property held for investment). For purposes of this discussion, the term <FONT
STYLE="white-space:nowrap">&#147;Non-U.S.</FONT> Holder&#148; means a beneficial owner of our shares that is not a partnership (or entity or arrangement treated as a partnership for U.S. federal income tax purposes) and is not: </P>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">an individual who is a citizen or resident of the United States; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">a corporation (or other entity treated as a corporation for U.S. federal income tax purposes) created or organized in the United States or under the laws of the United States or of any state thereof or the District of
Columbia; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">an estate, the income of which is subject to U.S. federal income tax regardless of its source; or </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">a trust if (1)&nbsp;a U.S. court can exercise primary supervision over the trust&#146;s administration and one or more U.S. persons have the authority to control all of the trust&#146;s substantial decisions or
(2)&nbsp;the trust has a valid election in effect under applicable U.S. Treasury Regulations to be treated as a U.S. person. </TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">If a
partnership (or entity or arrangement treated as a partnership for U.S. federal income tax purposes) or an entity that is treated as a disregarded entity for U.S. federal income tax purposes (regardless of its place of organization or formation) is
a beneficial owner of our common stock, the tax treatment of a partner in the partnership or the owner of the disregarded entity will generally depend upon the status of the partner or the owner of the disregarded entity and the activities of the
partnership or the disregarded entity. If you are a partner of a partnership holding our common stock or the owner of a disregarded entity holding our common stock, you should consult your tax advisor regarding the tax consequences of the purchase,
ownership, and disposition of our common stock. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">PROSPECTIVE INVESTORS SHOULD CONSULT THEIR TAX ADVISORS REGARDING THE PARTICULAR U.S. FEDERAL INCOME TAX
CONSEQUENCES TO THEM OF ACQUIRING, OWNING AND DISPOSING OF OUR COMMON STOCK, AS WELL AS ANY TAX CONSEQUENCES ARISING UNDER ANY STATE, LOCAL OR FOREIGN TAX LAWS AND ANY OTHER U.S. FEDERAL TAX LAWS. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">S-17 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Distributions on Our Common Stock </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">In general, subject to the discussion below under the headings &#147;Information Reporting and Backup Withholding&#148; and &#147;Foreign Accounts,&#148;
distributions, if any, paid on our common stock to a <FONT STYLE="white-space:nowrap">Non-U.S.</FONT> Holder (to the extent paid out of our current or accumulated earnings and profits, as determined under U.S. federal income tax principles) will
constitute dividends and be subject to U.S. withholding tax at a rate equal to 30% of the gross amount of the dividend, or a lower rate prescribed by an applicable income tax treaty, unless the dividends are effectively connected with a trade or
business carried on by the <FONT STYLE="white-space:nowrap">Non-U.S.</FONT> Holder within the United States. Any distribution not constituting a dividend (because such distribution exceeds our current and accumulated earnings and profits) will be
treated first as reducing the <FONT STYLE="white-space:nowrap">Non-U.S.</FONT> Holder&#146;s basis in its shares of common stock, but not below zero, and to the extent it exceeds the <FONT STYLE="white-space:nowrap">Non-U.S.</FONT> Holder&#146;s
basis, as capital gain from the sale or exchange of such stock (and will be treated as described below under &#147;Gain on Sale, Exchange or Other Disposition of Our Common Stock&#148;). </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">A <FONT STYLE="white-space:nowrap">Non-U.S.</FONT> Holder who claims the benefit of an applicable income tax treaty generally will be required to satisfy
certain certification and other requirements prior to the distribution date. <FONT STYLE="white-space:nowrap">Non-U.S.</FONT> Holders must generally provide the withholding agent with a properly executed IRS Form
<FONT STYLE="white-space:nowrap">W-8BEN,</FONT> Form <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">W-8BEN-E</FONT></FONT> or other appropriate form claiming an exemption from or reduction in withholding under an applicable income
tax treaty. This certification must be updated periodically. If a <FONT STYLE="white-space:nowrap">Non-U.S.</FONT> Holder holds our common stock through a financial institution or other agent acting on the
<FONT STYLE="white-space:nowrap">Non-U.S.</FONT> Holder&#146;s behalf, the <FONT STYLE="white-space:nowrap">Non-U.S.</FONT> Holder will be required to provide appropriate documentation to the agent, who then will be required to provide certification
to us or our paying agent, either directly or through other intermediaries. If tax is withheld in an amount in excess of the amount applicable under an income tax treaty, a refund of the excess amount may generally be obtained by timely filing an
appropriate claim for refund with the IRS. <FONT STYLE="white-space:nowrap">Non-U.S.</FONT> Holders should consult their tax advisors regarding their entitlement to benefits under an applicable income tax treaty. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Dividends that are effectively connected with a <FONT STYLE="white-space:nowrap">Non-U.S.</FONT> Holder&#146;s conduct of a U.S. trade or business (and, if
required by an applicable income tax treaty, attributable to a U.S. permanent establishment or fixed base of the <FONT STYLE="white-space:nowrap">Non-U.S.</FONT> Holder) generally will not be subject to U.S. withholding tax if the <FONT
STYLE="white-space:nowrap">Non-U.S.</FONT> Holder provides the withholding agent with the required forms, including IRS Form <FONT STYLE="white-space:nowrap">W-8ECI,</FONT> but instead generally will be subject to U.S. federal income tax on a net
income basis at the regular graduated rates in the same manner as if the <FONT STYLE="white-space:nowrap">Non-U.S.</FONT> Holder were a resident of the United States. A corporate <FONT STYLE="white-space:nowrap">Non-U.S.</FONT> Holder that receives
effectively connected dividends may also be subject to an additional branch profits tax at a rate of 30% (or a lower rate prescribed by an applicable income tax treaty) on its effectively connected earnings and profits for the taxable year, as
adjusted for certain items. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Gain on Sale, Exchange or Other Disposition of Our Common Stock </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">In general, subject to the discussion below under the headings &#147;Information Reporting and Backup Withholding&#148; and &#147;Foreign Accounts,&#148; a <FONT
STYLE="white-space:nowrap">Non-U.S.</FONT> holder will not be subject to any U.S. federal income tax or withholding tax on any gain realized upon such holder&#146;s sale, exchange or other disposition of shares of our common stock unless: </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">(i) the gain is effectively connected with a trade or business carried on by the <FONT STYLE="white-space:nowrap">Non-U.S.</FONT> Holder within the United
States (and, if required by an applicable income tax treaty, attributable to a U.S. permanent establishment or fixed base of the <FONT STYLE="white-space:nowrap">Non-U.S.</FONT> Holder); </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">(ii) the <FONT STYLE="white-space:nowrap">Non-U.S.</FONT> Holder is an individual who is present in the United States for 183 days or more in the taxable year
of disposition and certain other conditions are met; or </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">(iii) we are or have been a &#147;U.S. real property holding corporation&#148; for U.S. federal
income tax purposes at any time during the shorter of the five-year period ending on the date of disposition or the period that the <FONT STYLE="white-space:nowrap">Non-U.S.</FONT> </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">S-18 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
Holder held the common stock, and, in the case where shares of our common stock are regularly traded on an established securities market, the <FONT STYLE="white-space:nowrap">Non-U.S.</FONT>
Holder owns, or is treated as owning, more than five percent of our common stock at any time during the foregoing period. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Net gain realized by a <FONT
STYLE="white-space:nowrap">Non-U.S.</FONT> Holder described in clause (i)&nbsp;above generally will be subject to U.S. federal income tax in the same manner as if the <FONT STYLE="white-space:nowrap">Non-U.S.</FONT> Holder were a U.S. person. Any
gains of a corporate <FONT STYLE="white-space:nowrap">Non-U.S.</FONT> Holder described in clause (i)&nbsp;above may also be subject to an additional branch profits tax at a 30% rate, or such lower rate as may be specified by an applicable income tax
treaty. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Gain realized by an individual <FONT STYLE="white-space:nowrap">Non-U.S.</FONT> Holder described in clause (ii)&nbsp;above will be subject to a
flat 30% tax (or such lower rate specified by an applicable income tax treaty), which gain may be offset by certain U.S. source capital losses, even though the individual is not considered a resident of the U.S., provided that the <FONT
STYLE="white-space:nowrap">Non-U.S.</FONT> Holder has timely filed U.S. federal income tax returns with respect to such losses. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">For purposes of clause
(iii)&nbsp;above, a corporation is a &#147;U.S. real property holding corporation&#148; if the fair market value of its U.S. real property interests equals or exceeds 50% of the sum of the fair market value of its worldwide real property interests
plus its other assets used or held for use in a trade or business. We believe that we are not, and we do not anticipate that we will become, a U.S. real property holding corporation. However, because the determination of whether we are a U.S. real
property holding corporation depends on the fair market value of our U.S. real property interests relative to the fair market value of our other business assets, there can be no assurance that we will not become a U.S. real property holding
corporation in the future. If we become a U.S. real property holding corporation, as long as our common stock is regularly traded on an established securities market (within the meaning of the applicable Treasury Regulations), our common stock will
be treated as a U.S. real property interest only with respect to a <FONT STYLE="white-space:nowrap">Non-U.S.</FONT> Holder that directly or constructively held more than 5% of our common stock at any time during the shorter of the two periods
described in clause (iii), above. If we are a U.S. real property holding corporation and either our common stock is not regularly traded on an established securities market or a <FONT STYLE="white-space:nowrap">Non-U.S.</FONT> Holder holds more than
5% of our common stock, directly or constructively, during the applicable testing period, such <FONT STYLE="white-space:nowrap">Non-U.S.</FONT> Holder&#146;s proceeds received on the disposition of shares will generally be subject to withholding at
a rate of 10% and such <FONT STYLE="white-space:nowrap">Non-U.S.</FONT> Holder will generally be taxed on any gain in the same manner as gain that is effectively connected with the conduct of a U.S. trade or business, except that the branch profits
tax generally will not apply </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Information Reporting and Backup Withholding </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Generally, we must report annually to the IRS and to each <FONT STYLE="white-space:nowrap">Non-U.S.</FONT> Holder the amount of dividends paid, the name and
address of the recipient, and the amount, if any, of tax withheld. These information reporting requirements apply even if withholding was not required because the dividends were effectively connected with the
<FONT STYLE="white-space:nowrap">Non-U.S.</FONT> Holder&#146;s conduct of a trade or business within the United States or withholding was reduced by an applicable income tax treaty. Under applicable income tax treaties or other agreements, the IRS
may make its reports available to the tax authorities in the <FONT STYLE="white-space:nowrap">Non-U.S.</FONT> Holder&#146;s country of residence. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Dividends paid to a <FONT STYLE="white-space:nowrap">Non-U.S.</FONT> Holder that is not an exempt recipient generally will be subject to backup withholding,
currently at a rate of 28%, unless the <FONT STYLE="white-space:nowrap">Non-U.S.</FONT> Holder certifies to the withholding agent as to its foreign status, which certification may generally be made on IRS Form
<FONT STYLE="white-space:nowrap">W-8BEN,</FONT> Form <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">W-8BEN-E</FONT></FONT> or other appropriate version of IRS Form <FONT STYLE="white-space:nowrap">W-8.</FONT> Notwithstanding the
foregoing, backup withholding may apply if either we or our paying agent has actual knowledge, or reason to know, that the holder is a U.S. person that is not an exempt recipient. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Proceeds from the sale or other disposition of common stock by a <FONT STYLE="white-space:nowrap">Non-U.S.</FONT> Holder effected by or through a U.S. office
of a broker will generally be subject to information reporting and backup withholding, currently at a rate of 28%, unless the <FONT STYLE="white-space:nowrap">Non-U.S.</FONT> Holder certifies to the withholding agent under penalties of perjury as
to, among other things, its name, address and status as a <FONT STYLE="white-space:nowrap">Non-U.S.</FONT> Holder or otherwise establishes an exemption. Payment of </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">S-19 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
disposition proceeds effected outside the United States by or through a <FONT STYLE="white-space:nowrap">non-U.S.</FONT> office of a <FONT STYLE="white-space:nowrap">non-U.S.</FONT> broker
generally will not be subject to information reporting or backup withholding if the payment is not received in the United States. Information reporting, but generally not backup withholding (provided the broker does not have actual knowledge or
reason to know that the holder is a U.S. person that is not an exempt recipient), will apply to such a payment if the broker has certain connections with the United States unless the broker has documentary evidence in its records that the beneficial
owner thereof is a <FONT STYLE="white-space:nowrap">Non-U.S.</FONT> Holder and specified conditions are met or an exemption is otherwise established. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Backup withholding is not an additional tax. Any amount withheld under the backup withholding rules from a payment to a
<FONT STYLE="white-space:nowrap">Non-U.S.</FONT> Holder that results in an overpayment of taxes generally will be refunded, or credited against the holder&#146;s U.S. federal income tax liability, if any, provided that the required information is
timely furnished to the IRS. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Foreign Accounts </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The
Foreign Account Tax Compliance Act, or FATCA, generally imposes a 30% withholding tax on dividends on, and gross proceeds from the sale or disposition of, our common stock if paid to a foreign entity unless (i)&nbsp;if the foreign entity is a
&#147;foreign financial institution,&#148; the foreign entity undertakes certain due diligence, reporting, withholding, and certification obligations, (ii)&nbsp;if the foreign entity is not a &#147;foreign financial institution,&#148; the foreign
entity identifies certain U.S. holders of debt or equity interests in such foreign entity or (iii)&nbsp;the foreign entity is otherwise exempt from FATCA. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Withholding under FATCA generally (1)&nbsp;applies to payments of dividends on our common stock and (2)&nbsp;will apply to payments of gross proceeds from a
sale or other disposition of our common stock made after December&nbsp;31, 2018. An intergovernmental agreement between the United States and an applicable foreign country may modify the requirements described in this section. Under certain
circumstances, a <FONT STYLE="white-space:nowrap">Non-U.S.</FONT> Holder may be eligible for refunds or credits of the tax. <FONT STYLE="white-space:nowrap">Non-U.S.</FONT> Holders should consult their own tax advisors regarding the possible
implications of FATCA on their investment in our common stock. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">S-20 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="suptoc382980_11"></A>UNDERWRITING </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Subject to the terms and conditions set forth in the underwriting agreement, dated June&nbsp;28, 2017, between us and Citigroup Global Markets Inc. and
Jefferies LLC, as the representatives of the underwriters named below and the joint book-running managers of this offering, we have agreed to sell to the underwriters, and each of the underwriters has agreed, severally and not jointly, to purchase
from us, the respective number of shares of common stock shown opposite its name below: </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="68%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>
<TD WIDTH="82%"></TD>
<TD VALIGN="bottom" WIDTH="5%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom" NOWRAP> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00pt solid #000000; width:61.95pt; font-size:8pt; font-family:Times New Roman"><B>UNDERWRITER</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>NUMBER<BR>OF<BR>SHARES</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Citigroup Global Markets Inc.</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">2,125,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Jefferies LLC</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">2,125,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">JMP Securities LLC</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">750,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Total</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">5,000,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
</TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The underwriting agreement provides that the obligations of the several underwriters are subject to certain conditions
precedent such as the receipt by the underwriters of officers&#146; certificates and legal opinions and approval of certain legal matters by their counsel. The underwriting agreement provides that the underwriters will purchase all of the shares of
common stock if any of them are purchased. If an underwriter defaults, the underwriting agreement provides that the purchase commitments of the nondefaulting underwriters may be increased or the underwriting agreement may be terminated. We have
agreed to indemnify the underwriters and certain of their controlling persons against certain liabilities, including liabilities under the Securities Act, and to contribute to payments that the underwriters may be required to make in respect of
those liabilities. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The underwriters have advised us that, following the completion of this offering, they currently intend to make a market in the common
stock as permitted by applicable laws and regulations. However, the underwriters are not obligated to do so, and the underwriters may discontinue any market-making activities at any time without notice in their sole discretion. Accordingly, no
assurance can be given as to the liquidity of the trading market for the common stock, that you will be able to sell any of the common stock held by you at a particular time or that the prices that you receive when you sell will be favorable. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The underwriters are offering the shares of common stock subject to their acceptance of the shares of common stock from us and subject to prior sale. The
underwriters reserve the right to withdraw, cancel or modify offers to the public and to reject orders in whole or in part. In addition, the underwriters have advised us that they do not intend to confirm sales to any account over which they
exercise discretionary authority. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Commission and Expenses </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The underwriters have advised us that they propose to offer the shares of common stock to the public at the initial public offering price set forth on the
cover page of this prospectus and to certain dealers, which may include the underwriters, at that price less a concession not in excess of $0.279 per share of common stock. After the offering, the initial public offering price and concession may be
reduced by the representative. No such reduction will change the amount of proceeds to be received by us as set forth on the cover page of this prospectus. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">S-21 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The following table shows the public offering price, the underwriting discounts and commissions that we are to
pay the underwriters and the proceeds, before expenses, to us in connection with this offering. Such amounts are shown assuming both no exercise and full exercise of the underwriters&#146; option to purchase additional shares. </P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>
<TD WIDTH="88%"></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>PER SHARE</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>TOTAL</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>WITHOUT<BR>OPTION TO<BR>PURCHASE<BR>ADDITIONAL<BR>SHARES</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>WITH<BR>OPTION TO<BR>PURCHASE<BR>ADDITIONAL<BR>SHARES</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>WITHOUT<BR>OPTION TO<BR>PURCHASE<BR>ADDITIONAL<BR>SHARES</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>WITH<BR>OPTION TO<BR>PURCHASE<BR>ADDITIONAL<BR>SHARES</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Public offering price</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">7.75</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">7.75</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">38,750,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">44,562,500</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Underwriting discounts and commissions paid by us</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">0.465</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">0.465</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">2,325,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">2,673,750</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Proceeds to us, before expenses</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">7.285</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">7.285</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">36,425,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">41,888,750</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
</TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">We estimate expenses payable by us in connection with this offering, other than the underwriting discounts and commissions
referred to above, will be approximately $425,000. We have agreed to reimburse the underwriters a maximum of $20,000 for their FINRA counsel fee. In accordance with FINRA Rule 5110, this reimbursed fee is deemed underwriting compensation for this
offering. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Listing </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Our common stock is listed on The
NASDAQ Global Market under the trading symbol &#147;NERV&#148;. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Option to Purchase Additional Shares </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">We have granted to the underwriters an option, exercisable for 30 days from the date of this prospectus, to purchase, from time to time, in whole or in part,
up to an aggregate of 750,000&nbsp;shares from us at the public offering price set forth on the cover page of this prospectus, less underwriting discounts and commissions. If the underwriters exercise this option, each underwriter will be obligated,
subject to specified conditions, to purchase a number of additional shares proportionate to that underwriter&#146;s initial purchase commitment as indicated in the table above. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>No Sales of Similar Securities </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">We, our officers,
directors and certain of our principal stockholders have agreed, subject to specified exceptions, not to directly or indirectly: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">sell, offer, contract or grant any option to sell (including any short sale), pledge, transfer, establish an open &#147;put equivalent position&#148; within the meaning of Rule
<FONT STYLE="white-space:nowrap">16a-l(h)</FONT> under the Securities Exchange Act of 1934, as amended, or </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">otherwise dispose of any shares of common stock, options or warrants to acquire shares of common stock, or securities exchangeable or exercisable for or convertible into shares of common stock currently or hereafter
owned either of record or beneficially, or </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">publicly announce an intention to do any of the foregoing for a period of 90 days after the date of this prospectus without the prior written consent of Citigroup Global Markets Inc. and Jefferies LLC.
</TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">This restriction terminates after the close of trading of the common stock on and including the 90<SUP
STYLE="font-size:85%; vertical-align:top">th</SUP> day after the date of this prospectus. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Citigroup Global Markets Inc. and Jefferies LLC may, in their
sole discretion and at any time or from time to time before the termination of the <FONT STYLE="white-space:nowrap">90-day</FONT> period release all or any portion of the securities subject to <FONT STYLE="white-space:nowrap">lock-up</FONT>
agreements. There are no existing agreements between the underwriters and any of our shareholders who will execute a <FONT STYLE="white-space:nowrap">lock-up</FONT> agreement, providing consent to the sale of shares prior to the expiration of the <FONT
STYLE="white-space:nowrap">lock-up</FONT> period. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">S-22 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Stabilization </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The underwriters have advised us that they, pursuant to Regulation M under the Securities Exchange Act of 1934, as amended, and certain persons participating
in the offering may engage in short sale transactions, stabilizing transactions, syndicate covering transactions or the imposition of penalty bids in connection with this offering. These activities may have the effect of stabilizing or maintaining
the market price of the common stock at a level above that which might otherwise prevail in the open market. Establishing short sales positions may involve either &#147;covered&#148; short sales or &#147;naked&#148; short sales. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">&#147;Covered&#148; short sales are sales made in an amount not greater than the underwriters&#146; option to purchase additional shares of our common stock
in this offering. The underwriters may close out any covered short position by either exercising their option to purchase additional shares of our common stock or purchasing shares of our common stock in the open market. In determining the source of
shares to close out the covered short position, the underwriters will consider, among other things, the price of shares available for purchase in the open market as compared to the price at which they may purchase shares through the option to
purchase additional shares. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">&#147;Naked&#148; short sales are sales in excess of the option to purchase additional shares of our common stock. The
underwriters must close out any naked short position by purchasing shares in the open market. A naked short position is more likely to be created if the underwriters are concerned that there may be downward pressure on the price of the shares of our
common stock in the open market after pricing that could adversely affect investors who purchase in this offering. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">A stabilizing bid is a bid for the
purchase of shares of common stock on behalf of the underwriters for the purpose of fixing or maintaining the price of the common stock. A syndicate covering transaction is the bid for or the purchase of shares of common stock on behalf of the
underwriters to reduce a short position incurred by the underwriters in connection with the offering. Similar to other purchase transactions, the underwriter&#146;s purchases to cover the syndicate short sales may have the effect of raising or
maintaining the market price of our common stock or preventing or retarding a decline in the market price of our common stock. As a result, the price of our common stock may be higher than the price that might otherwise exist in the open market. A
penalty bid is an arrangement permitting the underwriters to reclaim the selling concession otherwise accruing to a syndicate member in connection with the offering if the common stock originally sold by such syndicate member are purchased in a
syndicate covering transaction and therefore have not been effectively placed by such syndicate member. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Neither we, nor any of the underwriters make any
representation or prediction as to the direction or magnitude of any effect that the transactions described above may have on the price of our common stock. The underwriters are not obligated to engage in these activities and, if commenced, any of
the activities may be discontinued at any time. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The underwriters may also engage in passive market making transactions in our common stock on The NASDAQ
Global Select Market in accordance with Rule 103 of Regulation M during a period before the commencement of offers or sales of shares of our common stock in this offering and extending through the completion of distribution. A passive market maker
must display its bid at a price not in excess of the highest independent bid of that security. However, if all independent bids are lowered below the passive market maker&#146;s bid, that bid must then be lowered when specified purchase limits are
exceeded. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Electronic Distribution </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">A prospectus in
electronic format may be made available by <FONT STYLE="white-space:nowrap">e-mail</FONT> or on the web sites or through online services maintained by one or more of the underwriters or their affiliates. In those cases, prospective investors may
view offering terms online and may be allowed to place orders online. The underwriters may agree with us to allocate </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">S-23 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
a specific number of shares of common stock for sale to online brokerage account holders. Any such allocation for online distributions will be made by the underwriters on the same basis as other
allocations. Other than the prospectus in electronic format, the information on the underwriters&#146; web sites and any information contained in any other web site maintained by any of the underwriters is not part of this prospectus, has not been
approved and/or endorsed by us or the underwriters and should not be relied upon by investors. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Other Activities and Relationships </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The underwriters and certain of their affiliates are full service financial institutions engaged in various activities, which may include securities trading,
commercial and investment banking, financial advisory, investment management, investment research, principal investment, hedging, financing and brokerage activities. The underwriters and certain of their affiliates have, from time to time,
performed, and may in the future perform, various commercial and investment banking and financial advisory services for us and our affiliates, for which they received or will receive customary fees and expenses. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">In the ordinary course of their various business activities, the underwriters and certain of their affiliates may make or hold a broad array of investments
and actively trade debt and equity securities (or related derivative securities) and financial instruments (including bank loans) for their own account and for the accounts of their customers, and such investment and securities activities may
involve securities and/or instruments issued by us and our affiliates. If the underwriters or their respective affiliates have a lending relationship with us, they routinely hedge their credit exposure to us consistent with their customary risk
management policies. The underwriters and their respective affiliates may hedge such exposure by entering into transactions which consist of either the purchase of credit default swaps or the creation of short positions in our securities or the
securities of our affiliates, including potentially the common stock offered hereby. Any such short positions could adversely affect future trading prices of the common stock offered hereby. The underwriters and certain of their respective
affiliates may also communicate independent investment recommendations, market color or trading ideas and/or publish or express independent research views in respect of such securities or instruments and may at any time hold, or recommend to clients
that they acquire, long and/or short positions in such securities and instruments. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">S-24 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="suptoc382980_11a"></A>NOTICE TO INVESTORS </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>European Economic Area </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">In relation to each member state
of the European Economic Area which has implemented the Prospectus Directive (each, a Relevant Member State), an offer to the public of any common shares which are the subject of the offering contemplated by this prospectus supplement and the
accompanying prospectus may not be made in that Relevant Member State except that an offer to the public in that Relevant Member State of any common shares may be made at any time under the following exemptions under the Prospectus Directive, if
they have been implemented in that Relevant Member State: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">to any legal entity which is a &#147;qualified investor&#148; as defined in the Prospectus Directive; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">to fewer than 150 natural or legal persons (other than qualified investors as defined in the Prospectus Directive), as permitted under the Prospectus Directive, subject to obtaining the prior consent of the underwriters
or the underwriters nominated by us for any such offer; or </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">in any other circumstances falling within Article&nbsp;3(2) of the Prospectus Directive, provided that no such offer of common shares shall require us or any of the underwriters to publish a prospectus pursuant to
Article&nbsp;3 of the Prospectus Directive or supplement a prospectus pursuant to Article&nbsp;16 of the Prospectus Directive. </TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">For the
purposes of this provision, the expression an &#147;offer common shares to the public&#148; in relation to the common shares in any Relevant Member State means the communication in any form and by any means of sufficient information on the terms of
the offer and the common shares to be offered so as to enable an investor to decide to purchase or subscribe to the common shares, as the same may be varied in that Relevant Member State by any measure implementing the Prospectus Directive in that
Relevant Member State and the expression &#147;Prospectus Directive&#148; means Directive 2003/71/EC (and amendments thereto, including Directive 2010/73/EU, the &#147;2010 PD Amending Directive&#148;), and includes any relevant implementing measure
in the Relevant Member State. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>United Kingdom </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">This
prospectus is only being distributed to, and is only directed at, persons in the United Kingdom that are qualified investors within the meaning of Article&nbsp;2(1)(e) of the Prospectus Directive that are also (i)&nbsp;investment professionals
falling within Article&nbsp;19(5) of the Financial Services and Markets Act 2000 (Financial Promotion) Order 2005, as amended (the &#147;Order&#148;) and/or (ii)&nbsp;high net worth entities falling within Article&nbsp;49(2)(a) to (d)&nbsp;of the
Order and other persons to whom it may lawfully be communicated (each such person being referred to as a &#147;relevant person&#148;). </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">This prospectus
supplement and the accompanying prospectus and their contents are confidential and should not be distributed, published or reproduced (in whole or in part) or disclosed by recipients to any other persons in the United Kingdom. Any person in the
United Kingdom that is not a relevant person should not act or rely on this document or any of its contents. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Bermuda </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Securities may be offered or sold in Bermuda only in compliance with the provisions of the Investment Business Act 2003 of Bermuda which regulates the sale of
securities in Bermuda and it is not intended for any offer or sale of shares to the public to take place in Bermuda. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Australia </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">This prospectus supplement and the accompanying prospectus are not a disclosure document for the purposes of Australia&#146;s Corporations Act 2001 (Cth) of
Australia, or Corporations Act, has not been lodged with the </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">S-25 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
Australian Securities&nbsp;&amp; Investments Commission and is only directed to the categories of exempt persons set out below. Accordingly, if you receive this prospectus supplement and the
accompanying prospectus in Australia: </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">You confirm and warrant that you are either: </P>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">a &#147;sophisticated investor&#148; under section&nbsp;708(8)(a) or (b)&nbsp;of the Corporations Act; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">a &#147;sophisticated investor&#148; under section&nbsp;708(8)(c) or (d)&nbsp;of the Corporations Act and that you have provided an accountant&#146;s certificate to the Company which complies with the requirements of
section&nbsp;708(8)(c)(i) or (ii)&nbsp;of the Corporations Act and related regulations before the offer has been made; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">a person associated with the Company under Section&nbsp;708(12) of the Corporations Act; or </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">a &#147;professional investor&#148; within the meaning of section&nbsp;708(11)(a) or (b)&nbsp;of the Corporations Act. </TD></TR></TABLE>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">To the extent that you are unable to confirm or warrant that you are an exempt sophisticated investor, associated person or professional investor under the
Corporations Act any offer made to you under this prospectus supplement and the accompanying prospectus is void and incapable of acceptance. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">You warrant
and agree that you will not offer any of the securities issued to you pursuant to this prospectus supplement and the accompanying prospectus for resale in Australia within 12&nbsp;months of those securities being issued unless any such resale offer
is exempt from the requirement to issue a disclosure document under section&nbsp;708 of the Corporations Act. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Hong Kong </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">No securities have been offered or sold, and no securities may be offered or sold, in Hong Kong, by means of any document, other than to persons whose ordinary
business is to buy or sell shares or debentures, whether as principal or agent; or to &#147;professional investors&#148; as defined in the Securities and Futures Ordinance (Cap. 571) of Hong Kong (&#147;SFO&#148;) and any rules made under that
Ordinance; or in other circumstances which do not result in the document being a &#147;prospectus&#148; as defined in the Companies Ordinance (Cap. 32)&nbsp;of Hong Kong (&#147;CO&#148;) or which do not constitute an offer or invitation to the
public for the purpose of the CO or the SFO. No document, invitation or advertisement relating to the securities has been issued or may be issued or may be in the possession of any person for the purpose of issue (in each case whether in Hong Kong
or elsewhere), which is directed at, or the contents of which are likely to be accessed or read by, the public of Hong Kong (except if permitted under the securities laws of Hong Kong) other than with respect to securities which are or are intended
to be disposed of only to persons outside Hong Kong or only to &#147;professional investors&#148; as defined in the SFO and any rules made under that Ordinance. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">This prospectus supplement and the accompanying prospectus have not been registered with the Registrar of Companies in Hong Kong. Accordingly, this prospectus
supplement and the accompanying prospectus may not be issued, circulated or distributed in Hong Kong, and the securities may not be offered for subscription to members of the public in Hong Kong. Each person acquiring the securities will be
required, and is deemed by the acquisition of the securities, to confirm that he is aware of the restriction on offers of the securities described in this prospectus and the relevant offering documents and that he is not acquiring, and has not been
offered any securities in circumstances that contravene any such restrictions. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Israel </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">This document does not constitute a prospectus under the Israeli Securities Law, 5728-1968, and has not been filed with or approved by the Israel Securities
Authority. In Israel, this prospectus is being distributed only to, and any offer of the shares of our common stock is directed only at investors listed in the first addendum, or the Addendum, to the Israeli Securities Law, consisting primarily of
joint investment in trust funds, provident funds, </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">S-26 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
insurance companies, banks, portfolio managers, investment advisors, members of the Tel Aviv Stock Exchange, underwriters, venture capital funds, entities with equity in excess of NIS
50&nbsp;million and &#147;qualified individuals,&#148; each as defined in the Addendum (as it may be amended from time to time), collectively referred to as qualified investors (in each case, purchasing for their own account or, where permitted
under the Addendum, for the accounts of their clients who are investors listed in the Addendum). Qualified investors are required to submit written confirmation that they fall within the scope of the Addendum. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Japan </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The offering has not been and will not be
registered under the Financial Instruments and Exchange Law of Japan (Law No.&nbsp;25 of 1948 of Japan, as amended), or FIEL, and the initial purchaser will not offer or sell any securities, directly or indirectly, in Japan or to, or for the benefit
of, any resident of Japan (which term as used herein means any person resident in Japan, including any corporation or other entity organized under the laws of Japan), or to others for <FONT STYLE="white-space:nowrap">re-offering</FONT> or resale,
directly or indirectly, in Japan or to, or for the benefit of, any resident of Japan, except pursuant to an exemption from the registration requirements of, and otherwise in compliance with, the FIEL and any other applicable laws, regulations and
ministerial guidelines of Japan. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Singapore </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">This
prospectus supplement and the accompanying prospectus have not been and will not be lodged or registered as a prospectus with the Monetary Authority of Singapore. Accordingly, this prospectus supplement and the accompanying prospectus and any other
document or material in connection with the offer or sale, or invitation for subscription or purchase, of the securities may not be circulated or distributed, nor may the securities be offered or sold, or be made the subject of an invitation for
subscription or purchase, whether directly or indirectly, to persons in Singapore other than (i)&nbsp;to an institutional investor under Section&nbsp;274 of the Securities and Futures Act, Chapter&nbsp;289 of Singapore (the &#147;SFA&#148;),
(ii)&nbsp;to a relevant person pursuant to Section&nbsp;275(1), or any person pursuant to Section&nbsp;275(1A), and in accordance with the conditions specified in Section&nbsp;275, of the SFA, or (iii)&nbsp;otherwise pursuant to, and in accordance
with the conditions of, any other applicable provision of the SFA. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Where the securities are subscribed or purchased under Section&nbsp;275 of the SFA by
a relevant person which is: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">a corporation (which is not an accredited investor (as defined in Section&nbsp;4A of the SFA)) the sole business of which is to hold investments and the entire share capital of which is owned by one or more individuals,
each of whom is an accredited investor; or </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">a trust (where the trustee is not an accredited investor) whose sole purpose is to hold investments and each beneficiary of the trust is an individual who is an accredited investor, </TD></TR></TABLE>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">securities (as defined in Section&nbsp;239(1) of the SFA) of that corporation or the beneficiaries&#146; rights and interest (howsoever described) in that
trust shall not be transferred within six months after that corporation or that trust has acquired the securities pursuant to an offer made under Section&nbsp;275 of the SFA except: </P>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">to an institutional investor or to a relevant person defined in Section&nbsp;275(2) of the SFA, or to any person arising from an offer referred to in Section&nbsp;275(1A) or Section&nbsp;276(4)(i)(B) of the SFA;
</TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">where no consideration is or will be given for the transfer; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">where the transfer is by operation of law; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">as specified in Section&nbsp;276(7) of the SFA; or </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">as specified in Regulation&nbsp;32 of the Securities and Futures (Offers of Investments) (Shares and Debentures) Regulations&nbsp;2005 of Singapore. </TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">S-27 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Switzerland </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The common shares may not be publicly offered in Switzerland and will not be listed on the SIX Swiss Exchange, or SIX, or on any other stock exchange or
regulated trading facility in Switzerland. This document has been prepared without regard to the disclosure standards for issuance prospectuses under art. 652a of the CO or the disclosure standards for listing prospectuses under art. 27 ff. of the
SIX Listing Rules or the listing rules of any other stock exchange or regulated trading facility in Switzerland. Neither this prospectus supplement and the accompanying prospectus nor any other offering or marketing relating to the common shares or
this offering may be publicly distributed or otherwise made publicly available in Switzerland. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Neither this document nor any other offering or marketing
material relating to this offering, the Company or the common shares has been or will be filed with or approved by any Swiss regulatory authority. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Canada </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Resale Restrictions </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The distribution of shares in Canada is being made only in the provinces of Ontario, Qu&eacute;bec, Manitoba, Alberta and British Columbia on a private
placement basis exempt from the requirement that we prepare and file a prospectus with the securities regulatory authorities in each province where trades of these securities are made. Any resale of the shares in Canada must be made under applicable
securities laws which may vary depending on the relevant jurisdiction, and which may require resales to be made under available statutory exemptions or under a discretionary exemption granted by the applicable Canadian securities regulatory
authority. Purchasers are advised to seek legal advice prior to any resale of the securities. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Representations of Canadian Purchasers </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">By purchasing shares in Canada and accepting delivery of a purchase confirmation, a purchaser is representing to us and the dealer from whom the purchase
confirmation is received that: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">the purchaser is entitled under applicable provincial securities laws to purchase the shares without the benefit of a prospectus qualified under those securities laws as it is an &#147;accredited investor&#148; as
defined under National Instrument <FONT STYLE="white-space:nowrap">45-106&#151;Prospectus</FONT> Exemptions, </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">the purchaser is a &#147;permitted client&#148; as defined in National Instrument <FONT STYLE="white-space:nowrap">31-103&#151;Registration</FONT> Requirements, Exemptions and Ongoing Registrant Obligations,
</TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">where required by law, the purchaser is purchasing as principal and not as agent, and </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">the purchaser has reviewed the text above under Resale Restrictions. </TD></TR></TABLE> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Conflicts of Interest </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Canadian purchasers are hereby notified that certain of the underwriters are relying on the exemption set out in section 3A.3 or 3A.4, if applicable, of
National Instrument <FONT STYLE="white-space:nowrap">33-105&#151;Underwriting</FONT> Conflicts from having to provide certain conflict of interest disclosure in this document. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Statutory Rights of Action </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Securities legislation
in certain provinces or territories of Canada may provide a purchaser with remedies for rescission or damages if the offering memorandum (including any amendment thereto) such as this document contains a misrepresentation, provided that the remedies
for rescission or damages are exercised by the purchaser within the time limit prescribed by the securities legislation of the purchaser&#146;s province or territory. The purchaser of these securities in Canada should refer to any applicable
provisions of the securities legislation of the purchaser&#146;s province or territory for particulars of these rights or consult with a legal advisor. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">S-28 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Enforcement of Legal Rights </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">All of our directors and officers as well as the experts named herein may be located outside of Canada and, as a result, it may not be possible for Canadian
purchasers to effect service of process within Canada upon us or those persons. All or a substantial portion of our assets and the assets of those persons may be located outside of Canada and, as a result, it may not be possible to satisfy a
judgment against us or those persons in Canada or to enforce a judgment obtained in Canadian courts against us or those persons outside of Canada. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Taxation and Eligibility for Investment </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Canadian
purchasers of shares should consult their own legal and tax advisors with respect to the tax consequences of an investment in the shares in their particular circumstances and about the eligibility of the shares for investment by the purchaser under
relevant Canadian legislation. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">S-29 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="suptoc382980_12"></A>LEGAL MATTERS </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The validity of the common stock being offered in this offering will be passed upon for us by Cooley LLP, Boston, Massachusetts. Goodwin Procter LLP, New
York, New York, is counsel to the underwriters in connection with this offering. </P> <P STYLE="margin-top:24pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="suptoc382980_13"></A>EXPERTS </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The consolidated financial statements of Minerva Neurosciences, Inc. at December&nbsp;31, 2016 and 2015, and for the three years in the period ended
December&nbsp;31, 2016, incorporated in this prospectus supplement by reference from the Company&#146;s Annual Report on Form <FONT STYLE="white-space:nowrap">10-K</FONT> have been audited by Deloitte&nbsp;&amp; Touche LLP, independent registered
public accounting firm, as stated in their report which is incorporated by reference herein. Such financial statements have been so incorporated in reliance upon the report of such firm given upon their authority as experts in accounting and
auditing. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">S-30 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="suptoc382980_14"></A>WHERE YOU CAN FIND MORE INFORMATION </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">This prospectus supplement and the accompanying prospectus form part of a registration statement on Form <FONT STYLE="white-space:nowrap">S-3</FONT> that we
filed with the SEC. This prospectus supplement and the accompanying prospectus do not contain all of the information set forth in the registration statement and the exhibits to the registration statement or the documents incorporated by reference
herein and therein. For further information with respect to us and the securities that we are offering under this prospectus supplement, we refer you to the registration statement and the exhibits and schedules filed as a part of the registration
statement and the documents incorporated by reference herein and therein. You should rely only on the information contained in this prospectus supplement or the accompanying prospectus or incorporated by reference herein or therein. We have not
authorized anyone else to provide you with different information. We are not making an offer of these securities in any state where the offer is not permitted. You should not assume that the information in this prospectus supplement is accurate as
of any date other than the date on the front page of this prospectus supplement, regardless of the time of delivery of this prospectus supplement or any sale of the securities offered hereby. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">We file annual, quarterly and current reports, proxy statements and other information with the SEC. You may read and copy the registration statement, as well
as any other document filed by us with the SEC, at the SEC&#146;s Public Reference Room at 100 F Street NE, Washington, D.C. 20549. You can also request copies of these documents by writing to the SEC and paying a fee for the copying cost. You may
obtain information on the operation of the Public Reference Room by calling the SEC at <FONT STYLE="white-space:nowrap">(800)&nbsp;SEC-0330.</FONT> The SEC maintains a website that contains reports, proxy statements and other information regarding
issuers that file electronically with the SEC, including Minerva Neurosciences. The address of the SEC website is <I>www.sec.gov</I>. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">We maintain a
website at <I>www.minervaneurosciences.com</I>. Information contained in or accessible through our website does not constitute a part of this prospectus. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">S-31 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="suptoc382980_15"></A>INCORPORATION OF CERTAIN INFORMATION BY REFERENCE </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The SEC allows us to &#147;incorporate by reference&#148; information into this prospectus supplement, which means that we can disclose important information
to you by referring you to another document filed separately with the SEC. The SEC file number for the documents incorporated by reference in this prospectus is <FONT STYLE="white-space:nowrap">001-36517.</FONT> The documents incorporated by
reference into this prospectus supplement contain important information that you should read about us. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The following documents are
incorporated by reference into this document: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">our Annual Report on Form <FONT STYLE="white-space:nowrap">10-K</FONT> for the fiscal year ended December&nbsp;31, 2016 filed with the SEC on March&nbsp;13, 2017; </TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">our Quarterly Report on Form <FONT STYLE="white-space:nowrap">10-Q</FONT> for the quarter ended March&nbsp;31, 2017 filed with the SEC on May&nbsp;4, 2017; </TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">those portions of our Definitive Proxy Statement on Schedule 14A for our 2017 Annual Meeting of Stockholders filed with the SEC on April&nbsp;18, 2017 that are incorporated by reference into our Annual Report on Form <FONT
STYLE="white-space:nowrap">10-K</FONT> for the fiscal year ended December&nbsp;31, 2016; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">our Current Reports on Form <FONT STYLE="white-space:nowrap">8-K</FONT> (other than information furnished rather than filed) filed with the SEC on January&nbsp;6, 2017, January&nbsp;20, 2017, February&nbsp;27, 2017,
March&nbsp;21, 2017, May&nbsp;15, 2017, May&nbsp;31, 2017, June&nbsp;2, 2017 and June&nbsp;14, 2017. </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">the description of our common stock, which is registered under Section&nbsp;12 of the Exchange Act, in our registration statement on Form <FONT STYLE="white-space:nowrap">8-A,</FONT> filed with the SEC on June&nbsp;23,
2014, including any amendments or reports filed for the purpose of updating such description. </TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">We also incorporate by reference into this
prospectus all documents (other than current reports furnished under Item&nbsp;2.02 or Item&nbsp;7.01 of Form <FONT STYLE="white-space:nowrap">8-K</FONT> and exhibits filed on such form that are related to such items) that are filed by us with the
SEC pursuant to Sections 13(a), 13(c), 14 or 15(d) of the Exchange Act after the date of this prospectus supplement but prior to the termination of the offering. These documents include periodic reports, such as Annual Reports on Form <FONT
STYLE="white-space:nowrap">10-K,</FONT> Quarterly Reports on Form <FONT STYLE="white-space:nowrap">10-Q</FONT> and Current Reports on Form <FONT STYLE="white-space:nowrap">8-K,</FONT> as well as proxy statements. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Any statement contained herein or in a document incorporated or deemed to be incorporated by reference into this document will be deemed to be modified or
superseded for purposes of the document to the extent that a statement contained in this document or any other subsequently filed document that is deemed to be incorporated by reference into this document modifies or supersedes the statement. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">S-32 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><B>PROSPECTUS </B></P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="margin-top:0pt;margin-bottom:0pt" ALIGN="center">


<IMG SRC="g382980g82i05.jpg" ALT="LOGO">
 </P> <P STYLE="margin-top:5pt; margin-bottom:0pt; font-size:18pt; font-family:ARIAL" ALIGN="center"><B>$150,000,000 </B></P>
<P STYLE="margin-top:5pt; margin-bottom:0pt; font-size:14pt; font-family:ARIAL" ALIGN="center"><B>Common Stock </B></P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:14pt; font-family:ARIAL" ALIGN="center"><B>Preferred Stock </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:14pt; font-family:ARIAL" ALIGN="center"><B>Debt Securities </B></P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:14pt; font-family:ARIAL" ALIGN="center"><B>Warrants </B></P>
<P STYLE="font-size:5pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><center> <P STYLE="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000;width:21%">&nbsp;</P></center>
<P STYLE="margin-top:5pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL">From time to time, we may offer and sell up to $150,000,000 of any combination of our common stock, preferred stock, debt securities or warrants described in this
prospectus, either individually or in combination. We may also offer common stock or preferred stock upon the conversion of debt securities, common stock upon the conversion of preferred stock, or common stock, preferred stock or debt securities
upon the exercise of warrants. </P> <P STYLE="margin-top:5pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL">This prospectus provides a general description of the securities we may offer. Each time we offer securities we will provide the
specific terms of the securities offered in a supplement to this prospectus. We may also authorize one or more free writing prospectuses to be provided to you in connection with these offerings. The prospectus supplement and any related free writing
prospectus may also add, update or change information contained in this prospectus. You should carefully read this prospectus, the applicable prospectus supplement and any related free writing prospectus, as well as any documents incorporated by
reference, before you invest in any of the securities being offered. </P> <P STYLE="margin-top:5pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL">Our common stock is traded on the Nasdaq Global Market under the symbol &#147;NERV.&#148; On
July&nbsp;20, 2015, the closing sale price of our common stock on the Nasdaq Global Market was $6.36 per share. The applicable prospectus supplement will contain information, where applicable, as to other listings, if any, on the Nasdaq Global
Market or any other securities exchange of the securities covered by the applicable prospectus supplement. </P> <P STYLE="font-size:5pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><center>
<P STYLE="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000;width:21%">&nbsp;</P></center> <P STYLE="margin-top:5pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><B>Investing in our securities involves a
high degree of risk. You should review carefully the risks and uncertainties described under the heading &#147;<A HREF="#rom 382980_3">Risk Factors</A>&#148; contained in the applicable prospectus supplement and in any free writing prospectuses we
have authorized for use in connection with a specific offering, and under similar headings in the documents that are incorporated by reference into this prospectus. </B></P>
<P STYLE="font-size:5pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><center> <P STYLE="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000;width:21%">&nbsp;</P></center>
<P STYLE="margin-top:5pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><B>This prospectus may not be used to consummate a sale of securities unless accompanied by a prospectus supplement. </B></P>
<P STYLE="margin-top:5pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL">The securities may be sold directly by us to investors, through agents designated from time to time or to or through underwriters or dealers, on a continuous or delayed
basis. For additional information on the methods of sale, you should refer to the section titled &#147;Plan of Distribution&#148; in this prospectus. If any agents or underwriters are involved in the sale of any securities with respect to which this
prospectus is being delivered, the names of such agents or underwriters and any applicable fees, commissions, discounts and over-allotment options will be set forth in a prospectus supplement. The price to the public of such securities and the net
proceeds we expect to receive from such sale will also be set forth in a prospectus supplement. </P> <P STYLE="margin-top:5pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><B>Neither the Securities and Exchange Commission nor any state
securities commission has approved or disapproved of these securities or determined if this prospectus is truthful or complete. Any representation to the contrary is a criminal offense. </B></P>
<P STYLE="margin-top:5pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center"><B>Prospectus dated July 27, 2015. </B></P>

<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center"><B>TABLE OF CONTENTS </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" ALIGN="center">


<TR>
<TD WIDTH="96%"></TD>
<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL"><A HREF="#rom382980_1">ABOUT THIS PROSPECTUS</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">i</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL"><A HREF="#rom382980_2">PROSPECTUS SUMMARY</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL"><A HREF="#rom382980_3">RISK FACTORS</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">5</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL"><A HREF="#rom382980_4">SPECIAL NOTE REGARDING FORWARD-LOOKING STATEMENTS</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">5</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL"><A HREF="#rom382980_5">USE OF PROCEEDS</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">6</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL"><A HREF="#rom382980_6">DESCRIPTION OF CAPITAL STOCK</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">7</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL"><A HREF="#rom382980_7">DESCRIPTION OF DEBT SECURITIES</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">12</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL"><A HREF="#rom382980_8">DESCRIPTION OF WARRANTS</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">19</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL"><A HREF="#rom382980_9">LEGAL OWNERSHIP OF SECURITIES</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">22</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL"><A HREF="#rom382980_10">PLAN OF DISTRIBUTION</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">26</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL"><A HREF="#rom382980_11">LEGAL MATTERS</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">28</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL"><A HREF="#rom382980_12">EXPERTS</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">28</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL"><A HREF="#rom382980_13">WHERE YOU CAN FIND MORE INFORMATION</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">28</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL"><A HREF="#rom382980_14">INCORPORATION OF CERTAIN INFORMATION BY REFERENCE</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">28</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
</TABLE> <P STYLE="margin-top:24pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center"><B><A NAME="rom382980_1"></A>ABOUT THIS PROSPECTUS </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL">This prospectus is part of a registration statement on Form S-3 that we filed with the Securities and Exchange Commission, or SEC, utilizing a &#147;shelf&#148;
registration process. Under this shelf registration process, we may offer and sell, either individually or in combination, in one or more offerings, up to a total dollar amount of $150,000,000 of any combination of the securities described in this
prospectus. This prospectus provides you with a general description of the securities we may offer. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL">Each time we offer securities under this prospectus, we will
provide a prospectus supplement that will contain specific information about the terms of that offering. We may also authorize one or more free writing prospectuses to be provided to you that may contain material information relating to these
offerings. The prospectus supplement and any related free writing prospectus that we may authorize to be provided to you may also add, update or change any of the information contained in this prospectus or in the documents that we have incorporated
by reference into this prospectus. We urge you to read this prospectus, any applicable prospectus supplement and any free writing prospectuses we have authorized for use in connection with a specific offering, together with the information
incorporated herein by reference as described under the heading &#147;Incorporation of Certain Information by Reference,&#148; carefully before buying any of the securities being offered. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><B>This prospectus may not be used to consummate a sale of securities unless it is accompanied by a prospectus supplement. </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL">You should rely only on the information contained in, or incorporated by reference into, this prospectus and any applicable prospectus supplement, along with the
information contained in any free writing prospectuses we have authorized for use in connection with a specific offering. We have not authorized anyone to provide you with different or additional information. This prospectus is an offer to sell only
the securities offered hereby, but only under circumstances and in jurisdictions where it is lawful to do so. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL">You should not assume that the information contained
in this prospectus, any applicable prospectus supplement or any related free writing prospectus is accurate on any date subsequent to the date set forth on the front of the document or that any information we have incorporated by reference is
correct on any date subsequent to the date of the document incorporated by reference, even though this prospectus, any applicable prospectus supplement or any related free writing prospectus is delivered, or securities are sold, on a later date. Our
business, financial condition, results of operations and prospects may have changed since those dates. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center">i </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL">To the extent there is a conflict between the information contained in this prospectus, on the one hand, and the
information contained in any document incorporated by reference filed with the SEC before the date of this prospectus, on the other hand, you should rely on the information in this prospectus. If any statement in a document incorporated by reference
is inconsistent with a statement in another document incorporated by reference having a later date, the statement in the document having the later date modifies or supersedes the earlier statement. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL">This prospectus contains summaries of certain provisions contained in some of the documents described herein, but reference is made to the actual documents for complete
information. All of the summaries are qualified in their entirety by the actual documents. Copies of some of the documents referred to herein have been filed, will be filed or will be incorporated by reference as exhibits to the registration
statement of which this prospectus is a part, and you may obtain copies of those documents as described below in the section titled &#147;Where You Can Find More Information.&#148; </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center">ii </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<div style ="BORDER-BOTTOM:1.00pt solid #000000;BORDER-LEFT:1.00pt solid #000000;BORDER-RIGHT:1.00pt solid #000000;BORDER-TOP:1.00pt solid #000000;MARGIN-LEFT:0px;MARGIN-RIGHT:0px;max-width:100%"><div style="width:97%; margin-top:1.5%; margin-left:1.5%; margin-right:-1.25%">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center"><B><A NAME="rom382980_2"></A>PROSPECTUS SUMMARY </B></P>
<P STYLE="margin-top:11pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:ARIAL"><I>This summary highlights selected information contained elsewhere in this prospectus or incorporated by reference in this prospectus, and does not
contain all of the information that you need to consider in making your investment decision. You should carefully read the entire prospectus (as supplemented and amended), including the risks of investing in our securities discussed under the
heading &#147;Risk Factors&#148; contained in this prospectus (as supplemented and amended), and under similar headings in the other documents that are incorporated by reference into this prospectus. You also should carefully read the information
incorporated by reference into this prospectus, including our financial data and related notes, and the exhibits to the registration statement of which this prospectus is a part. Unless otherwise mentioned or unless the context requires otherwise,
all references in this report to &#147;we,&#148; &#147;our,&#148; &#147;us,&#148; or similar references mean Minerva Neurosciences, Inc., a Delaware corporation. </I></P>
<P STYLE="margin-top:17pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center"><B>Minerva Neurosciences, Inc. </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL">We are a clinical-stage
biopharmaceutical company focused on the development and commercialization of a portfolio of product candidates to treat patients suffering from central nervous system, or CNS, diseases. Leveraging our deep domain expertise, we have acquired or
in-licensed four development-stage proprietary compounds that we believe have innovative mechanisms of action with potentially positive therapeutic profiles. Our lead product candidate is MIN-101, a compound for the potential treatment of patients
with schizophrenia. In addition, our portfolio includes MIN-202, a compound we are co-developing with Janssen Pharmaceuticals for the treatment of patients suffering from primary and comorbid insomnia, MIN-117, a compound we are developing for the
treatment of patients suffering from major depressive disorder, and MIN-301, a compound we are developing for the treatment of patients suffering from Parkinson&#146;s disease. </P>
<P STYLE="margin-top:17pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><B>Company Information </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL">We were incorporated under the name Cyrenaic
Pharmaceuticals, Inc. under the laws of the State of Delaware on April&nbsp;23, 2007. In November 2013, we merged with Sonkei Pharmaceuticals, Inc. and the combined company was renamed Minerva Neurosciences, Inc. </P>
<P STYLE="margin-top:11pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL">Our principal executive offices are located at 1601 Trapelo Road, Suite 284, Waltham, Massachusetts 02451 and our phone number is (617)&nbsp;600-7373. Our website
address is www.minervaneurosciences.com. The information contained on our website is not incorporated by reference into this prospectus, and you should not consider any information contained on, or that can be accessed through, our website as part
of this prospectus (other than those filings with the SEC that we specifically incorporate by reference into this prospectus). </P> <P STYLE="margin-top:11pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL">We are an &#147;emerging growth
company,&#148; as defined in the Jumpstart Our Business Startups Act of 2012, or JOBS Act. We will cease to be an emerging growth company on the date that is the earliest of (i)&nbsp;the last day of the fiscal year in which we have total annual
gross revenues of $1.0 billion or more; (ii)&nbsp;December&nbsp;31, 2019; (iii)&nbsp;the date on which we have issued more than $1.0 billion in non-convertible debt during the previous three years; or (iv)&nbsp;the date on which we are deemed to be
a large accelerated filer under the rules of the SEC. </P> <P STYLE="margin-top:17pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><B>The Securities We May Offer </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL">We may offer shares of our common stock and preferred stock, various series of debt securities and/or warrants to purchase any of such securities, either individually or
in combination, up to a total dollar amount of $150,000,000, from time to time under this prospectus, together with the applicable prospectus supplement and any related free writing prospectus, at prices and on terms to be determined
</P>
</div><br clear="All"></div><br clear="All">


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<div style ="BORDER-BOTTOM:1.00pt solid #000000;BORDER-LEFT:1.00pt solid #000000;BORDER-RIGHT:1.00pt solid #000000;BORDER-TOP:1.00pt solid #000000;MARGIN-LEFT:0px;MARGIN-RIGHT:0px;max-width:100%"><div style="width:97%; margin-top:1.5%; margin-left:1.5%; margin-right:-1.25%">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL">
by market conditions at the time of the relevant offering. We may also offer common stock, preferred stock and/or debt securities upon the exercise of warrants. This prospectus provides you with
a general description of the securities we may offer. Each time we offer a type or series of securities under this prospectus, we will provide a prospectus supplement that will describe the specific amounts, prices and other important terms of the
securities, including, to the extent applicable: </P> <P STYLE="font-size:5pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">designation or classification; </TD></TR></TABLE> <P STYLE="font-size:5pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">aggregate principal amount or aggregate offering price; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">maturity date, if applicable; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">original issue discount, if any; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">rates and times of payment of interest or dividends, if any; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">redemption, conversion, exercise, exchange or sinking fund terms, if any; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">conversion or exchange prices or rates, if any, and, if applicable, any provisions for changes to or adjustments in the conversion or exchange prices or rates and in the securities or other property receivable upon
conversion or exchange; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">ranking, if applicable; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">restrictive covenants, if any; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">voting or other rights, if any; and </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">material or special U.S. federal income tax considerations, if any. </TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL">The applicable prospectus supplement and any
related free writing prospectus that we may authorize to be provided to you may also add, update or change any of the information contained in this prospectus or in the documents we have incorporated by reference. However, no prospectus supplement
or free writing prospectus will offer a security that is not registered and described in this prospectus at the time of the effectiveness of the registration statement of which this prospectus is a part. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><B>This prospectus may not be used to consummate a sale of securities unless it is accompanied by a prospectus supplement. </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL">We may sell the securities directly to investors or to or through agents, underwriters or dealers. We, and our agents or underwriters, reserve the right to accept or
reject all or part of any proposed purchase of securities. If we do offer securities to or through agents or underwriters, we will include in the applicable prospectus supplement: </P>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">the names of those agents or underwriters; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">applicable fees, discounts and commissions to be paid to them; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">details regarding over-allotment options, if any; and </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">the estimated net proceeds to us. </TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><I>Common Stock</I>. We may issue shares of our common stock from time to time. The
holders of our common stock are entitled to one vote for each share held of record on all matters submitted to a vote of stockholders. Subject to preferences that may be applicable to any then outstanding shares of preferred stock, the holders of
common stock are entitled to receive ratably such dividends as may be declared by our board of directors out of legally available funds. Upon our liquidation, dissolution or winding up, holders of our common stock are entitled to share ratably in
all assets legally available for<I> </I></P>
 <P STYLE="margin-top:0pt;margin-bottom:0pt; font-size:8pt">&nbsp;</P></div><br clear="All"></div><br clear="All">

 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center">2 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<div style ="BORDER-BOTTOM:1.00pt solid #000000;BORDER-LEFT:1.00pt solid #000000;BORDER-RIGHT:1.00pt solid #000000;BORDER-TOP:1.00pt solid #000000;MARGIN-LEFT:0px;MARGIN-RIGHT:0px;max-width:100%"><div style="width:97%; margin-top:1.5%; margin-left:1.5%; margin-right:-1.25%">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><I>
</I>distribution to stockholders remaining after payment of liabilities and the liquidation preferences of any outstanding shares of preferred stock. Holders of common stock have no<I>
</I>preemptive rights and no right to convert their common stock into any other securities. There are no redemption<I> </I>or sinking fund provisions applicable to our common stock. When we issue shares of common stock under this prospectus, the
shares will be fully paid and non-assessable. The rights, preferences and privileges of the holders of common stock are subject to, and may be adversely affected by, the rights of the holders of shares of any series of preferred stock which we may
designate in the future. <I> </I></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><I>Preferred Stock</I>. We may issue shares of our preferred stock from time to time, in one or more series. If we sell any series
of preferred stock under this prospectus and any applicable prospectus supplement, our board of<I> </I>directors will determine the designations, voting powers, preferences and rights of the preferred stock being<I> </I>offered, as well as the
qualifications, limitations or restrictions thereof, including dividend rights, conversion rights, preemptive rights, terms of redemption or repurchase, liquidation preferences, sinking fund terms and the number of shares constituting any series or
the designation of any series. Convertible preferred stock may be convertible into our common stock or exchangeable for our other securities. Conversion may be mandatory or at the holder&#146;s option and would be at prescribed conversion rates. <I>
</I></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL">We will file as an exhibit to the registration statement of which this prospectus is a part, or will incorporate by reference from reports that we file with
the SEC, the form of the certificate of designation that describes the terms of the series of preferred stock that we are offering before the issuance of the related series of preferred stock. We urge you to read the applicable prospectus supplement
(and any free writing prospectus that we may authorize to be provided to you) related to the series of preferred stock being offered, as well as the complete certificate of designation that contains the terms of the applicable series of preferred
stock. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><I>Debt Securities</I>. We may issue debt securities from time to time, in one or more series, as either senior or subordinated debt or as senior or
subordinated convertible debt. The senior debt securities will rank equally with any other unsecured and unsubordinated debt. The subordinated debt securities will be subordinate and junior in right of payment, to the extent and in the manner
described in the instrument governing the debt, to all of our senior indebtedness. Convertible debt securities will be convertible into our common stock or preferred stock. Conversion may be mandatory or at the holder&#146;s option and would be at
prescribed conversion rates. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL">The debt securities will be issued under one or more documents called indentures, which are contracts between us and a national
banking association or other eligible party, as trustee. A form of indenture has been filed as an exhibit to the registration statement of which this prospectus is a part, and supplemental indentures and forms of debt securities containing the terms
of the debt securities being offered will be filed as exhibits to the registration statement of which this prospectus is a part or will be incorporated by reference from reports that we file with the SEC. We urge you to read the applicable
prospectus supplement (and any free writing prospectus that we may authorize to be provided to you) related to the series of debt securities being offered, as well as the complete indentures that contain the terms of the debt securities. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><I>Warrants</I>. We may issue warrants for the purchase of common stock, preferred stock and/or debt securities in one or more series. We may issue warrants
independently or together with common stock, preferred stock and/or debt securities, and the warrants may be attached to or separate from these securities. Forms of the warrant agreements and forms of warrant certificates containing the terms of the
warrants being offered have been filed as exhibits to the registration statement of which this prospectus is a part, and supplemental warrant agreements and forms of warrant certificates will be<I>
</I></P>
 <P STYLE="margin-top:0pt;margin-bottom:0pt; font-size:8pt">&nbsp;</P></div><br clear="All"></div><br clear="All">

 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center">3 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<div style ="BORDER-BOTTOM:1.00pt solid #000000;BORDER-LEFT:1.00pt solid #000000;BORDER-RIGHT:1.00pt solid #000000;BORDER-TOP:1.00pt solid #000000;MARGIN-LEFT:0px;MARGIN-RIGHT:0px;max-width:100%"><div style="width:97%; margin-top:1.5%; margin-left:1.5%; margin-right:-1.25%">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><I>
</I>filed as exhibits to the registration statement of which this prospectus is a part or will be incorporated by reference from reports that we file with the SEC. We urge you to read the
applicable prospectus supplement (and any free writing prospectus that we may authorize to be provided to you) related to the particular series of warrants being offered, as well as the complete warrant agreements and warrant certificates that
contain the terms of the warrants.<I> </I></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL">We will evidence each series of warrants by warrant certificates that we will issue. Warrants may be issued under an
applicable warrant agreement that we enter into with a warrant agent. We will indicate the name and address of the warrant agent, if applicable, in the prospectus supplement relating to the particular series of warrants being offered. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><B>Use of Proceeds </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL">Except as described in any applicable prospectus supplement
or in any free writing prospectuses we have authorized for use in connection with a specific offering, we currently intend to use the net proceeds from the sale of the securities offered by us hereunder, if any, for working capital and general
corporate purposes, including research and development expenses, and selling, general and administrative expenses. See &#147;Use of Proceeds&#148; in this prospectus. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><B>Nasdaq Global Market Listing </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL">Our common stock is listed on the Nasdaq Global
Market under the symbol &#147;NERV.&#148; The applicable prospectus supplement will contain information, where applicable, as to other listings, if any, on the Nasdaq Global Market or other securities exchange of the securities covered by the
applicable prospectus supplement. </P>
 <P STYLE="margin-top:0pt;margin-bottom:0pt; font-size:8pt">&nbsp;</P></div><br clear="All"></div><br clear="All">

 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center">4 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center"><B><A NAME="rom382980_3"></A>RISK FACTORS </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL">Investing in our securities involves a high degree of risk. Before deciding whether to invest in our securities, you should consider carefully the risks and
uncertainties described under the heading &#147;Risk Factors&#148; contained in the applicable prospectus supplement and any related free writing prospectus, and discussed in the section titled &#147;Risk Factors&#148; contained in our most recent
Annual Report on Form 10-K for the year ended December&nbsp;31, 2014 and in our most recent Quarterly Report on Form 10-Q, as well as any amendments thereto reflected in subsequent filings with the SEC, which are incorporated by reference into this
prospectus in their entirety, together with other information in this prospectus, our quarterly reports, and documents incorporated by reference and any free writing prospectus that we may authorize for use in connection with this offering. The
risks described in these documents are not the only ones we face, but those that we consider to be material. There may be other economic, business, competitive, regulatory or other factors that are not presently known to us or that we currently
believe are immaterial that could have material adverse effects on our future results. Past financial performance may not be a reliable indicator of future performance, and historical trends should not be used to anticipate results or trends in
future periods. If any of these risks actually occurs, our business, financial condition, results of operations or cash flow could be seriously harmed. This could cause the trading price of our common stock to decline, resulting in a loss of all or
part of your investment. Please also read carefully the section below titled &#147;Special Note Regarding Forward-Looking Statements.&#148; </P> <P STYLE="margin-top:24pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center"><B><A NAME="rom382980_4">
</A>SPECIAL NOTE REGARDING FORWARD-LOOKING STATEMENTS </B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL">This prospectus, each prospectus supplement and the information incorporated by reference in this
prospectus and each prospectus supplement, contain forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995, as amended, that involve substantial risks and uncertainties. All statements other than
statements of historical facts contained in this prospectus, including statements regarding our future operating results and financial position, business strategy, and plans and objectives of management for future operations, are forward-looking
statements. In many cases, you can identify forward-looking statements by terms such as &#147;may,&#148; &#147;should,&#148; &#147;expects,&#148; &#147;plans,&#148; &#147;anticipates,&#148; &#147;could,&#148; &#147;intends,&#148; &#147;target,&#148;
&#147;projects,&#148; &#147;contemplates,&#148; &#147;believes,&#148; &#147;estimates,&#148; &#147;predicts,&#148; &#147;potential,&#148; or &#147;continue&#148; or the negative of these terms or other similar expressions. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL">The forward-looking statements contained in this prospectus reflect our views as of the date of this prospectus about future events and are subject to risks,
uncertainties, assumptions, and changes in circumstances that may cause our actual results, performance, or achievements to differ significantly from those expressed or implied in any forward-looking statement. Although we believe that the
expectations reflected in the forward-looking statements are reasonable, we cannot guarantee future events, results, performance, or achievements. A number of important factors could cause actual results to differ materially from those indicated by
the forward-looking statements, including, without limitation, those factors described or referenced in &#147;Risk Factors.&#148; In addition, those &#147;Risk Factors&#148; may be updated from time to time by our filings under the Securities
Exchange Act of 1934, as amended, or the Exchange Act. Except as required by law, after the date of this prospectus, we are under no duty to update or revise any of the forward-looking statements contained or incorporated by reference herein,
whether as a result of new information, future events or otherwise. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL">You should read this prospectus, each prospectus supplement and the information that we
incorporate by reference, completely and with the understanding that our actual future results may be materially different from what we expect. We qualify all of our forward-looking statements by these cautionary statements. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center">5 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center"><B><A NAME="rom382980_5"></A>USE OF PROCEEDS </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL">We will retain broad discretion over the use of the net proceeds from the sale of the securities offered hereby.&nbsp;Except as described in any applicable prospectus
supplement or in any free writing prospectuses we have authorized for use in connection with a specific offering, we currently intend to use the net proceeds from the sale of the securities offered by us hereunder, if any, for general corporate
purposes, which may include research and development, capital expenditures, working capital and general and administrative expenses. We may also use a portion of the net proceeds to acquire or invest in businesses, products and technologies that are
complementary to our own, although we have no current plans, commitments or agreements with respect to any acquisitions as of the date of this prospectus. We will set forth in the applicable prospectus supplement or free writing prospectus our
intended use for the net proceeds received from the sale of any securities sold pursuant to the prospectus supplement or free writing prospectus. Pending these uses, we intend to invest the net proceeds in short-term, investment-grade,
interest-bearing securities and an institutional money market mutual fund. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center">6 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center"><B><A NAME="rom382980_6"></A>DESCRIPTION OF CAPITAL STOCK </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL">Our authorized capital stock consists of 125,000,000 shares of common stock, $0.0001 par value per share, and 100,000,000 shares of preferred stock, $0.0001 par value
per share. A description of material terms and provisions of our certificate of incorporation and bylaws affecting the rights of holders of our capital stock is set forth below. The description is intended as a summary, and is qualified in its
entirety by reference to our certificate of incorporation and the bylaws. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL">As of July&nbsp;15, 2015 there were 24,721,143 shares of common stock outstanding, no
shares of preferred stock outstanding and warrants and options to purchase an aggregate of 9,420,487 shares of common stock outstanding. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><B><I>Common stock
</I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><I>Voting rights</I>. Each holder of our common stock is entitled to one vote for each share of common stock on all matters submitted to a vote of the
stockholders, including the election of directors.<I> </I></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><I>Dividend rights</I>. Subject to preferences that may be applicable to any then outstanding preferred
stock, holders of our common stock are entitled to receive ratably such dividends, if any, as may be declared from time to time by our board of directors out of legally available funds.<I> </I></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><I>Liquidation. </I>In the event of our liquidation, dissolution or winding up, holders of our common stock will be entitled to share ratably in the net assets legally
available for distribution to stockholders after the payment of all of our debts and other liabilities and the satisfaction of any liquidation preference granted to the holders of any then outstanding shares of preferred stock. <I> </I></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><I>Rights and Preferences. </I>Holders of our common stock have no preemptive, conversion, subscription or other rights, and there are no redemption or sinking fund
provisions applicable to our common stock. The rights, preferences and privileges of the holders of our common stock are subject to and may be adversely affected by, the rights of the holders of shares of any series of our preferred stock that we
may designate in the future. All outstanding shares of common stock are fully paid and nonassessable, and the shares of common stock to be issued under this prospectus, when they are paid for, will be fully paid and nonassessable.<I> </I></P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><B><I>Preferred stock </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL">Our board of directors has the authority, without
further action by our stockholders, to issue up to 100,000,000 shares of preferred stock in one or more series and to fix the rights, preferences, privileges and restrictions thereof. These rights, preferences and privileges could include dividend
rights, conversion rights, voting rights, terms of redemption, liquidation preferences, sinking fund terms and the number of shares constituting any series or the designation of such series, any or all of which may be greater than the rights of
common stock. The issuance of our preferred stock could adversely affect the voting power of holders of common stock and the likelihood that such holders will receive dividend payments and payments upon liquidation. In addition, the issuance of
preferred stock could have the effect of delaying, deferring or preventing a change of control of our company or other corporate action. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL">Our board of directors
will fix the designations, voting powers, preferences and rights of the preferred stock of each series we issue under this prospectus, as well as the qualifications, limitations or restrictions thereof, in the certificate of designation relating to
that series. We will file as an exhibit to the registration statement of which this prospectus is a part, or will incorporate by reference from reports that we file with the SEC, the form of any certificate of designation that contains the terms of
</P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center">7 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL">
the series of preferred stock we are offering. We will describe in the applicable prospectus supplement the terms of the series of preferred stock being offered, including, to the extent
applicable: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">the title and stated value; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">the number of shares we are offering; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">the liquidation preference per share; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">the purchase price; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">the dividend rate, period and payment date and method of calculation for dividends; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">whether dividends will be cumulative or non-cumulative and, if cumulative, the date from which dividends will accumulate; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">the procedures for any auction and remarketing, if applicable; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">the provisions for a sinking fund, if applicable; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">the provisions for redemption or repurchase, if applicable, and any restrictions on our ability to exercise those redemption and repurchase rights; </TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">any listing of the preferred stock on any securities exchange or market; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">whether the preferred stock will be convertible into our common stock or other equity securities, and, if applicable, the conversion price, or how it will be calculated, and the conversion period; </TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">whether the preferred stock will be exchangeable into debt securities, and, if applicable, the exchange price, or how it will be calculated, and the exchange period; </TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">voting rights, if any; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">preemptive rights, if any; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">restrictions on transfer, sale or other assignment, if any; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">whether interests in the preferred stock will be represented by depositary shares; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">a discussion of material or special U.S. federal income tax considerations applicable to the preferred stock; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">the relative ranking and preferences of the preferred stock as to dividend rights and rights if we liquidate, dissolve or wind up our affairs; </TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">any limitations on the issuance of any class or series of preferred stock ranking senior to or on parity with the series of preferred stock as to dividend rights and rights if we liquidate, dissolve or wind up our
affairs; and </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">any other specific terms, preferences, rights or limitations of, or restrictions on, the preferred stock. </TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL">The laws of
the state of Delaware, the state of our incorporation, provide that the holders of preferred stock will have the right to vote separately as a class on any proposal involving fundamental changes in the rights of holders of such preferred stock. This
right is in addition to any voting rights that may be provided for in the applicable certificate of designation. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL">If we issue and sell shares of preferred stock
pursuant to this prospectus, the shares will be fully paid and nonassessable and will not have, or be subject to, any preemptive or similar rights. The issuance of preferred stock could adversely affect the voting power, conversion or other rights
of holders of common stock and reduce the likelihood that common stockholders will receive dividend payments and payments </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center">8 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL">
upon liquidation. Preferred stock could be issued quickly with terms designed to delay, deter or prevent a change in control of our company or make removal of management more difficult.
Additionally, the issuance of preferred stock may have the effect of decreasing the market price of our common stock. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><B><I>Forum </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL">Our amended and restated certificate of incorporation provides that, unless we consent in writing to the selection of an alternative forum, the Court of Chancery of the
State of Delaware will be the sole and exclusive forum for any derivative action or proceeding brought on our behalf, any action asserting a claim of breach of a fiduciary duty owed by any director, officer or other employee of the company to us or
our stockholders, any action asserting a claim arising pursuant to any provision of the Delaware General Corporation Law, or any action asserting a claim governed by the internal affairs doctrine. Our amended and restated certificate of
incorporation further provides that any person or entity purchasing or otherwise acquiring any interest in shares of our capital stock is deemed to have notice of and consented to the foregoing provision. Although our amended and restated
certificate of incorporation includes these provisions, it is possible that a court could rule that such provisions are inapplicable or unenforceable </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><B><I>Anti-takeover Provisions </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><I>Certificate of Incorporation and Bylaws.
</I>Our amended and restated certificate of incorporation provides for our board of directors to be divided into three classes, with staggered three-year terms. Only one class of directors will be elected at each annual meeting of our stockholders,
with the other classes continuing for the remainder of their respective three-year terms. Because our stockholders do not have cumulative voting rights, our stockholders holding a majority of the shares of common stock outstanding will be able to
elect all of our directors. Our amended and restated certificate of incorporation and amended and restated bylaws provide that all stockholder action must be effected at a duly called meeting of stockholders and not by a consent in writing, and that
only our board of directors or chairman of the board may call a special meeting of stockholders. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL">Our amended and restated certificate of incorporation requires a
66<SUP STYLE="font-size:85%; vertical-align:top">2</SUP>/<SUB STYLE="font-size:85%; vertical-align:bottom">3</SUB>% stockholder vote for the amendment, repeal or modification of certain provisions of our amended and restated certificate of
incorporation and amended and restated bylaws relating to the classification of our board of directors, the requirement that stockholder actions be effected at a duly called meeting, and the designated parties entitled to call a special meeting of
the stockholders. The combination of the classification of our board of directors, the lack of cumulative voting and the 66<SUP STYLE="font-size:85%; vertical-align:top">2</SUP>/<SUB STYLE="font-size:85%; vertical-align:bottom">3</SUB>% stockholder
voting requirements will make it more difficult for our existing stockholders to replace our board of directors as well as for another party to obtain control of us by replacing our board of directors. Since our board of directors has the power to
retain and discharge our officers, these provisions could also make it more difficult for existing stockholders or another party to effect a change in management. In addition, the authorization of undesignated preferred stock makes it possible for
our board of directors to issue preferred stock with voting or other rights or preferences that could impede the success of any attempt to change control of our company. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL">These provisions may have the effect of deterring hostile takeovers or delaying changes in control of our company or management. These provisions are intended to
enhance the likelihood of continued stability in the composition of our board of directors and its policies and to discourage certain types of transactions that may involve an actual or threatened acquisition of us. These provisions are designed to
reduce our vulnerability to an unsolicited acquisition proposal. The provisions also are intended to discourage certain tactics that may be used in proxy fights. However, such provisions could have the effect of discouraging others from making
tender offers for our shares and, as a consequence, they also </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center">9 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL">
may inhibit fluctuations in the market price of our shares that could result from actual or rumored takeover attempts. Such provisions may also have the effect of preventing changes in our
management. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><B><I>Section&nbsp;203 of the Delaware General Corporation Law </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL">We are subject to Section&nbsp;203 of the Delaware General Corporation Law, which prohibits a publicly-held Delaware corporation from engaging in any business
combination with any interested stockholder for a period of three years after the date that such stockholder became an interested stockholder, with the following exceptions: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">before such date, the board of directors of the corporation approved either the business combination or the transaction that resulted in the stockholder becoming an interested holder; </TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">upon completion of the transaction that resulted in the stockholder becoming an interested stockholder, the interested stockholder owned at least 85% of the voting stock of the corporation outstanding at the time the
transaction began, excluding for purposes of determining the voting stock outstanding (but not the outstanding voting stock owned by the interested stockholder) those shares owned (i)&nbsp;by persons who are directors and also officers and
(ii)&nbsp;employee stock plans in which employee participants do not have the right to determine confidentially whether shares held subject to the plan will be tendered in a tender or exchange offer; or </TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">on or after such date, the business combination is approved by the board of directors and authorized at an annual or special meeting of the stockholders, and not by written consent, by the affirmative vote of at least
50% of the outstanding voting stock that is not owned by the interested stockholder. </TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL">In general, Section&nbsp;203 defines business combination to
include the following: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">any merger or consolidation involving the corporation and the interested stockholder; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">any sale, transfer, pledge or other disposition of 10% or more of the assets of the corporation involving the interested stockholder; </TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">subject to certain exceptions, any transaction that results in the issuance or transfer by the corporation of any stock of the corporation to the interested stockholder; </TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">any transaction involving the corporation that has the effect of increasing the proportionate share of the stock or any class or series of the corporation beneficially owned by the interested stockholder; or
</TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">the receipt by the interested stockholder of the benefit of any loss, advances, guarantees, pledges or other financial benefits by or through the corporation. </TD></TR></TABLE>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL">In general, Section&nbsp;203 defines an &#147;interested stockholder&#148; as an entity or person who, together with the person&#146;s affiliates and associates,
beneficially owns, or within three years prior to the time of determination of interested stockholder status did own, 15% or more of the outstanding voting stock of the corporation. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><B><I>Transfer Agent and Registrar </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL">The transfer agent and registrar for our
common stock is Computershare Trust Company, N.A. The transfer agent and registrar&#146;s address is P.O. Box 43078, Providence, Rhode Island 02940. The transfer agent for any series of preferred stock that we may offer under this prospectus will be
named and described in the prospectus supplement for that series. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center">10 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><B><I>Listing on the Nasdaq Global Market </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL">Our common stock is listed on the Nasdaq Global Market under the symbol &#147;NERV&#148;. The applicable prospectus supplement will contain information, where
applicable, as to other listing, if any, on the Nasdaq Global Market or other securities exchange of the preferred stock covered by such prospectus supplement. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center">11 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center"><B><A NAME="rom382980_7"></A>DESCRIPTION OF DEBT SECURITIES </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL">We may issue debt securities from time to time, in one or more series, as either senior or subordinated debt or as senior or subordinated convertible debt. While the
terms we have summarized below will apply generally to any debt securities that we may offer under this prospectus, we will describe the particular terms of any debt securities that we may offer in more detail in the applicable prospectus
supplement. The terms of any debt securities offered under a prospectus supplement may differ from the terms described below. Unless the context requires otherwise, whenever we refer to the indenture, we also are referring to any supplemental
indentures that specify the terms of a particular series of debt securities. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL">We will issue the debt securities under the indenture that we will enter into with the
trustee named in the indenture. The indenture will be qualified under the Trust Indenture Act of 1939, as amended, or the Trust Indenture Act. We have filed the form of indenture as an exhibit to the registration statement of which this prospectus
is a part, and supplemental indentures and forms of debt securities containing the terms of the debt securities being offered will be filed as exhibits to the registration statement of which this prospectus is a part or will be incorporated by
reference from reports that we file with the SEC. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL">The following summary of material provisions of the debt securities and the indenture is subject to, and
qualified in its entirety by reference to, all of the provisions of the indenture applicable to a particular series of debt securities. We urge you to read the applicable prospectus supplements and any related free writing prospectuses related to
the debt securities that we may offer under this prospectus, as well as the complete indenture that contains the terms of the debt securities. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><B>General </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL">The indenture does not limit the amount of debt securities that we may issue. It provides that we may issue debt securities up to the principal amount that we may
authorize and may be in any currency or currency unit that we may designate. Except for the limitations on consolidation, merger and sale of all or substantially all of our assets contained in the indenture, the terms of the indenture do not contain
any covenants or other provisions designed to give holders of any debt securities protection against changes in our operations, financial condition or transactions involving us. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL">We may issue the debt securities issued under the indenture as &#147;discount securities,&#148; which means they may be sold at a discount below their stated principal
amount. These debt securities, as well as other debt securities that are not issued at a discount, may be issued with &#147;original issue discount,&#148; or OID, for U.S. federal income tax purposes because of interest payment and other
characteristics or terms of the debt securities. Material U.S. federal income tax considerations applicable to debt securities issued with OID will be described in more detail in any applicable prospectus supplement. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL">We will describe in the applicable prospectus supplement the terms of the series of debt securities being offered, including: </P>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">the title of the series of debt securities; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">any limit upon the aggregate principal amount that may be issued; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">the maturity date or dates; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">the form of the debt securities of the series; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">the applicability of any guarantees; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">whether or not the debt securities will be secured or unsecured, and the terms of any secured debt; </TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center">12 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">whether the debt securities rank as senior debt, senior subordinated debt, subordinated debt or any combination thereof, and the terms of any subordination; </TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">if the price (expressed as a percentage of the aggregate principal amount thereof) at which such debt securities will be issued is a price other than the principal amount thereof, the portion of the principal amount
thereof payable upon declaration of acceleration of the maturity thereof, or if applicable, the portion of the principal amount of such debt securities that is convertible into another security or the method by which any such portion shall be
determined; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">the interest rate or rates, which may be fixed or variable, or the method for determining the rate and the date interest will begin to accrue, the dates interest will be payable and the regular record dates for interest
payment dates or the method for determining such dates; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">our right, if any, to defer payment of interest and the maximum length of any such deferral period; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">if applicable, the date or dates after which, or the period or periods during which, and the price or prices at which, we may, at our option, redeem the series of debt securities pursuant to any optional or provisional
redemption provisions and the terms of those redemption provisions; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">the date or dates, if any, on which, and the price or prices at which we are obligated, pursuant to any mandatory sinking fund or analogous fund provisions or otherwise, to redeem, or at the holder&#146;s option to
purchase, the series of debt securities and the currency or currency unit in which the debt securities are payable; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">the denominations in which we will issue the series of debt securities, if other than denominations of $1,000 and any integral multiple thereof; </TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">any and all terms, if applicable, relating to any auction or remarketing of the debt securities of that series and any security for our obligations with respect to such debt securities and any other terms which may be
advisable in connection with the marketing of debt securities of that series; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">whether the debt securities of the series shall be issued in whole or in part in the form of a global security or securities; the terms and conditions, if any, upon which such global security or securities may be
exchanged in whole or in part for other individual securities; and the depositary for such global security or securities; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">if applicable, the provisions relating to conversion or exchange of any debt securities of the series and the terms and conditions upon which such debt securities will be so convertible or exchangeable, including the
conversion or exchange price, as applicable, or how it will be calculated and may be adjusted, any mandatory or optional (at our option or the holders&#146; option) conversion or exchange features, the applicable conversion or exchange period and
the manner of settlement for any conversion or exchange; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">if other than the full principal amount thereof, the portion of the principal amount of debt securities of the series which shall be payable upon declaration of acceleration of the maturity thereof; </TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">additions to or changes in the covenants applicable to the particular debt securities being issued, including, among others, the consolidation, merger or sale covenant; </TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">additions to or changes in the events of default with respect to the securities and any change in the right of the trustee or the holders to declare the principal, premium, if any, and interest, if any, with respect to
such securities to be due and payable; </TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center">13 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">additions to or changes in or deletions of the provisions relating to covenant defeasance and legal defeasance; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">additions to or changes in the provisions relating to satisfaction and discharge of the indenture; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">additions to or changes in the provisions relating to the modification of the indenture both with and without the consent of holders of debt securities issued under the indenture; </TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">the currency of payment of debt securities if other than U.S. dollars and the manner of determining the equivalent amount in U.S. dollars; </TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">whether interest will be payable in cash or additional debt securities at our or the holders&#146; option and the terms and conditions upon which the election may be made; </TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">the terms and conditions, if any, upon which we will pay amounts in addition to the stated interest, premium, if any and principal amounts of the debt securities of the series to any holder that is not a &#147;United
States person&#148; for federal tax purposes; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">any restrictions on transfer, sale or assignment of the debt securities of the series; and </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">any other specific terms, preferences, rights or limitations of, or restrictions on, the debt securities, any other additions or changes in the provisions of the indenture, and any terms that may be required by us or
advisable under applicable laws or regulations. </TD></TR></TABLE> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><B>Conversion or Exchange Rights </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL">We will set forth in the applicable prospectus supplement the terms on which a series of debt securities may be convertible into or exchangeable for our common stock or
our other securities. We will include provisions as to settlement upon conversion or exchange and whether conversion or exchange is mandatory, at the option of the holder or at our option. We may include provisions pursuant to which the number of
shares of our common stock or our other securities that the holders of the series of debt securities receive would be subject to adjustment. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><B>Consolidation,
Merger or Sale </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL">Unless we provide otherwise in the prospectus supplement applicable to a particular series of debt securities, the indenture will not contain any
covenant that restricts our ability to merge or consolidate, or sell, convey, transfer or otherwise dispose of our assets as an entirety or substantially as an entirety. However, any successor to or acquirer of such assets (other than a subsidiary
of ours) must assume all of our obligations under the indenture or the debt securities, as appropriate. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><B>Events of Default under the Indenture </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL">Unless we provide otherwise in the prospectus supplement applicable to a particular series of debt securities, the following are events of default under the indenture
with respect to any series of debt securities that we may issue: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">if we fail to pay any installment of interest on any series of debt securities, as and when the same shall become due and payable, and such default continues for a period of 90 days; provided, however, that a valid
extension of an interest payment period by us in accordance with the terms of any indenture supplemental thereto shall not constitute a default in the payment of interest for this purpose; </TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">if we fail to pay the principal of, or premium, if any, on any series of debt securities as and when the same shall become
due and payable whether at maturity, upon redemption, by </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center">14 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="8%">&nbsp;</TD>
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">
declaration or otherwise, or in any payment required by any sinking or analogous fund established with respect to such series; provided, however, that a valid extension of the maturity of such
debt securities in accordance with the terms of any indenture supplemental thereto shall not constitute a default in the payment of principal or premium, if any; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">if we fail to observe or perform any other covenant or agreement contained in the debt securities or the indenture, other than a covenant specifically relating to another series of debt securities, and our failure
continues for 90 days after we receive written notice of such failure, requiring the same to be remedied and stating that such is a notice of default thereunder, from the trustee or holders of at least 25% in aggregate principal amount of the
outstanding debt securities of the applicable series; and </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">if specified events of bankruptcy, insolvency or reorganization occur. </TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL">If an event of default with respect to debt
securities of any series occurs and is continuing, other than an event of default specified in the last bullet point above, the trustee or the holders of at least 25% in aggregate principal amount of the outstanding debt securities of that series,
by notice to us in writing, and to the trustee if notice is given by such holders, may declare the unpaid principal of, premium, if any, and accrued interest, if any, due and payable immediately. If an event of default specified in the last bullet
point above occurs with respect to us, the principal amount of and accrued interest, if any, of each issue of debt securities then outstanding shall be due and payable without any notice or other action on the part of the trustee or any holder. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL">The holders of a majority in principal amount of the outstanding debt securities of an affected series may waive any default or event of default with respect to the
series and its consequences, except defaults or events of default regarding payment of principal, premium, if any, or interest, unless we have cured the default or event of default in accordance with the indenture. Any waiver shall cure the default
or event of default. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL">Subject to the terms of the indenture, if an event of default under an indenture shall occur and be continuing, the trustee will be under no
obligation to exercise any of its rights or powers under such indenture at the request or direction of any of the holders of the applicable series of debt securities, unless such holders have offered the trustee reasonable indemnity. The holders of
a majority in principal amount of the outstanding debt securities of any series will have the right to direct the time, method and place of conducting any proceeding for any remedy available to the trustee, or exercising any trust or power conferred
on the trustee, with respect to the debt securities of that series, provided that: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">the direction so given by the holder is not in conflict with any law or the applicable indenture; and </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">subject to its duties under the Trust Indenture Act, the trustee need not take any action that might involve it in personal liability or might be unduly prejudicial to the holders not involved in the proceeding.
</TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL">A holder of the debt securities of any series will have the right to institute a proceeding under the indenture or to appoint a receiver or trustee,
or to seek other remedies only if: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">the holder has given written notice to the trustee of a continuing event of default with respect to that series; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">the holders of at least 25% in aggregate principal amount of the outstanding debt securities of that series have made written request, and such holders have offered to the trustee indemnity satisfactory to it against
the costs, expenses and liabilities to be incurred by the trustee in compliance with the request; and </TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center">15 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">the trustee does not institute the proceeding, and does not receive from the holders of a majority in aggregate principal amount of the outstanding debt securities of that series other conflicting directions within 90
days after the notice, request and offer. </TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL">These limitations do not apply to a suit instituted by a holder of debt securities if we default in the
payment of the principal, premium, if any, or interest on, the debt securities. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL">We will periodically file statements with the trustee regarding our compliance with
specified covenants in the indenture. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><B>Modification of Indenture; Waiver </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL">We and the trustee may change an indenture without the consent of any holders with respect to specific matters: </P>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">to cure any ambiguity, defect or inconsistency in the indenture or in the debt securities of any series; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">to comply with the provisions described above under &#147;Description of Debt Securities&#151;Consolidation, Merger or Sale;&#148; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">to provide for uncertificated debt securities in addition to or in place of certificated debt securities; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">to add to our covenants, restrictions, conditions or provisions such new covenants, restrictions, conditions or provisions for the benefit of the holders of all or any series of debt securities, to make the occurrence,
or the occurrence and the continuance, of a default in any such additional covenants, restrictions, conditions or provisions an event of default or to surrender any right or power conferred upon us in the indenture; </TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">to add to, delete from or revise the conditions, limitations, and restrictions on the authorized amount, terms, or purposes of issue, authentication and delivery of debt securities, as set forth in the indenture;
</TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">to make any change that does not adversely affect the interests of any holder of debt securities of any series in any material respect; </TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">to provide for the issuance of and establish the form and terms and conditions of the debt securities of any series as provided above under &#147;Description of Debt Securities&#151;General&#148; to establish the form
of any certifications required to be furnished pursuant to the terms of the indenture or any series of debt securities, or to add to the rights of the holders of any series of debt securities; </TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">to evidence and provide for the acceptance of appointment under any indenture by a successor trustee; or </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">to comply with any requirements of the SEC in connection with the qualification of any indenture under the Trust Indenture Act. </TD></TR></TABLE>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL">In addition, under the indenture, the rights of holders of a series of debt securities may be changed by us and the trustee with the written consent of the holders of
at least a majority in aggregate principal amount of the outstanding debt securities of each series that is affected. However, unless we provide otherwise in the prospectus supplement applicable to a particular series of debt securities, we and the
trustee may make the following changes only with the consent of each holder of any outstanding debt securities affected: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">extending the fixed maturity of any debt securities of any series; </TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center">16 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">reducing the principal amount, reducing the rate of or extending the time of payment of interest, or reducing any premium payable upon the redemption of any series of any debt securities; or </TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">reducing the percentage of debt securities, the holders of which are required to consent to any amendment, supplement, modification or waiver. </TD></TR></TABLE>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><B>Discharge </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL">The indenture provides that we can elect to be discharged from our
obligations with respect to one or more series of debt securities, except for specified obligations, including obligations to: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">provide for payment; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">register the transfer or exchange of debt securities of the series; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">replace stolen, lost or mutilated debt securities of the series; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">pay principal of and premium and interest on any debt securities of the series; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">maintain paying agencies; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">hold monies for payment in trust; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">recover excess money held by the trustee; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">compensate and indemnify the trustee; and </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">appoint any successor trustee. </TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL">In order to exercise our rights to be discharged, we must deposit with the trustee money
or government obligations sufficient to pay all the principal of, any premium, if any, and interest on, the debt securities of the series on the dates payments are due. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><B>Form, Exchange and Transfer </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL">We will issue the debt securities of each series
only in fully registered form without coupons and, unless we provide otherwise in the applicable prospectus supplement, in denominations of $1,000 and any integral multiple thereof. The indenture provides that we may issue debt securities of a
series in temporary or permanent global form and as book-entry securities that will be deposited with, or on behalf of, The Depository Trust Company, or DTC, or another depositary named by us and identified in the applicable prospectus supplement
with respect to that series. To the extent the debt securities of a series are issued in global form and as book-entry, a description of terms relating to any book entry securities will be set forth in the applicable prospectus supplement. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL">At the option of the holder, subject to the terms of the indenture and the limitations applicable to global securities described in the applicable prospectus
supplement, the holder of the debt securities of any series can exchange the debt securities for other debt securities of the same series, in any authorized denomination and of like tenor and aggregate principal amount. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL">Subject to the terms of the indenture and the limitations applicable to global securities set forth in the applicable prospectus supplement, holders of the debt
securities may present the debt securities for exchange or for registration of transfer, duly endorsed or with the form of transfer endorsed thereon duly executed if so required by us or the security registrar, at the office of the security
registrar or at the office of any transfer agent designated by us for this purpose. Unless otherwise provided in the debt securities that the holder presents for transfer or exchange, we will impose no service charge for any registration of transfer
or exchange, but we may require payment of any taxes or other governmental charges. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center">17 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL">We will name in the applicable prospectus supplement the security registrar, and any transfer agent in addition to the
security registrar, that we initially designate for any debt securities. We may at any time designate additional transfer agents or rescind the designation of any transfer agent or approve a change in the office through which any transfer agent
acts, except that we will be required to maintain a transfer agent in each place of payment for the debt securities of each series. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL">If we elect to redeem the debt
securities of any series, we will not be required to: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">issue, register the transfer of, or exchange any debt securities of that series during a period beginning at the opening of business 15 days before the day of mailing of a notice of redemption of any debt securities
that may be selected for redemption and ending at the close of business on the day of the mailing; or </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">register the transfer of or exchange any debt securities so selected for redemption, in whole or in part, except the unredeemed portion of any debt securities we are redeeming in part. </TD></TR></TABLE>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><B>Information Concerning the Trustee </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL">The trustee, other than during the
occurrence and continuance of an event of default under an indenture, undertakes to perform only those duties as are specifically set forth in the applicable indenture. Upon an event of default under an indenture, the trustee must use the same
degree of care as a prudent person would exercise or use in the conduct of his or her own affairs. Subject to this provision, the trustee is under no obligation to exercise any of the powers given it by the indenture at the request of any holder of
debt securities unless it is offered reasonable security and indemnity against the costs, expenses and liabilities that it might incur. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><B>Payment and Paying
Agents </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL">Unless we otherwise indicate in the applicable prospectus supplement, we will make payment of the interest on any debt securities on any interest payment
date to the person in whose name the debt securities, or one or more predecessor securities, are registered at the close of business on the regular record date for the interest. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL">We will pay principal of and any premium and interest on the debt securities of a particular series at the office of the paying agents designated by us, except that
unless we otherwise indicate in the applicable prospectus supplement, we will make interest payments by check that we will mail to the holder or by wire transfer to certain holders. Unless we otherwise indicate in the applicable prospectus
supplement, we will designate the corporate trust office of the trustee as our sole paying agent for payments with respect to debt securities of each series. We will name in the applicable prospectus supplement any other paying agents that we
initially designate for the debt securities of a particular series. We will maintain a paying agent in each place of payment for the debt securities of a particular series. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL">All money we pay to a paying agent or the trustee for the payment of the principal of or any premium or interest on any debt securities that remains unclaimed at the
end of two years after such principal, premium or interest has become due and payable will be repaid to us, and the holder of the debt security thereafter may look only to us for payment thereof. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><B>Governing Law </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL">The indenture and the debt securities will be governed by and
construed in accordance with the laws of the State of New York, except to the extent that the Trust Indenture Act of 1939 is applicable. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center">18 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center"><B><A NAME="rom382980_8"></A>DESCRIPTION OF WARRANTS </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL">The following description, together with the additional information we may include in any applicable prospectus supplements and free writing prospectuses, summarizes
the material terms and provisions of the warrants that we may issue under this prospectus, which may consist of warrants to purchase common stock, preferred stock or debt securities and may be issued in one or more series. Warrants may be issued
independently or together with common stock, preferred stock or debt securities offered by any prospectus supplement, and may be attached to or separate from those securities. While the terms we have summarized below will apply generally to any
warrants that we may offer under this prospectus, we will describe the particular terms of any series of warrants that we may offer in more detail in the applicable prospectus supplement and any applicable free writing prospectus. The following
description of warrants will apply to the warrants offered by this prospectus unless we provide otherwise in the applicable prospectus supplement. The applicable prospectus supplement for a particular series of warrants may specify different or
additional terms. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL">We have filed forms of the warrant agreements and forms of warrant certificates containing the terms of the warrants that may be offered as
exhibits to the registration statement of which this prospectus is a part. We will file as exhibits to the registration statement of which this prospectus is a part, or will incorporate by reference from reports that we file with the SEC, the form
of warrant and/or the warrant agreement and warrant certificate, as applicable, that contain the terms of the particular series of warrants we are offering, and any supplemental agreements, before the issuance of such warrants. The following
summaries of material terms and provisions of the warrants are subject to, and qualified in their entirety by reference to, all the provisions of the form of warrant and/or the warrant agreement and warrant certificate, as applicable, and any
supplemental agreements applicable to a particular series of warrants that we may offer under this prospectus. We urge you to read the applicable prospectus supplement related to the particular series of warrants that we may offer under this
prospectus, as well as any related free writing prospectuses, and the complete form of warrant and/or the warrant agreement and warrant certificate, as applicable, and any supplemental agreements, that contain the terms of the warrants. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><B>General </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL">We will describe in the applicable prospectus supplement the terms
of the series of warrants being offered, including: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">the offering price and aggregate number of warrants offered; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">the currency for which the warrants may be purchased; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">if applicable, the designation and terms of the securities with which the warrants are issued and the number of warrants issued with each such security or each principal amount of such security; </TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">if applicable, the date on and after which the warrants and the related securities will be separately transferable; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">in the case of warrants to purchase debt securities, the principal amount of debt securities purchasable upon exercise of one warrant and the price at, and currency in which, this principal amount of debt securities may
be purchased upon such exercise; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">in the case of warrants to purchase common stock or preferred stock, the number of shares of common stock or preferred stock, as the case may be, purchasable upon the exercise of one warrant and the price at which these
shares may be purchased upon such exercise; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">the effect of any merger, consolidation, sale or other disposition of our business on the warrant agreements and the warrants; </TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center">19 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">the terms of any rights to redeem or call the warrants; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">the terms of any rights to force the exercise of the warrants; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">any provisions for changes to or adjustments in the exercise price or number of securities issuable upon exercise of the warrants; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">the dates on which the right to exercise the warrants will commence and expire; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">the manner in which the warrant agreements and warrants may be modified; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">a discussion of any material or special U.S. federal income tax considerations of holding or exercising the warrants; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">the terms of the securities issuable upon exercise of the warrants; and </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">any other specific terms, preferences, rights or limitations of or restrictions on the warrants. </TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL">Before exercising
their warrants, holders of warrants will not have any of the rights of holders of the securities purchasable upon such exercise, including: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">in the case of warrants to purchase debt securities, the right to receive payments of principal of, or premium, if any, or interest on, the debt securities purchasable upon exercise or to enforce covenants in the
applicable indenture; or </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">in the case of warrants to purchase common stock or preferred stock, the right to receive dividends, if any, or, payments upon our liquidation, dissolution or winding up or to exercise voting rights, if any.
</TD></TR></TABLE> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><B>Exercise of Warrants </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL">Each warrant will entitle the holder
to purchase the securities that we specify in the applicable prospectus supplement at the exercise price that we describe in the applicable prospectus supplement. Unless we otherwise specify in the applicable prospectus supplement, holders of the
warrants may exercise the warrants at any time up to the specified time on the expiration date that we set forth in the applicable prospectus supplement. After the close of business on the expiration date, unexercised warrants will become void. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL">Unless we otherwise specify in the applicable prospectus supplement, holders of the warrants may exercise the warrants by delivering the warrant or warrant certificate,
as applicable, representing the warrants to be exercised together with specified information, and paying the required amount to the warrant agent in immediately available funds, as provided in the applicable prospectus supplement. We will set forth
in the applicable warrant or warrant certificate and in the applicable prospectus supplement the information that the holder of the warrant will be required to deliver to the warrant agent in connection with the exercise of the warrant. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL">Upon receipt of the required payment and the warrant or warrant certificate, as applicable, properly completed and duly executed at the corporate trust office of the
warrant agent, if any, or any other office, including ours, indicated in the prospectus supplement, we will, as soon as practicable, issue and deliver the securities purchasable upon such exercise. If less than all of the warrants (or the warrants
represented by such warrant certificate) are exercised, a new warrant or a new warrant certificate, as applicable, will be issued for the remaining warrants. If we so indicate in the applicable prospectus supplement, holders of the warrants may
surrender securities as all or part of the exercise price for warrants. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center">20 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><B>Governing Law </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL">Unless we
otherwise specify in the applicable prospectus supplement, the warrants and any warrant agreements will be governed by and construed in accordance with the laws of the State of New York. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><B>Enforceability of Rights by Holders of Warrants </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL">Each warrant agent, if any,
will act solely as our agent under the applicable warrant agreement and will not assume any obligation or relationship of agency or trust with any holder of any warrant. A single bank or trust company may act as warrant agent for more than one issue
of warrants. A warrant agent will have no duty or responsibility in case of any default by us under the applicable warrant agreement or warrant, including any duty or responsibility to initiate any proceedings at law or otherwise, or to make any
demand upon us. Any holder of a warrant may, without the consent of the related warrant agent or the holder of any other warrant, enforce by appropriate legal action its right to exercise, and receive the securities purchasable upon exercise of, its
warrants. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center">21 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center"><B><A NAME="rom382980_9"></A>LEGAL OWNERSHIP OF SECURITIES </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL">We can issue securities in registered form or in the form of one or more global securities. We describe global securities in greater detail below. We refer to those
persons who have securities registered in their own names on the books that we or any applicable trustee, depositary or warrant agent maintain for this purpose as the &#147;holders&#148; of those securities. These persons are the legal holders of
the securities. We refer to those persons who, indirectly through others, own beneficial interests in securities that are not registered in their own names, as &#147;indirect holders&#148; of those securities. As we discuss below, indirect holders
are not legal holders, and investors in securities issued in book-entry form or in street name will be indirect holders. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><B>Book-Entry Holders </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL">We may issue securities in book-entry form only, as we will specify in the applicable prospectus supplement. This means securities may be represented by one or more
global securities registered in the name of a financial institution that holds them as depositary on behalf of other financial institutions that participate in the depositary&#146;s book-entry system. These participating institutions, which are
referred to as participants, in turn, hold beneficial interests in the securities on behalf of themselves or their customers. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL">Only the person in whose name a
security is registered is recognized as the holder of that security. Securities issued in global form will be registered in the name of the depositary or its participants. Consequently, for securities issued in global form, we will recognize only
the depositary as the holder of the securities, and we will make all payments on the securities to the depositary. The depositary passes along the payments it receives to its participants, which in turn pass the payments along to their customers who
are the beneficial owners. The depositary and its participants do so under agreements they have made with one another or with their customers; they are not obligated to do so under the terms of the securities. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL">As a result, investors in a book-entry security will not own securities directly. Instead, they will own beneficial interests in a global security, through a bank,
broker or other financial institution that participates in the depositary&#146;s book-entry system or holds an interest through a participant. As long as the securities are issued in global form, investors will be indirect holders, and not holders,
of the securities. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><B>Street Name Holders </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL">We may terminate a global
security or issue securities in non-global form. In these cases, investors may choose to hold their securities in their own names or in &#147;street name.&#148; Securities held by an investor in street name would be registered in the name of a bank,
broker or other financial institution that the investor chooses, and the investor would hold only a beneficial interest in those securities through an account he or she maintains at that institution. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL">For securities held in street name, we or any applicable trustee or depositary will recognize only the intermediary banks, brokers and other financial institutions in
whose names the securities are registered as the holders of those securities, and we or any such trustee or depositary will make all payments on those securities to them. These institutions pass along the payments they receive to their customers who
are the beneficial owners, but only because they agree to do so in their customer agreements or because they are legally required to do so. Investors who hold securities in street name will be indirect holders, not holders, of those securities. </P>

 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center">22 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><B>Legal Holders </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL">Our obligations,
as well as the obligations of any applicable trustee or third party employed by us or a trustee, run only to the legal holders of the securities. We do not have obligations to investors who hold beneficial interests in global securities, in street
name or by any other indirect means. This will be the case whether an investor chooses to be an indirect holder of a security or has no choice because we are issuing the securities only in global form. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL">For example, once we make a payment or give a notice to the holder, we have no further responsibility for the payment or notice even if that holder is required, under
agreements with depositary participants or customers or by law, to pass it along to the indirect holders but does not do so. Similarly, we may want to obtain the approval of the holders to amend an indenture, to relieve us of the consequences of a
default or of our obligation to comply with a particular provision of the indenture or for other purposes. In such an event, we would seek approval only from the legal holders, and not the indirect holders, of the securities. Whether and how the
holders contact the indirect holders is up to the legal holders. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><B>Special Considerations for Indirect Holders </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL">If you hold securities through a bank, broker or other financial institution, either in book-entry form or in street name, you should check with your own institution to
find out: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">how it handles securities payments and notices; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">whether it imposes fees or charges; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">how it would handle a request for the holders&#146; consent, if ever required; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">whether and how you can instruct it to send you securities registered in your own name so you can be a holder, if that is permitted in the future; </TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">how it would exercise rights under the securities if there were a default or other event triggering the need for holders to act to protect their interests; and </TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">if the securities are in book-entry form, how the depositary&#146;s rules and procedures will affect these matters. </TD></TR></TABLE>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><B>Global Securities </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL">A global security is a security that represents one or any
other number of individual securities held by a depositary. Generally, all securities represented by the same global securities will have the same terms. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL">Each
security issued in book-entry form will be represented by a global security that we deposit with and register in the name of a financial institution or its nominee that we select. The financial institution that we select for this purpose is called
the depositary. Unless we specify otherwise in the applicable prospectus supplement, DTC will be the depositary for all securities issued in book-entry form. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL">A
global security may not be transferred to or registered in the name of anyone other than the depositary, its nominee or a successor depositary, unless special termination situations arise. We describe those situations below in the section titled
&#147;Special Situations When a Global Security Will Be Terminated&#148; in this prospectus. As a result of these arrangements, the depositary, or its nominee, will be the sole registered owner and holder of all securities represented by a global
security, and investors will be permitted to own only beneficial interests in a global security. Beneficial interests must be held by means of an account with a broker, bank or other financial institution that in turn has an account with the
depositary or with another institution that does. Thus, an investor whose security is represented by a global security will not be a holder of the security, but only an indirect holder of a beneficial interest in the global security. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center">23 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL">If the prospectus supplement for a particular security indicates that the security will be issued in global form only, then
the security will be represented by a global security at all times unless and until the global security is terminated. If termination occurs, we may issue the securities through another book-entry clearing system or decide that the securities may no
longer be held through any book-entry clearing system. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><B>Special Considerations for Global Securities </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL">The rights of an indirect holder relating to a global security will be governed by the account rules of the investor&#146;s financial institution and of the depositary,
as well as general laws relating to securities transfers. We do not recognize an indirect holder as a holder of securities and instead deal only with the depositary that holds the global security. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL">If securities are issued only in the form of a global security, an investor should be aware of the following: </P>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">an investor cannot cause the securities to be registered in his or her name, and cannot obtain non-global certificates for his or her interest in the securities, except in the special situations we describe below;
</TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">an investor will be an indirect holder and must look to his or her own bank or broker for payments on the securities and protection of his or her legal rights relating to the securities, as we describe above;
</TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">an investor may not be able to sell interests in the securities to some insurance companies and to other institutions that are required by law to own their securities in non-book-entry form; </TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">an investor may not be able to pledge his or her interest in a global security in circumstances where certificates representing the securities must be delivered to the lender or other beneficiary of the pledge in order
for the pledge to be effective; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">the depositary&#146;s policies, which may change from time to time, will govern payments, transfers, exchanges and other matters relating to an investor&#146;s interest in a global security; </TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">we and any applicable trustee have no responsibility for any aspect of the depositary&#146;s actions or for its records of ownership interests in a global security, nor do we or any applicable trustee supervise the
depositary in any way; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">the depositary may, and we understand that DTC will, require that those who purchase and sell interests in a global security within its book-entry system use immediately available funds, and your broker or bank may
require you to do so as well; and </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">financial institutions that participate in the depositary&#146;s book-entry system, and through which an investor holds its interest in a global security, may also have their own policies affecting payments, notices and
other matters relating to the securities. </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">There may be more than one financial intermediary in the chain of ownership for an investor. We do not monitor and are not responsible for the actions of any of those intermediaries. </TD></TR></TABLE>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><B>Special Situations When a Global Security Will Be Terminated </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL">In a few
special situations described below, the global security will terminate and interests in it will be exchanged for physical certificates representing those interests. After that exchange, the choice of whether to hold securities directly or in street
name will be up to the investor. Investors must consult their own banks or brokers to find out how to have their interests in securities transferred to their own names, so that they will be direct holders. We have described the rights of holders and
street name investors above. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center">24 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL">Unless we provide otherwise in the applicable prospectus supplement, the global security will terminate when the following
special situations occur: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">if the depositary notifies us that it is unwilling, unable or no longer qualified to continue as depositary for that global security and we do not appoint another institution to act as depositary within 90 days;
</TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">if we notify any applicable trustee that we wish to terminate that global security; or </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">if an event of default has occurred with regard to securities represented by that global security and has not been cured or waived. </TD></TR></TABLE>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL">The applicable prospectus supplement may also list additional situations for terminating a global security that would apply only to the particular series of securities
covered by the applicable prospectus supplement. When a global security terminates, the depositary, and not we or any applicable trustee, is responsible for deciding the names of the institutions that will be the initial direct holders. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center">25 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center"><B><A NAME="rom382980_10"></A>PLAN OF DISTRIBUTION </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL">We may sell the securities from time to time pursuant to underwritten public offerings, direct sales to the public, negotiated transactions, block trades or a
combination of these methods. We may sell the securities to or through underwriters or dealers, through agents, or directly to one or more purchasers. We may distribute securities from time to time in one or more transactions: </P>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">at a fixed price or prices, which may be changed; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">at market prices prevailing at the time of sale; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">at prices related to such prevailing market prices; or </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">at negotiated prices. </TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL">We may also sell equity securities covered by this registration statement in an &#147;at the
market offering&#148; as defined in Rule 415 under the Securities Act of 1933, as amended, or the Securities Act. Such offering may be made into an existing trading market for such securities in transactions at other than a fixed price, either: </P>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">on or through the facilities of the Nasdaq Global Market or any other securities exchange or quotation or trading service on which such securities may be listed, quoted or traded at the time of sale; and/or
</TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">to or through a market maker otherwise than on the Nasdaq Global Market or such other securities exchanges or quotation or trading services. </TD></TR></TABLE>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL">Such at-the-market offerings, if any, may be conducted by underwriters acting as principal or agent. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL">A prospectus supplement or supplements (and any related free writing prospectus that we may authorize to be provided to you) will describe the terms of the offering of
the securities, including, to the extent applicable: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">the name or names of the underwriters, if any; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">the purchase price of the securities or other consideration therefor, and the proceeds, if any, we will receive from the sale; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">any over-allotment options under which underwriters may purchase additional securities from us; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">any agency fees or underwriting discounts and other items constituting agents&#146; or underwriters&#146; compensation; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">any public offering price; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">any discounts or concessions allowed or reallowed or paid to dealers; and </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">any securities exchange or market on which the securities may be listed. </TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL">Only underwriters named in the prospectus
supplement will be underwriters of the securities offered by the prospectus supplement. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL">If underwriters are used in the sale, they will acquire the securities for
their own account and may resell the securities from time to time in one or more transactions at a fixed public offering price or at varying prices determined at the time of sale. The obligations of the underwriters to purchase the securities will
be subject to the conditions set forth in the applicable underwriting agreement. We may offer the securities to the public through underwriting syndicates represented by managing underwriters or by underwriters without a syndicate. Subject to
certain conditions, the underwriters will be obligated to </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center">26 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL">
purchase all of the securities offered by the prospectus supplement, other than securities covered by any over-allotment option. Any public offering price and any discounts or concessions allowed
or reallowed or paid to dealers may change from time to time. We may use underwriters with whom we have a material relationship. We will describe in the prospectus supplement, naming the underwriter, the nature of any such relationship. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL">We may sell securities directly or through agents we designate from time to time. We will name any agent involved in the offering and sale of securities and we will
describe any commissions we will pay the agent in the prospectus supplement. Unless the prospectus supplement states otherwise, our agent will act on a best-efforts basis for the period of its appointment. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL">We may authorize agents or underwriters to solicit offers by certain types of institutional investors to purchase securities from us at the public offering price set
forth in the prospectus supplement pursuant to delayed delivery contracts providing for payment and delivery on a specified date in the future. We will describe the conditions to these contracts and the commissions we must pay for solicitation of
these contracts in the prospectus supplement. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL">We may provide agents and underwriters with indemnification against civil liabilities related to this offering,
including liabilities under the Securities Act, or contribution with respect to payments that the agents or underwriters may make with respect to these liabilities. Agents and underwriters may engage in transactions with, or perform services for, us
in the ordinary course of business. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL">All securities we may offer, other than common stock, will be new issues of securities with no established trading market. Any
underwriters may make a market in these securities, but will not be obligated to do so and may discontinue any market making at any time without notice. We cannot guarantee the liquidity of the trading markets for any securities. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL">Any underwriter may engage in over-allotment, stabilizing transactions, short-covering transactions and penalty bids in accordance with Regulation M under the Exchange
Act. Over-allotment involves sales in excess of the offering size, which create a short position. Stabilizing transactions permit bids to purchase the underlying security so long as the stabilizing bids do not exceed a specified maximum price.
Short-covering transactions involve purchases of the securities in the open market after the distribution is completed to cover short positions. Penalty bids permit the underwriters to reclaim a selling concession from a dealer when the securities
originally sold by the dealer are purchased in a stabilizing or covering transaction to cover short positions. Those activities may cause the price of the securities to be higher than it would otherwise be. If commenced, the underwriters may
discontinue any of the activities at any time. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL">Any underwriters or agents that are qualified market makers on the Nasdaq Global Market may engage in passive market
making transactions in the securities on the Nasdaq Global Market in accordance with Regulation M under the Exchange Act, during the business day prior to the pricing of the offering, before the commencement of offers or sales of the securities.
Passive market makers must comply with applicable volume and price limitations and must be identified as passive market makers. In general, a passive market maker must display its bid at a price not in excess of the highest independent bid for such
security; if all independent bids are lowered below the passive market maker&#146;s bid, however, the passive market maker&#146;s bid must then be lowered when certain purchase limits are exceeded. Passive market making may stabilize the market
price of the securities at a level above that which might otherwise prevail in the open market and, if commenced, may be discontinued at any time. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL">In compliance
with guidelines of the Financial Industry Regulatory Authority, Inc. or FINRA, the maximum consideration or discount to be received by any FINRA member or independent broker dealer may not exceed 8% of the aggregate amount of the securities offered
pursuant to this prospectus and any applicable prospectus supplement. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center">27 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center"><B><A NAME="rom382980_11"></A>LEGAL MATTERS </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL">Unless otherwise indicated in the applicable prospectus supplement, the validity of the securities offered by this prospectus, and any supplement thereto, will be
passed upon for us by Cooley LLP, Boston, Massachusetts. </P> <P STYLE="margin-top:24pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center"><B><A NAME="rom382980_12"></A>EXPERTS </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL">The consolidated financial statements, incorporated in this prospectus by reference from the Company&#146;s Annual Report on Form 10-K have been audited by
Deloitte&nbsp;&amp; Touche LLP, an independent registered public accounting firm, as stated in their report, which is incorporated herein by reference. Such financial statements have been so incorporated in reliance upon the report of such firm
given upon their authority as experts in accounting and auditing. </P> <P STYLE="margin-top:24pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center"><B><A NAME="rom382980_13"></A>WHERE YOU CAN FIND MORE INFORMATION </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL">This prospectus is part of the registration statement filed with the SEC under the Securities Act and does not contain all the information set forth in the registration
statement. Whenever a reference is made in this prospectus to any of our contracts, agreements or other documents, the reference may not be complete and you should refer to the exhibits that are a part of the registration statement or the exhibits
to the reports or other documents incorporated by reference into this prospectus for a copy of such contract, agreement or other document. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL">Because we are subject
to the information and reporting requirements of the Exchange Act, we file annual, quarterly and current reports, proxy statements and other information with the SEC. Our SEC filings are available to the public over the internet at the SEC&#146;s
website at http://www.sec.gov. You may also read and copy any document we file at the SEC&#146;s Public Reference Room at 100 F Street, N.E., Washington, D.C. 20549. Please call the SEC at 1-800-SEC-0330 for further information on the operation of
the Public Reference Room. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL">You may also access our filings with the SEC on our web site, www.minervaneurosciences.com. Other than those filings with the SEC that
we specifically incorporate by reference into this prospectus or any supplement to this prospectus, information found on, or accessible through, our website is not a part of, and is not incorporated into, this prospectus, and you should not consider
it part of this prospectus. </P> <P STYLE="margin-top:24pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center"><B><A NAME="rom382980_14"></A>INCORPORATION OF CERTAIN INFORMATION BY REFERENCE </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL">The SEC allows us to &#147;incorporate by reference&#148; information from other documents that we file with it, which means that we can disclose important information
to you by referring you to those documents. The information incorporated by reference is considered to be part of this prospectus. Information in this prospectus supersedes information incorporated by reference that we filed with the SEC prior to
the date of this prospectus, while information that we file later with the SEC will automatically update and supersede the information in this prospectus. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL">We
incorporate by reference into this prospectus and the registration statement of which this prospectus forms a part the information or documents listed below that we have filed with the SEC: </P>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">our Annual Report on Form 10-K for the year ended December&nbsp;31, 2014, filed on March&nbsp;26, 2015; </TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center">28 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">our Quarterly Report on Form 10-Q for the quarter ended March&nbsp;31, 2015, filed on May&nbsp;7, 2015; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">our Current Reports on Form 8-K filed on January&nbsp;5, 2015,&nbsp;January&nbsp;20, 2015,&nbsp;January&nbsp;21, 2015,&nbsp;March&nbsp;3, 2015,&nbsp;March&nbsp;13, 2015,&nbsp;March&nbsp;18, 2015,&nbsp;March&nbsp;26,
2015,&nbsp;April&nbsp;17, 2015,&nbsp;May&nbsp;19, 2015,&nbsp;June&nbsp;16, 2015 and June&nbsp;18, 2015 (other than any portions thereof deemed furnished and not filed); and </TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">the description of our common stock contained in our Registration Statement on Form 8-A, filed on June&nbsp;23, 2014, including any amendments or reports filed for the purposes of updating this description.
</TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL">We also incorporate by reference any filings we may make with the SEC under Section&nbsp;13(a), 13(c), 14 or 15(d) of the Exchange Act (i)&nbsp;after
the date of the filing of the registration statement of which this prospectus is a part and prior to effectiveness of such registration statement, and (ii)&nbsp;after the date of this prospectus but prior to the termination of the offering of the
securities covered by this prospectus. We will not, however, incorporate by reference in this prospectus any documents or portions thereof that are not deemed &#147;filed&#148; with the SEC, including any information furnished pursuant to
Item&nbsp;2.02 or Item&nbsp;7.01 of our current reports on Form 8-K unless, and except to the extent, specified in such current reports. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL">We will furnish without
charge to each person, including any beneficial owner, to whom a prospectus is delivered, on written or oral request, a copy of any or all of the documents incorporated by reference in this prospectus, including exhibits to these documents. You
should direct any requests for documents to Mark S. Levine, Vice President and General Counsel, Minerva Neurosciences, Inc., 1601 Trapelo Road, Suite 284, Waltham, Massachusetts 02451; telephone: (617)&nbsp;600-7375; E-mail:
mlevine@minervaneurosciences.com. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL">You also may access these filings on our website at www.minervaneurosciences.com. We do not incorporate the information on our
website into this prospectus or any supplement to this prospectus and you should not consider any information on, or that can be accessed through, our website as part of this prospectus or any supplement to this prospectus (other than those filings
with the SEC that we specifically incorporate by reference into this prospectus or any supplement to this prospectus). </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL">Any statement contained in a document
incorporated or deemed to be incorporated by reference in this prospectus will be deemed modified, superseded or replaced for purposes of this prospectus to the extent that a statement contained in this prospectus or in any other subsequently filed
document that also is or is deemed to be incorporated by reference in this prospectus modifies, supersedes or replaces such statement. Any statement that is modified or superseded will not constitute a part of this prospectus, except as modified or
superseded. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center">29 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="line-height:2.0pt;margin-top:0pt;margin-bottom:0pt;border-bottom:2.00pt solid #000000">&nbsp;</P>
<P STYLE="line-height:3.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000">&nbsp;</P> <P STYLE="margin-top:24pt; margin-bottom:0pt; font-size:16pt; font-family:Times New Roman" ALIGN="center"><B>5,000,000 Shares </B></P>
<P STYLE="font-size:55pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="margin-top:0pt;margin-bottom:0pt" ALIGN="center">


<IMG SRC="g382980g82i05.jpg" ALT="LOGO">
 </P> <P STYLE="margin-top:55pt; margin-bottom:0pt; font-size:14pt; font-family:Times New Roman" ALIGN="center"><B>Common Stock </B></P> <P STYLE="font-size:55pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><center>
<P STYLE="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000;width:21%">&nbsp;</P></center> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman" ALIGN="center"><B>PROSPECTUS
SUPPLEMENT </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><center> <P STYLE="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000;width:21%">&nbsp;</P></center>
<P STYLE="margin-top:55pt; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman" ALIGN="center"><B><I>Joint Book-Running Managers </I></B></P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:16pt" ALIGN="center">


<TR>
<TD WIDTH="51%"></TD>
<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD WIDTH="47%"></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:16pt">
<TD VALIGN="top"><B>Citigroup</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" ALIGN="right"><B>Jefferies</B></TD></TR>
</TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman" ALIGN="center"><B><I>Lead Manager </I></B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:14pt; font-family:Times New Roman" ALIGN="center"><B>JMP Securities </B></P> <P STYLE="font-size:48pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><center>
<P STYLE="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000;width:21%">&nbsp;</P></center> <P STYLE="margin-top:48pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>June&nbsp;29,
2017 </B></P> <P STYLE="font-size:30pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="line-height:1.0pt;margin-top:0pt;margin-bottom:0pt;border-bottom:1px solid #000000">&nbsp;</P>
<P STYLE="line-height:4.5pt;margin-top:0pt;margin-bottom:2pt;border-bottom:2.00pt solid #000000">&nbsp;</P>
</BODY></HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>2
<FILENAME>g382980g60u25.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g382980g60u25.jpg
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M&"-!L[>XU@HD)55WF#E14F'2)T)Q)BA38V21_\0 ' $!  ,! 0$! 0
M      $" P0%!@<(_\0 7A$  0," P(&"! +!0<$ @(# 0 " P01!1(A$S$&
M%")!46$R4W&!H;'2X146%R-"4E1SD9.4E<'1T_ S57)T=9*BLK34X@<T-;.U
M)#9B@K;#\25$5G9#8Z/5)D7"_]H # ,!  (1 Q$ /P#P7Y^X+^#TX1.$3A$X
M1.$3A%N'0?\ )I[V?^F%*_\ ,I5W.&I_O>'>_3_PDR]_"_\ !^$WYEAW^L42
MT\YW+P$X1.$3A$X1.$3A$X1;A=4?XI=T/ZGLF_XW4/SAK>SH/SYG\/4KWL$_
MN_"'] R_ZEA:T]YW+P4X1.$3A$X1.$3A$X1.$3A%N#W"_#NMG]3[K_\ X>>\
MX:'=5_GU3^^%[^/]GA'Z PK_ ""M/N=R\!.$3A$X1.$3A$X1.$6X7B!_RV.S
MO_K!+OT[;G#AG^'T?YO'^Z%[W"C_ 'BQG](5'[Y6GO.Y>"G")PB<(MP>N_\
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M[V"?W?A#^@9?]2PM:>\[EX*<(G")PB<(G")PB<(G")PBW![A?AW6S^I]U_\
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MLS,0(]S#M,Q(_!Y\OLK)3\&,=JSA(IZ R''6U3L+M44K14MH@34DET[13[,
MVXR83):T><Z+5DG$I.'T46) 2K9JF9?1[#_9DNH,6.#5=D'PMH42T4'O7C93
M3;"B+1RMMY/)OCRZ;:[9[0]CMSFDY0ZUQ?*=SB-X!Z2%XKX98P2^-X;M'19L
MI+#(SLF->+M<X6U#2=-=ROXF@;D.1*>S897T@< :Q/PF,3G&R"3<V!-6*-F!
MB'M5(LZ61E#U,J+@4L?J/1H=XQ%M1.5B[EAH]'Y=Y.J8&OBC,K0Z9LCX]Y:Y
ML1C;(0\#(,KI6"Q<"XNY(-C;ICPS$)8*JH92RF*BDIH:K0"2*2K9424[3"2)
MG9V4L[RYD;FL:R\CFAS<V.T(Q)'3!D5;1XXX%D2>@0>20$OUF#\RIY/,$LGB
M;?9NZ)[^7'F,$%-W6WEQY$L^7FI>P$@N:"!F(+A<-Z2+W Z]RY1#*6M>(I"Q
M[]DQX8XM=)OV;7 6<^WL 2[J5D'5?-R(N8%\!]!K2#1(9.#J4A)"XR04C)F1
M@XJ-( !4@>C2<LW=%Y$,\QC%VA=_@;E\;W:ZAA11^SJ9HP6-S7,CS&W*"\9V
ML<\AQ:"&6:QVKRT9K-OF<T'9M'4.9/)L\C::!E3*)7LA>89)HH&/B9*YCY\T
MDT?)A;([(72$;-CW-B<P6;X)^Q<PZ58,X2:+Y$YCQ?VGA AG&&"WJ'J?K7HG
MN=M<-%/1>8YSMC".=_+CD[2/+FSLRZ\K,,NF_6]M.=9\6J,^SV$VTLTY-D_/
M9W8G+ES6=?DFVO,N!"'2YT_8"FT6D;@H588*BQJ 0FL_)"\Z*J8),&:;79P\
M89307WP\;IJ-\Z(J[84\B>^<3G8 79VV!RDYA8'H)O8'4:'750()W.:QL,KG
MO;G8P1O+GLL3G:T"[FV!.8 BP.NA5>VUVTVVTWUVUWUVSKMKMC.NVNVN?)MK
MMKGR9QMC.,XSC./+C/W,\LLEN!X@?\MCL[_ZP2[].VYPX9_A]'^;Q_NA>]PH
M_P!XL9_2%1^^5@"IZJGEXV1#JDJ\'B2V#/S3:.Q,#L4#A=2AAWC?+=IDM("
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M"2 02TV(!!(/0>@]U><Z.1@8Y['L$C<S"YKFA[?;,) #F]8N%&<E46X/7?\
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M"HB#[%KB)L/XFT/#8LQ#) 'ESI)"]MK-C++.[*;AQA5/3TT+*7$0V&OPVM=
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M0-#Y"YA$."S:+M4'3CU-30!,01X840?;MD";9@];^L#FSS"[1'9V(,=!25$
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ML#FD<X()!'0O<_L1T"ZJZRSL8J+ULF#S5V^\1:T(3@#((6.I.N(_U2[-2J!
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MP\6T6J^0  D&K2",A4QJ* 2T>HVII"0,JID1!B="/69.7083*3H(8;(-W&2
M1^H,D+<TVUTUUH_"Z1[B^TS7.EFE+HYY6&]1DV[ 6N!$<KF-<YH/)<+L+5O#
MPLQ>&*.&]'+%%34=,V.HH*6=EL/$K:&9S9(W-?/31SRQ,D<#GC<63"1JNEA^
M)-:AN%UC!Z]CT(A;&'U/1%>3,V3K^NY3*K$<T;(DIJ*8R X5BJJI2MGLX8!Y
M2I71M(H'7>#$61/V@(_\.Y2/"H1)-+*Z20R35$K&B65C(N,,V;BQK7C+*(RY
MFU;9P#B6Y2;KHJ^%U;)34=-2Q4U.VGH<,I*B5]+2SSU9PV85,;99)("7T;JE
ML<YI)!)&YT8:_/'R%K+V&[/VMV=+0XG9SP!AM7T75AT) 16.#8Q'HV <GB\G
M>,QX\>GC;;UP\=*$%5':[G='#A)@SRU%LF+%MU4M)#2"00AUY7[21SWN>Y[P
MUK 22>9K6C0"]KF[B2?'Q7&:[&7T[ZQT5J6$T]-%#"R&*&(R/F<UC& =E+(]
MY+BZUPQN6-K&-UYYU+RDX1.$3A$X1.$3A$X1.$3A%N'0?\FGO9_Z84K_ ,RE
M7<X:G^]X=[]/_"3+W\+_ ,'X3?F6'?ZQ1+3SG<O 3A$X1.$3A$X1.$3A%N%U
M1_BEW0_J>R;_ (W4/SAK>SH/SYG\/4KWL$_N_"'] R_ZEA:T]YW+P4QGR?=Q
M]S./NXSC_9PB^^55,_?4WSY<;8SY=]L^7&^?+OC[N?O;9^[M_P#5G[N?+PBY
M-W3E7S/2.%U/,3U1T\]53?S$M-/1Z):>=MGS4]4_VFNF/)KKI^UQC&/N<(==
M^NEM>@: =P#2R^^'SW&R.^'CK&S9'9NWVPX5QLW0W])C=!'.-_*DCMZ57SD]
M,ZZ;>D4\NN?/V\JPZ%-SH;FXT!N=!KH.C>?A/2N+TZ^-=M<+*XUVSKMMKZ3?
MS=LZZ;)ZYVQY?)G.J>^VFN<_=QIMMKC]KG.,E"^=G+C?1%/=PMLFVUWU;I[*
MJ;:-]5-L[J:HZYVSJEJIOMMOOC3&N-]ML[;>7.<YX4W)L"20- .C6^G1J2>Z
MOE)TY0\_*+E='TB.[93T2RB?GMU/N*-]_,VQYR.^/W:6WE3V_P#W:YX4 D;C
M;0C3H.\=P\X7!PB<(MP>X7X=UL_J?=?_ /#SWG#0[JO\^J?WPO?Q_L\(_0&%
M?Y!6GW.Y> N;UA?T.&WIUO5]5<KZH>DW]#JOG7&F5L)>=YF%<Z:ZZ94QKY^=
M<8U\ODQC'"FYM:YM>]N:_3;I7'Y^_P"V_;;?M_W?[;/[?[OG?MON_MOVV/+]
MWR_=^[]_A0N5-RY2QOA)PNGA5'9NIA-533"C??.-MT-\:[8QNCMMC&VR6WET
MVSC&<ZYSCA 2+V-KBQMSCH/2.I?3*RNVFJ6RJF4],>35/.^V=-<>=G?R:Z9S
MYN,>=MMMY,8Q^VSG/W\YSPB^ZSERX4W57<+KJJ8TUW465444WPEKKJGC???;
M;;;">NFFNF,YSC3777&ODQKCR+*223<DD])U*X<YSMG.VV<[;9SG.<YSG.<Y
MS]_.<Y^[G.?]N<\*%\<(MPO$#_EL=G?_ %@EWZ=MSAPS_#Z/\WC_ '0O>X4?
M[Q8S^D*C]\K411TY6VQLLX75VU230UV454WVU01QKJBCC.VV<X22UUUPFGC]
MIIC77&N,8QCG=:V[NKP2;[];"VO1T=Q<?I5/_P"YO]W&V,_M]ONXWSYVV/O_
M 'MMON[8_P!N?NY\N>$7W]9<>B50]86]"LIHJLCZ53T2RJ>-\)J*I^=YBBB>
M%-\:;[XSMIC??&N<>=GRDN;6OH=XYC;=\%U\JNG*^V^Z[A=;=3]WNJJHIMO]
MS3'[?;?;.=ON)Z8^[G/W--,?_MQY"$DZDW/2=5MUUW_D_P#?G^KY5W_.'ULY
MPU7]YPW\ZF_@*M>]A/\ AG"?]$T?_4&#+3[G<O!3A%\YVVV\GG9SGR8QKCRY
MSGR:X^]C'E^]C'^S&/N8X1?'"+<+HI_*!7_J^]R/^3V]N<.(_P!V'YU0?Q],
MO>X-_P")N_1/"'_I_$UI[SN7@IPB<(G")PB<(MP>XO\ "G7/^I]UU_P?GG#0
M[JO\^J?WPOH.$/9X1_\ 7\(_AUI]SN7SZ<(G")PB<(G")PB<(G"+</N?_&NB
M?ZGG5'_@Q&.<-!V%1^?5O\0]>]P@_O&'?H' _P#3:=:><[EX*<(G")PB<(G"
M)PB<(G")PB<(G")PB<(G")PB<(G")PBW#H/^33WL_P#3"E?^92KN<-3_ 'O#
MO?I_X29>_A?^#\)OS+#O]8HEIYSN7@)PB<(G")PB<(G")PBW"ZH_Q2[H?U/9
M-_QNH?G#6]G0?GS/X>I7O8)_=^$/Z!E_U+"UI[SN7@IPB<(G")PB<(G")PB<
M(G"+<'N%^'=;/ZGW7_\ P\]YPT.ZK_/JG]\+W\?[/"/T!A7^05I]SN7@)PB<
M(G")PB<(G")PBW"\0/\ EL=G?_6"7?IVW.'#/\/H_P WC_="][A1_O%C/Z0J
M/WRM/>=R\%.$3A$X1;@]=_Y/_?G^KY5W_.'ULYPU7]YPW\ZF_@*M>]A/^&<)
M_P!$T?\ U!@RT^YW+P4X1.$3A%N%T4_E K_U?>Y'_)[>W.'$?[L/SJ@_CZ9>
M]P;_ ,3=^B>$/_3^)K3WG<O!3A$X1.$3A$X1;@]Q?X4ZY_U/NNO^#\\X:'=5
M_GU3^^%]!PA[/"/_ *_A'\.M/N=R^?3A$X1.$3A$X1.$3A$X1;A]S_XUT3_4
M\ZH_\&(QSAH.PJ/SZM_B'KWN$']XP[] X'_IM.M/.=R\%.$3A$X1.$3A$X1.
M$3A$X1.$3A%[3?$ >)9^+2N?KJK3[?YX'IFPGMTOR>;R%^A^I=PP]QTGSC1_
M:I\0!XEGXM*Y^NJM/M_CTS83VZ7Y/-Y">I=PP]QTGSC1_:I\0!XEGXM*Y^NJ
MM/M_CTS83VZ7Y/-Y">I=PP]QTGSC1_:I\0!XEGXM*Y^NJM/M_CTS83VZ7Y/-
MY">I=PP]QTGSC1_:I\0!XEGXM*Y^NJM/M_CTS83VZ7Y/-Y">I=PP]QTGSC1_
M:I\0!XEGXM*Y^NJM/M_CTS83VZ7Y/-Y">I=PP]QTGSC1_:I\0!XEGXM*Y^NJ
MM/M_CTS83VZ7Y/-Y">I=PP]QTGSC1_:K8RIO!#\0:*TGVIAAFO8&B>M"#5F$
MB""-NU\Y0=D(W=4%F15-V[1-[(#DT@00@NDL[W33773T:I;;+K)Z;<L_"'"W
MU%&]LLF6&29S_6)00'4\D8L,MSRG :;AKN7K4/\ 9QPJ@P[&Z>2DI1+6TU'%
M3@5](0Y\.(TU0\.<);, BB>07$7(#1J5KG\0!XEGXM*Y^NJM/M_G5Z9L)[=+
M\GF\A>3ZEW##W'2?.-']JGQ 'B6?BTKGZZJT^W^/3-A/;I?D\WD)ZEW##W'2
M?.-']JGQ 'B6?BTKGZZJT^W^/3-A/;I?D\WD)ZEW##W'2?.-']JGQ 'B6?BT
MKGZZJT^W^/3-A/;I?D\WD)ZEW##W'2?.-']JGQ 'B6?BTKGZZJT^W^/3-A/;
MI?D\WD)ZEW##W'2?.-']JGQ 'B6?BTKGZZJT^W^/3-A/;I?D\WD)ZEW##W'2
M?.-']JGQ 'B6?BTKGZZJT^W^/3-A/;I?D\WD)ZEW##W'2?.-']JGQ 'B6?BT
MKGZZJT^W^/3-A/;I?D\WD)ZEW##W'2?.-']JMBZ"\$+Q!H)'NRS"1U] F[FQ
M^NANO8MJWMVOGFKJ3O;/JB2MVSK=N;WU8-MA,6,+;/G64VVBJ*3?*GIG*.F_
M+4\(<+D=2%LLA$54V5]X)19@AF9<7;J<SVZ#7X%ZV%_V<<*J:+&&2TM*TU>$
MR4L-J^E=FF-;0S!I+9#E&S@D.9UFW !-R%KI\0!XEGXM*Y^NJM/M_G5Z9L)[
M=+\GF\A>3ZEW##W'2?.-']JGQ 'B6?BTKGZZJT^W^/3-A/;I?D\WD)ZEW##W
M'2?.-']JGQ 'B6?BTKGZZJT^W^/3-A/;I?D\WD)ZEW##W'2?.-']JGQ 'B6?
MBTKGZZJT^W^/3-A/;I?D\WD)ZEW##W'2?.-']JGQ 'B6?BTKGZZJT^W^/3-A
M/;I?D\WD)ZEW##W'2?.-']JGQ 'B6?BTKGZZJT^W^/3-A/;I?D\WD)ZEW##W
M'2?.-']JGQ 'B6?BTKGZZJT^W^/3-A/;I?D\WD)ZEW##W'2?.-']JGQ 'B6?
MBTKGZZJT^W^/3-A/;I?D\WD)ZEW##W'2?.-']JGQ 'B6?BTKGZZJT^W^/3-A
M/;I?D\WD)ZEW##W'2?.-']JGQ 'B6?BTKGZZJT^W^/3-A/;I?D\WD)ZEW##W
M'2?.-']JMB^QG@A>(-83JEE8Q7T"=:0WKI4=>G<N;=KYCE"3Q0.Y:&FJ&'1M
M/+ILBLKIJB^0\]JYQG.R"F^N,YYRTO"'"XQ49Y9!GJIY&V@E-V/<"TZ--C;F
M.HYPO6Q?^SCA55NPXPTE*X4^$T%++>OI&VF@C+9&C-*,P!W.%VGF*UT^( \2
MS\6E<_756GV_SJ],V$]NE^3S>0O)]2[AA[CI/G&C^U3X@#Q+/Q:5S]=5:?;_
M !Z9L)[=+\GF\A/4NX8>XZ3YQH_M4^( \2S\6E<_756GV_QZ9L)[=+\GF\A/
M4NX8>XZ3YQH_M4^( \2S\6E<_756GV_QZ9L)[=+\GF\A/4NX8>XZ3YQH_M4^
M( \2S\6E<_756GV_QZ9L)[=+\GF\A/4NX8>XZ3YQH_M4^( \2S\6E<_756GV
M_P >F;">W2_)YO(3U+N&'N.D^<:/[5/B /$L_%I7/UU5I]O\>F;">W2_)YO(
M3U+N&'N.D^<:/[5/B /$L_%I7/UU5I]O\>F;">W2_)YO(3U+N&'N.D^<:/[5
M;%]NO!"\0:V.S=XV3"Z^@3V*36Q9#(0#MY;M?#73@80=Y5;*KL'IM)VT4VT^
M[L@X3T5TS]S;7&><M#PAPN&CIHI)9 ^.%C' 02N <T6-B&D'O%>MCO\ 9QPJ
MK<9Q*KIZ2E=!45<TT3G5](QQ8]UVDL=('--MX(!"UT^( \2S\6E<_756GV_S
MJ],V$]NE^3S>0O)]2[AA[CI/G&C^U3X@#Q+/Q:5S]=5:?;_'IFPGMTOR>;R$
M]2[AA[CI/G&C^U3X@#Q+/Q:5S]=5:?;_ !Z9L)[=+\GF\A/4NX8>XZ3YQH_M
M4^( \2S\6E<_756GV_QZ9L)[=+\GF\A/4NX8>XZ3YQH_M5L73O@A>(-$:C[9
MQ,W7T"0-6K4,%B4-11MVOG2+PT#[&4K81!!XY0-[HC44XQ#3SI-R\W206<H(
M,4]]G3I!/?EGX0X6^>B>V60MAGD?(=A*+-=25$0L"VYY<C187-KG<"O6P_\
MLXX504..0R4M*)*W#Z:"G KZ1P=)'B^&U;PXB0A@$--*<SB 7 -'*< M=/B
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MESK-!*UT^( \2S\6E<_756GV_P ZO3-A/;I?D\WD+R?4NX8>XZ3YQH_M4^(
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MIS&^G3S]2T%2VW8.!NTDAU[N:6'-8BUSE-SE+KF^8[E:JOZ72^"V;6=A&;*
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M'%]SX$XA*R-5QZ?24'#BL+F.@B0F:$:=B=X0&%(RH?84C45@#QLZ#3!K D8
M1($1(!>5,9*[4#-XS#P7[FE^[NZE9U*\$V(MG+6EP<VX$IBS$Y2QO*&K2_,!
M<VMJLN1'N/54Q$[%QS.1:HIJULBKJV=P23ML;VI<A&CXQEM(()-Y9$BJ:<N&
MJO"RP:0D46 15/?TBQE)X%:3F'B\)M]_K5# \&VGL_;#L&"0Z.:TBX-A<#7?
M86)P; _$0"O8:*DMEUC(XM@GFL6;0J+D%>Z1<H_G5$UM<Q/U8C,IQ%-63D7O
M8*04+$E'#Z:S%-%LO$ A\@G(1D>@.TUZNCG%^<K1U,<Y:QX=;/I9^8!LCXQH
MUIO?+<D:#6Y RD^D7++E3A$X16R7_A03\DXQ_<[;A:R[X_>H_$JGPLEYIO*9
M[F#@:3Z+VG(]YL[A2"#W>2SG0W'F<O*TU=3"2+-0BVNHS"2%J9HI<#OHAEN'
M3$/R W1N@5G6)'!OS??0_39=0?"39S&Y<WL6V):'QVUU/8;2_3N]K:"VJ'NP
M85$B'\Y/-8D_ $1C5LY*X:EXTW(RJP=I2PG19K=<H?/79N D84#A175>]C$>
M),%WR$EA)9NK)"46/3][F^X]%K;^\K;2 7(8TG2]AH2&MRE@+!N<"7#UL.!L
M0X:*4B-)]J(^!(.QLH-Q(B&84<K"1+B5M##+#UF6 B[B>6"-$;E]9X43K]F_
M9)[$WDA6+$=='@==P>;AB;19W3T6\%[\_A4.? 2!E!!,F8V(.XF,-)[$9M=+
M :7L+A2M,D>PLQH>XR,1]XXZ<"9Y!"54,[J+NDWDES%(+3LDG,?V,DV6SUI"
M[!G+6PXTJL]1W4C_ +=*L,#8NJ%Q$HW(O;G[_>ZMU]/%S*)!&)69LN4M.?9C
M1N9T@:;#V36%AZ["]SJ:7(>N/:N0"0C692Q_/'49D'LQ@40E8T%(3,3C,LJ:
M/1TN>>,/8"#E>:1N)2VU)Y'/6,BMS,C<A<LRC\>%;<:^'Q=RV_?W[*PEA!.5
MN0$ D6N XAY(&\V87!C3OL+[B2LK*=<[0)];)E1IXP]-X(2^BL1I:2&A,M<,
M8='!U"/[&2VVDS P&<MTI?'+2)BXT8%D8]NBY;!V0;2+KC@B$6TMW/@%K]/7
MO\2IM6"42#VLM[ MNYQE#=UCV)9<@@\][W*HLTZC/QLDDH6#U='9"H;IVK(7
M6EUK"*>A3NE9W&[.O.72">MA4."1!X$+A4+#B9X#BMX2GK*C$>0'2-VPVV=F
M\LOB%CIIJ>CHNK">X:7/(M(]SV7>X/:61-#>47 AV5P.=W)!N!N"RS2--W;"
M+7M:Q)J3C),;V!"&CTH#"VCMB1@4LC,E=-*M"OB2\J-C9H]VJ>3H0([)@0.*
M,D$*AB>NS CL2R_TD ZD\_W\7<W+.1\;F-:W,#'9K2;6<TMY9L!=O+&8 N<?
M7';K66#F%$]R(3#JUA,*G9M$''(U'F"V'$E1D)43.F]:U('9F'#MW-85I[MH
M[+@EH.B<5UVF@#;!T2F+J&2ATVK,$^KG\'G6AD@<7.<W4EVX6&7,\V L3G(+
M+'DG0W>#ONM64=>D?LNIEYB@8=1FOK!.R=B[;S80K!@<()T3,X2WCR</3=ID
MGD^]Z$KD1]S(4Q&Z&T3D;)BO(W_LUL#CC6_?OX+>,JKY(RU^6UW- /).8N$C
M3>^[+D:!;347MJ2?1ODKF3A%K//NV%45MV,IKJ_)]I&A9%Z!)0=A+ML(17B:
M36)LW[Q\B>-[/TE!3M[D>HS$I^H.$WI!PS9^F25=)XS%[$#IOX-5JV%[HGS"
MV2,@.UUUMN%M=]ST"Y6M$7\5_JO+X8E/@J=F*QQR%[*R%HX7B#)!9X'ZK0&+
M658[YLAM(,YW0)168A'<+WSMKJ>564T7R-2UT64@.!%QUGX+?7HM74<S793D
MO>(=E?69SFLYN8M.;H[JV#I_N92%[%Z@$5N4,F=[LI647M#WNPQ)!@WB<+E<
M5A$I#R!7UW=<5, <IEK,,1!>KN-6ST<914>Z[L==5YN#;KU^_P *S?!)&'EX
M V<@B<+ZYG-<YI'2TAI(/<Z5.N^V-&LKW-=<5I=CWG1:L));TQ9X8NM L0A4
M87B2;YU(#JVB3!L]7;S,22:L&V[M; S1T\>^I:>J8=KB]N=5V,FS$N7D%XC!
MTN7.#B !O]B=>E80#^)AU5(5W8%G%CTUA,;KV(1*PW*$[KV41@Y*Z^L(;("E
M<S>"AGK++R3QV>MXL>TCCEKJFX]88;)%VHK*S?*L9A8GN<UM^[>M32S![6 -
M<7.<V[7 AKF$![7'F+<S;]1%KK=N'2D5.8C%9L"RXR$F,<!RD/EVCZN[R*D
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MMVJC24-FA!RR5];09@G&K=!MM(=X(W^#X+??<K,J '-+LYY0S.+K\G;[8OL
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M_NR"K%0DI8.^SE/-H*K0];=_XZ==]^?Q]-Q(J&@GDOLZY/+!RW+#E8"+!MV
M=S+[2SLG4_TY*519,"DFDBA9F/UZI.G;(TK%B_O5D2D^B4>CCD5(9>3D1=9R
M%CBL?2U#9>+%R#P G' SURDXB>2D@6U!Z/#<6^_W)J^</8YN5P+\MQF&0923
M<"PU=?7<!J1OL*=MT&)YF&Q[%ELL1_:[-^P'P3^#2_JF+4SVT7N_2;>M>U_.
MR>Q2SA2B=U,H^@V0U3.^9A+7V;E;QWW<][^+13Q@6MEUV>RS7%\FPV>7=V.T
M]<W]2Q,_Z(VO&P>41LK&F9E*EJ/@.DH@X5*,-H2"!M+E@%SV,X$OY&,!A&TC
MIJZ9OI%H? 0Z#")SQG!F[,0>08NY#QETZ]!\%QX0=W_E7XPPGL2&C:.LXW))
MV;HVAP!)M)&V[G7):7:CL5ZYCAS$0/8"1;1N/&"V;4<.8-$M$&K)BR0T;-&C
M9%/&-$6[9NDFBBEIC&B:>FNFN,8QC'++B))))U)U)ZRKQ+_PH)^2<8_N=MPM
M9=\?O4?B6LU W6G?<&=SA.LK7J?5I+Y9$LQ>Y(EF%RQ?:*EUA6QUN(R]?^D
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M4!"&;LDZ*$7<C$Q]$BXC:^_J\_U;N_=1Q<$ M<;'(+EMS=[82- =!FD-S<Z
M"USKF.)=J6QUM:)DU # *.P".6E+Q"S(GH<D<GC]0V%/*YD^7,9R,%9 &WQ.
M#*$8Z%U*&MWHTNS3)N@Q5NZ&Z3?0GHOX%F8;9 ' EQ8TWT +VM<-1>X&:Q/5
MH"+%="N^PL[L&\ U<*16'1X$+BEF/ITL/ECF:.',CCXKKA*(EK$#S0.#&.@>
M\7OQGF0*O!^CI0^V<M!F?8XEH9E:^MOOS?6CHVMC+LSB<S0WDY>23*TY@22'
M7BT .XZZFPQH&[XH$,0XJ8@B($ =KR%6^7<,Y4/DK$!5=@.P.C>4R"1)MPS$
M"5KP,O)998\;U9&FS"-"&A =)'6I%''%] >Y\!^^O0M#3=D ZY:XL%QES/;?
M0#6^8V:PW%R=0++XDO>,ZE'M2L8JIDB[)G(=%P328S%4<0TD$EB-<VDYTE$?
M%QQ^1CT=:5E8+3.)'ZP^60L!!*+/@2 PB'D96,W1S[KFW-?HZ/#I9&TX)L7G
M0$NLW2P<]FAS:G.W=87;R@="!=(-V\S8]IQJOP,;;#F3^8L6KLLXW//4S4%D
M=?\ 86114R&7) 8FW3)/#%'^LN'83X<0IU'B[? &7&'J[K<,OK;K\%CW.CK'
M6JN@R-+B;D-.FFCFOB:X&Q=H!)SY77&K0-^[G++G3A$X1.$3A$X1.$3A$X1.
M$5L!_P 79K\VA_\ $(WA:L_!S=QG[X53X62<(H,M&@)TA&"I<6U?D88;<R.+
M.W&NVRP0X[C9^(.2;'.-M<:.5HS*9"&WVVQOKEF6=Z8UQMMKMJ4@D @'1PL>
ML7#K?"T'O+%4<ZV4C$Y$QE8" L&)\6LDJ)?;DCSW A-JH:5&L [,@5=,1(8)
MO))'\'00YLV"QS20GDP3 <F8(Z.5E<RR$%I<2#OW:[KDFUR3E%R=387.@4$0
MZC=<2B:K9_581PP6'KBU1&7Q[0"HV=UZYJ5^IL 2+:!<D"E7.E:[+EO4/:I>
M%ZMXT3>.Q#1HT0BP^^[HW;MVBD3RC<\WO>]A?LLXY5KZ/Y0%[!VHL5)*]7Z(
M<,68]S7[-VDU>F'JSAX8DCLH:Q(D #0^-EAIR95+S./&V$3B0PM&):^-1PB)
MB<6$NQ2PV.!6K%8??[]7?4;60;G6T T  %KV(%K-(S.L18@N)!N2L^<E9IPB
MMD8_!)A^2;C^^@?*N]C^4%K'V,WO7_<C53Y99)PB<(G")PB<(G")PB<(G"*V
M2S]W'OR3!?H^_(&[OGQE:R[X_>H_$O*?K%7_ (B,>[D=I)7V-M&(RGJE(EC&
M:"B(G87N1$ZKRIFZA>S-FT",B0)..P30B!F*)8@ZW/R5RS*-E"B;;<GF!FN;
MG3F^_<6TSZ4T\+8F.;.W\*X[CR>5SF]W:LMV+00;;EAV;4I:S6;VJ^KJEWA.
M1R(KV6?D34Y@L >EF3.;AIR[B9**74..!D+1B<R.;PH6/I*T87--X.#?,6;P
MH#UJ6.9>01OMU[P.@VUYQU&_>LKMD9E9GDL (@ U[K$M+;YH['(YH!.T8YN8
MZ@'.;<T-L"][0N#6N(W:-F/5QY@IM>ZT=-5@]C482;7TZCBJ$"(C&Y,G&ABL
M%#D@:+-_JT/M&C!QNBFWLP1.73"0>:]SY^_S<W>&J.;&Q@>6, +1L[AV8WC!
M&87U.<W)')W:Y"U2)H1WL"PH"$;%+FD1F1UK51PQ(]"-?JDX[<CB,7RVF<>W
M8"V,>RI'O; ^E,Y:-CL6BHPOLW*R"0O09*9##+E> ?#8W^C=IX5 -.7$G( '
M/ %G6R7C+3K?763F<XC0 $-(RK1L1F)[L".LR;5+,ZW.M03A0S,'H-@Y,V@>
M.U_%F)K2;S%&0[8C]=Q\BQ<L8/4 T"19-#P<9+U#@9?=:.:M;ZCFW]/T[^KO
M\RI(6B(M:]KA?1M^P <;91;5Y!NYY.H);8V#EZ1<LN5.$3A%^*#QC_\ XI?=
M/\NZR_Y<Z6Y^@<$_\/J/SZ3^'I5^&?VO?[Q8=^@H?]6QA>:W/J%^5)PB<(G"
M)PB<(G")PB<(G")PB<(G"+C553034664T212TV4554VUT333TUSMNHIOMG&N
MFFFN,[;;;9QKKKC.<YQC'*N<UC7/>X-:T%SG.(#6M N22=  -22KQQR32,BB
M8^665[8XXXVN?))(]P:QC&-!<][W$-:UH+G.( !)7OYX6'A8JV*K&>T/:",J
M(P!%1G(*<IV0,]DU)LJGMHZ%6-8HEWIC;2)Z;82?0R&/DL9D>V&\CD3?V)@8
M,+?G>-XXZO<ZFIB64338G4.J2#V3N<1 ZL8=7=F\=BUO]#<"N!4?!Z-N(XBU
MDN.2L.5O)?'A4;VV=%$X7:ZN>TEM14-)$+2ZG@<0999?U(8QY/N8^YC'W,8Q
M_LY\ZOOU;);^^1_\DP'Z+GD#=WSXRM9=\?O4?B7EGW^86X5=T[FM(A,Y3I#2
MQ6R/9,2&2-_O.I/&3$.;A*NU/@Q1<74IZ1BB<C,QVX)BBTCT><1YU'E"P'25
M/)&%@\WW[QWCOG=;FWK6G+0),SFMS ,NX@90X.N^Q(+P+ %C=3>]C8 W^]6+
M65R>@Y9:M;RVP*%S [#5G$"$U[,K#1&6O(M:P>UD<F5/B !.8GQH,"QM<$VV
M?0XCB'R0\+?&A Y]EH8 R>O=T6OT6T[RI'<"1K'M;)F;E<7-9=@SAP:\D 7)
M8;!W* -B;:ZT D.U#&&G:\R]["0=F0B-A^XJ-QR$1J8>;#)5*;]>1 5:]FR@
M.<?P6<5E6JE.APXU:?AS#(LR%-$AEG$UC[%*-;6UY[;NNUS?FT\_-L=B7!WK
M;C=FT)<6\H"+-E8+!S7NVA)REI!)NP64/-2_;0Y 6\<:NK^)OM7$+V.BEJA&
MMFPFK08NO#@"R(Q(%*]"EY'=Q.5--<3"MRAE_P"IJ$)\P*UJ"%  SC=KTG>.
M;FTUW"_6-+7(4M$ ??UNUG6.?>\YP6$9B&L (RN %[-(<22%>VM@=U]K!B(Y
MCFPR%:N)4$TALFDU<M ,EG\=6N(H/F?OIC8Z@7#:"Z!ZT0%.8JN],];73@40
M5-J8F,F15CK)K<='<\>GU=_55+:?(>Q#\IS-#KAIR#+LW&7E7=>XRRZZ7:+%
M91E*MF)]4JU?VX'M.V;&DY:&%9?$V,?+"&HPJ3%+O7H*P %'5X2E^]7Q5VAL
MY(B1L8-F3I] .%.$=0A)WNR7-ATFW3I\&OCZ-RHW+MGY"UC6Y@'$@D@&UV&1
MP;G<-UR &W(U&N(:F@%F"K$KP8Z(7I)CS*;0K4-:1^/VI$H]_HSM>L.0$J#'
MT)?NNSCQ7>^<2=RP@<V=D[4R9>P&8%,G& 763L [_5W+<]^OFW[E=[V%KB!&
M!E==@+"=KM;M(RVOZV6W<WD6#VZ$Y31["K[L0&AL$&-6EF2=C&"'>16/""HJ
MVYK(I?9;OLJL2ZYZ263P27Q@U!,2:N,%,Q.[)&[S&(&,?O"+E\(W(B/6%CUG
M?SG?>XOWMQ*LUT9<XW8TN%.">0UK6;*TN5KFD&SNR8-7&PMH5[-8\ODQY?N9
M_P!N/O\ DS__ !^YY>67"K9+_P *"?DG&/[G;<+67?'[U'XE4^%DO-Z-=QH2
M;=,!SBDPQ4(>D#@4AM6KS>RG@0FO(2%>8$6 !:UZ#3C4V/LG3Y01'6#V2ID(
MRA,%"9H6,#N5']<W?YM-;=W[]*ZS3N%_7""T>S&0$6#KM.8W:"=386);SG2\
M'.QW2MQJLB?'Q=VCB'B+?:>VZK6T0)@Y\XA_JDC8X-1U#&7!=]>,;2*%'>K5
M!-_,#Z)0@FY#SG4+-Q\/F^L+,13\UQRBS1^XM!N#8\PC-@.9HL-6WNL:N+JM
M8D];5.+'QE],2J0B:8CYNNE1:F3:D?96H-P_;G0+39K-&4=FB,WT;/44BS/4
MP4=Z;ZDT#238"/O\/T_?5063-;M"2!JVX?<V!R'<>QNW+IIH.:RB85V>BL@L
MN,P0?7.PE_*Y"ZCVII-V.QZON_*]QWCURLD@-2673>$^IQXDZ2POKEP]GC1T
MMMNX%O5""^MOOS_4I,1#"_-<-%[:\VP'3_\ N '4WKT^(YV,I$"[?1:,P5[$
M"46L,A7V1K>NS 4(S0+W>,J0B=9%XU%R0E!E+)KLBX#L?.;N)239I9>Y9-V1
M(R(7'W!YS;HZ4,4A&9SKAS0ZY<"=(\X!!(.C>[9O>!Z-#V/UB+-@55TQ$03:
M##H;93<RH] 8$Z!/=R)HH<8"2MN?88)&"<BAMMPT@<*&7;DANW'J#97LH:2?
M,QP$;AT>*WUI(R87>\G-F9;6]\QDL6V-AE<QP &ESR=-_*$[/]0K&4:'Q^X>
M0/)\_&U(T(.:S*NR4K5.-0QZ-P==5>.JO';&1!CF).)"$\Z-/9(68DGK9E\"
M9?@*N#KWOILABG;R3<9/7+9@ VUP7;[7:18D:W+;7S-O!H=M^E\)9,YG_P"&
M0162L6<^:.W=3F8C(#$3D(HN=3M+#9Q&1Y9W%'S!Q(5%91G13UEZJ5%:^G+O
M=F+J+M'5WC?ZU.PG=R>RRW;8/#@T@@9-Y -P-!U'=J+_ "3N93D768.">)JE
M%W+R7).YVM Y8UAK87#(M.Y.4D# VY$)MY*+6Q74B%C?@SDJ](N]1KMFT7$G
M 1 I-Q]QU$]_=S*H@>=ULUF\C,"Z[G-: 0.Q/*!.:UAU@@<#7NA3Q_:,-X.K
M()B]D,L@\4?),(Z=091%><6.3K5@M+#.XM82'4V,1V5K#&[AYJF=0C^=A[O*
M!J/N2@$'=K\/U(8'C-FLVP<1<B[LK<W)%[D:MN>:_2"!MQR5BG")PB<(G")P
MB<(G"*V _P"+LU^;0_\ B$;PM6?@YNXS]\*I\+).$3A$X1.$3A$X1.$5LC'X
M),/R3<?WT#Y5WL?R@M8^QF]Z_P"Y&JGRRR3A$X1.$3A$X1.$3A$X1.$5LEG[
MN/?DF"_1]^0-W?/C*UEWQ^]1^)>:,M[Q/0%D'*]"U<RDN<$R "&F\2^6 QTA
M/A+]H_KU(!Y,F4J/$6;)AY?=&BC]>#2FRU1.\5(A)*UCYUWJP9Q?6WWW@='7
MTK1M/=@<7VTNX6:; Q22BP#\VK8],S67O=MP+FO->ZMD?"F1,7]8PE%%BS'Q
M41&64UL"0&"%IB[][%U!+VPQQ$:5DDED474"T*9EP=477N#C-BTRN;$,AKHN
M2BB_T?#<@^+H[J;!MARW<[B<K0,FSB>W>\ .]= -W6Z#>V:&;^(6W1@K2W4*
M7'HP!Z-%.)0JA8B+>?XECWJ>][5JM0<37@C0=+(^C$6+6(,Y2\EP$H\D"979
M2*LA(!RZ49N>VGAW9MW<ZU;BW*R9^7<VY/)R[?8ZN#B0;G-ERD6MRKE7"5]U
MIW$"DWCC^E8B^D-4PNU['LO(>Z"+R--(;5$1H2<O]82=4J!L]E4M,1Z^!N64
M=.@(.Q:OP"^KR0IB30<RL)ZMU[Z] !TTZ^I5; UV4YW /<QK;L%\TCI6C,-I
MHT&,W(+C8Z"X(5&G?>Z:Q0#92 : "G3N.,NQJ$?FLMD9O80I-*QD/8-I&HR]
M90NL"$:8)*,ZB$J-QLTF\%E!X8:UUCZ$M=BWYI\O]/3S7ZK<W3=2VG:XMNXV
M.RN&M%[/$=SRGWWO.H:YHMK:^4>F %T0? PSTLW9LRKP4.=$V@YVL0'M2#AF
MBJ];L7[ED-</6:#G=1)J[7'#UG*&NBRK)KOOL@G9<QT) W FUU*\*$X1:6]H
M/"_Z37_?]GW%:E4'#]AS<VR7DYL=;]TQ- FL! !XF*5R#B%A H^U4;1\ ('[
M;LA;;9QJSU<.LK.E%EU-XJJJ@:60553 PNS%L,\L32X@-+BUCV@N(:T$VO8
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MK^33XE[PYOQ)2K_W!=CO\V>/1'$/QA7?+*C[1/0/ OQ!@'S'A7\FK#%_!/\
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M2>==SA$X16R=_P <9)\[._[?"UG_  K^[] 53X62<(G")PBM@#^ IS\PC?\
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M'S)Q>/V[_P!1OEJ=.UH"=["<J2 LEZN"&--/,"LU/2)MTMM=5=O.,I^9OO\
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M.$4J,_>BWS4I^F,N%=FY_P"0?&U17"HG")PB<(G")PB<(G")PB<(I0I]\?\
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MFJ?F$L""66_HU-]O^Z*^DQI^U\XJV-@>8WMWM_C78-GP<;9H$) 7'!6+DN
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M+1-JG0G*TNFBT<["9[P@G(,+;SK:]7&Y> 'C&\.06K$?J,G\ "SBJ(2[E&&
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MXW]X*+X5$X1:"V[U-MZW)J2E)>]XZFS""Y,$JQIFK5T3((!-;HZ]V^?C\ID
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MD]V=[G;LQ)^%92X55*C/WHM\U*?IC+A79N?^0?&U17"HG")PB<(JW$H?%X&
M91:&@1D:CP]1^NT$"&J;1FDY+$G9@L[RFGCRJO2I<@_+%'JV5'1$F]=OWBRS
MMRLMN4DEQN3<]:LG"A.$3A$X1.$4H4^^/^:V7]C;A:2>P][;]*\FNJ'ACH=7
M>\';;N<GV&L&Q%.TBQU7-7GQN&8:'?"&8LIDIE\;^$!+,P5BRC'$8KQ7(2.?
M!&&O"(/S2F7>729:23[2*.+(UN2W*'/86W6TOO.^Y5,)]#K^+1=Y#V4E@<%B
MK*/QX<\@@"U+&G586P5 6[5<[V59UK<M:V!#^K,**Q>"2R-/JHKT5;U=/O>
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MC;A:2>P][;]*\=I7B6_#B:>EQV"_TN_]*D#FL]A>+IS4WN$]Z,8]C>K[#_\
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M=8'>;<U["^4;AON=ZO+CI[69"H(Q2Q613LI&(P7L0T,?K$XVT+9WLN%6A 3
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MHNTQ;A8DXC@Z0E.PO:SP;GF#CID:\'07]D 1O'PKGT\2&F5(J.L36#V]FKG
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M]P2</H344K:BD&^=G+^2JA@R:&/:/K*%*G <#I'B.:6N:2QLF;:0Y QU1#3
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MX,"^2U__ /9)\;OXG7\\N=?5KUW_ ,F./2EAG;*SXV+[!/5<X1^X,"^2U_\
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MX*SY--Y">C^ ?C[ _GC#OYE/CJ_#N_&U-_J"OO\ RWX]#,2]P5GR:;R$]'\
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MG!P]988F<;BGHTFL*V=ZI>O),'[-WNW])JW<)*9UWQ!T!/4M(F!\K&.N&N<
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MXB.[M;'_ $#F-!I=--"\0$3L$!AXAH1E/P3R%(F9<?))O3 ^/*#HEHT:LG6
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M5#II'C*X@@VOR&7.6]N4&YM+D#7<;*1L"H*EF9=VM+QCW613W6N ^"8N1RT
M676I*12NT:[V%/X\68; GT3/G)0>1(#MQ[DGASL.,.";%!BP26'B\&H1KWM'
M)(LW,;$-(]<#6.N' W! :+$$#>+'5<\*HN#0 6>C<?5E>T/D %T"=1(W.)A)
MA3?VM*9_+I,79K2,X4)MSLI*V(6T.&-'^"#I@-CH_#C1F!%HM9^^]0Z1SB"<
MN8&^8-:T[F@ V ! RBPMO)/.5(5;2]?4VQ>L((/,M]'[8&/</)'+Y?."_LB+
MCO9,9!(G)L<D!AN!CP_99$.%1?)CF:KPD^T;^T2I-V\ 61\CI#=Q!WG1K6BY
M-R;- %R=YM<K*G"HOPZ]Q7HX;XI'98B76;MA+#NM,GI1P[\WU5N.:V0FN]6<
M^=C.OJZ39-7=;SL9U]'KMY<9Q]SGZ+P?!=@@#=7$U8 '.3)(!X5^"_VCN8WA
MWFD($;8\&<\N[$,%/ 7%U^8"]^I>FMO^(#UEG=G]IXY\#H]8L:B4=[F.Z]FE
MSGPKX196TUF=<,:ZJ"MEJIC]7RD13S=A#G\HB(E:9$)<HW-O$&DF%:Z+K/<8
M,,JXX:-VT?&^1V'B5D#7!T.SCE,L\NV?,PSDR!CW;,,NP<AU[#KK^%&#U-;C
M<7%X:N&GAX0FDJ<0EC?'6&IJ*1E)049H8J*=F'AM.9X&&I?4$2. FC )=2I+
M5GA5I0N[G0@]2R^Y*5'S5;9;V?93&4Q!)C,:;5&0D>24L"2O2<4>0\A:6S9]
MM2LW>Z#TM\JSHW.!@N-):,EQG:4X<VHL&-;+>*$LDO'47D<-DP-?G$%QQB(7
M-MFV,EZYIJ'@2*?$G1RX>2Z:62CM6UC9J?+48>64S'FJF=) ZG?6Y7^AM4[*
M-:F6H8R$9&S6'@_(6-)W;AU2#EDO%X X85YI9<_91,#&-K%M%G991I8H_L5(
M&!RSTX*TJ]>)K,)$_+ZB7STJ^ZY.IM@D"3RVN.;)@_V@'/*#+L8G/<_8P&%I
MB-(PMAVIG$EVAN9H:VK$>5Z[.)< 163$NPXM,-*YM**RK;!%#QNN96/;5MQ:
M:.6LXLVB,!;.Z3(YTKL)=49XEJKT/M?KM J:L4%.)?#@KYU=ELDXVUF.6.3C
MF)$/#^[E0*-O=O3,\;>A=V/+*^!)9T312S*RX3T:*3CT&R79B4-5)41NC9(Y
MHIX \QYLN<8I02/%@>:%DKCO.S#M;77A\&JW":;#ZJ*HGIXWG$J]\3:C)M33
MOX*\(*6%QNW<ZLGI8A:PV\D=@"0JAW+K_H5&@/6M"F)%7Z[I*RC48NL_4LEE
M!MZ;JA&,TX_"3IY'Y/8UFK#S[PH2M3T&Z*,1(*KM=!IZ 1IRQ9AV^E!+B3WU
M>W9*!LFOIVSM8T-F+Z@.C#V119F!K8.V 7);*^Y)QX04G!B&/"!A\U*XBLEA
MQ&6@FFD=+0B'#WQ5)AGJZTLF<]]=:P@<2 R2EB+6QMV <U_X>FMH3EJR"=)U
M%VB;32IHXMV([$[T\>JG-T.AI&961+%9@.?!+[2I;0>2%1(/8^S-\JY*$B5=
MB9JS'Q=YS"7$]E&2[$ /_P SQ24FW;-Q?,(XF",A]-QB[72.AN+- F,9+QZ;
MJ3@KQVI:V/@Y=H'$83B^+'#Y:+T1+'5%74&H8Z+$QAP:^.".M+7%SY'T;*AK
M(7?8<W\)J// X<1!ZEL",>M0$BC,+"L:]A$S)BI/WAM6L9*TDXV-VC$Q(MY&
M>HOP&LK#-E'A#H68T'20UH4:;/ ;F'>C3LSC)-$XYP8XHJ9T;7,PV"9A87PO
M<X/KMK"27N!%V @Y7"6-X#1.9''34-5#>E>V>JK,4CJ)&3<)*ZBF;.R*M@CC
M=#@/%JS*V&-S),DT@>W-$<Q5_6G0"@I!U7G\D;TI$D-CW5RVH;83^S+#,VI)
MS"?=)\!G+Z7P8M)7M=I4;CKG%SQ]](48:.23E IDF@<7>/E(^EA+-B=2RMC9
MQAY#:R"2)L,386#T/#XA'(U@F-1QM[6!NT<2QQNT!H>>^EH^"V&2X)52C#X
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M5-@NHWU1/!#+]DZ.KZB/I5FNRAXM?.T-W[K/8^_7V%K:;[\UCJ%!NCIN.6D
ML>2W WEZ0 ['C>@5>%R1+9XM%25K$PZNFQNUI/&XTXV=VL2>/6D%A\4BVA$2
MP?!(L$45<Z[U UN3?_P>L]/<ZENZH!86AF6X(OF!L'9+^P!=HP"[G%VINXZ+
M',B\-\\>C:$.Q?2*$;90LU#Q[1>O)$X2:IG>J,MZM.55(\UN$=7Y%-LSF!2<
M,WY>$D)KHYVTA>\VVAC9@,9LO7][$??X.BUA5 '-L];@FS@-1,V;?LRX:M#2
M ZWLK9KDW&:]"2MA'#\MDUL#,22=XGHJ?M8Y$K%AD+?Q6>PVCH&^&1N-1&^
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M\:S7V+.IY(DMBT;0J",*&T3 :9I,'HVQIQ9+]JD-5 +R@Q'GFB#5;4Z:'?\
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MMNQ[$VYKK7A?P^7$"8/3L5DV+),B1]<M0PJ21YR_-R)*'2>BR;YE,MCEL1^
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M#W,^,R)*82B2-XMK]]-U[=%];].G6M#,S*1F<;-<W<XF0.:YK0]Q(OD<<VX
M \D @!9C?]1Q,B!,(1+H/ I3%779.<V&8=2QNA,3PNM#K@G,?9P$I)V18@B3
MF<P"PJ.S-IAXGZS"G\@0P^RLW8:ZR1>VE^[]'?MWEF)K$N:YS2(FM&7D@O%F
MW(&EFM+BTVT< M[>2N=.$3A$X1.$3A$X1.$3A$X1.$3A$X16P'_%V:_-H?\
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M"5D4?<0I2T8_.Y7$ 8$B14:&2K 1:::^!66\F>,5IH).,V11"7"&,W'2/O\
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M<A%=@*G<0F!1F1",GT:D,5T>OV:D6Z]->[K?G[_1S*146 Y );DM<W R"/4
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M)XV6WVV+![LY!UN&M:;F]R!:ZS1PJ+^=%W["/9-XDO<*.#/0^TI!VYLX(/\
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M1&#K<->3_P#C( !S$V) O8G4[Q<M$38-Q>(<WK85*6L.L>/SLD&L1XSAL3@
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M.KZ] -C:ZL!O:L(J3E&ZN@KS6BLLIN 2KL FGHCH7B]@6,D"!JM3$8&#AY=
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M0KGM.!)CIR_M* Q45+JQ(6M (+)RL/C96M+"E+N96HYZL/)-56L?7/5E(([
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M^!-)P68^IEDCKL7F#F.K&L<V*E@=<&&C$@#P96_AYW-;(\'8L#(L^V_3\Q_
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MG"*5&?O1;YJ4_3&7"NS<_P#(/C:HKA43A$X1.$3A$X1.$3A$X1.$4H4^^/\
MFME_8VX6DGL/>V_2HOA9IPB<(G")PB<(G")PBE#?\+$/Z4K_ &N%>3LW=U1?
M"HG")PB<(I1C^!&OZ"W_ +U'\+1G82_DM_?:HOA9IPB<(G"*4#_AN?Z"5_NI
M[PM(NS_Y7_N.47PLTX1.$3A$X1.$4H4_=,?FMC_NN%I)[#WMOTJ+X6:<(G")
MPB<(G")PB<(G"*4*_OC/YK&_HJ?"N_>W\AOB47PJ)PB<(G")PB<(G")PB<(G
'")PB<(O_V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>3
<FILENAME>g382980g82i05.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g382980g82i05.jpg
M_]C_X  02D9)1@ ! 0$#P /   #_[1@(4&AO=&]S:&]P(#,N,  X0DE-! 0
M     !\< 5H  QLE1QP"   "   < G@  PT@(!P"!0 ##2 @ #A"24T$)0
M    $.?*ZC5G0BD4C@C:$-)%*8DX0DE-!#H      .4    0     0
M"W!R:6YT3W5T<'5T    !0    !0<W138F]O; $     26YT965N=6T
M26YT90    !#;')M    #W!R:6YT4VEX=&5E;D)I=&)O;VP     "W!R:6YT
M97).86UE5$585     $       ]P<FEN=%!R;V]F4V5T=7!/8FIC    # !0
M '( ;P!O &8 ( !3 &4 = !U '        IP<F]O9E-E='5P     0    !"
M;'1N96YU;0    QB=6EL=&EN4')O;V8    )<')O;V9#35E+ #A"24T$.P
M   "+0   !     !       2<')I;G1/=71P=71/<'1I;VYS    %P    !#
M<'1N8F]O;       0VQB<F)O;VP      %)G<TUB;V]L      !#<FY#8F]O
M;       0VYT0V)O;VP      $QB;'-B;V]L      !.9W1V8F]O;
M16UL1&)O;VP      $EN=')B;V]L      !"8VMG3V)J8P    $       !2
M1T)#     P    !29" @9&]U8D!OX            $=R;B!D;W5B0&_@
M        0FP@(&1O=6) ;^            !"<F1456YT1B-2;'0
M      !";&0@56YT1B-2;'0               !2<VQT56YT1B-0>&Q 6
M          IV96-T;W)$871A8F]O; $     4&=0<V5N=6T     4&=0<P
M  !09U!#     $QE9G15;G1&(U)L=                %1O<"!5;G1&(U)L
M=                %-C;"!5;G1&(U!R8T!9            $&-R;W!7:&5N
M4')I;G1I;F=B;V]L      YC<F]P4F5C=$)O='1O;6QO;F<         #&-R
M;W!296-T3&5F=&QO;F<         #6-R;W!296-T4FEG:'1L;VYG
M  MC<F]P4F5C=%1O<&QO;F<      #A"24T#[0      $ /      0 ! \
M   !  $X0DE-!"8       X             /X   #A"24T$#0      !
M '@X0DE-!!D       0    >.$))30/S       )           ! #A"24TG
M$       "@ !          $X0DE- _4      $@ +V9F  $ ;&9F  8
M  $ +V9F  $ H9F:  8       $ ,@    $ 6@    8       $ -0    $
M+0    8       $X0DE- _@      '   /__________________________
M__\#Z     #_____________________________ ^@     ____________
M_________________P/H     /____________________________\#Z
M.$))300(       0     0   D    )      #A"24T$'@      !      X
M0DE-!!H      TT    &              !4   !00    P 30!I &X 90!R
M '8 80!? &P ;P!G &\    !                          $
M     4$   !4                      $
M$     $       !N=6QL     @    9B;W5N9'-/8FIC     0       %)C
M=#$    $     %1O<"!L;VYG          !,969T;&]N9P          0G1O
M;6QO;F<   !4     %)G:'1L;VYG   !00    9S;&EC97-6;$QS     4]B
M:F,    !       %<VQI8V4    2    !W-L:6-E241L;VYG          =G
M<F]U<$E$;&]N9P         &;W)I9VEN96YU;0    Q%4VQI8V5/<FEG:6X
M   -875T;T=E;F5R871E9     !4>7!E96YU;0    I%4VQI8V54>7!E
M $EM9R     &8F]U;F1S3V)J8P    $       !28W0Q    !     !4;W @
M;&]N9P          3&5F=&QO;F<          $)T;VUL;VYG    5     !2
M9VAT;&]N9P   4$    #=7)L5$585     $       !N=6QL5$585     $
M      !-<V=E5$585     $       9A;'1486=415A4     0      #F-E
M;&Q497AT27-(5$U,8F]O; $    (8V5L;%1E>'1415A4     0      "6AO
M<GI!;&EG;F5N=6T    /15-L:6-E2&]R>D%L:6=N    !V1E9F%U;'0    )
M=F5R=$%L:6=N96YU;0    ]%4VQI8V5697)T06QI9VX    '9&5F875L=
M  MB9T-O;&]R5'EP965N=6T    115-L:6-E0D=#;VQO<E1Y<&4     3F]N
M90    ET;W!/=71S971L;VYG          IL969T3W5T<V5T;&]N9P
M   ,8F]T=&]M3W5T<V5T;&]N9P         +<FEG:'1/=71S971L;VYG
M   X0DE-!"@       P    "/_         X0DE-!!0       0    '.$))
M300,      V[     0   *     J   !X   3L    V? !@  ?_8_^T #$%D
M;V)E7T--  +_[@ .061O8F4 9(     !_]L A  ," @("0@,"0D,$0L*"Q$5
M#PP,#Q48$Q,5$Q,8$0P,# P,#!$,# P,# P,# P,# P,# P,# P,# P,# P,
M# P, 0T+"PT.#1 .#A 4#@X.%!0.#@X.%!$,# P,#!$1# P,# P,$0P,# P,
M# P,# P,# P,# P,# P,# P,# P,# S_P  1"  J * # 2(  A$! Q$!_]T
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MUOK73NL9'4ZKK\C&P\MU=]+K7N86VON#:7,<YS6^HRFST;-OZ.YE:/"M.8
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MKV_S=U7Z2S_#4I5XJ&2R 8D<0N/B]VDN._Q:]8NS>FY&#E6/LR,*R0;"7/\
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MUCZ5^Q_\7E_3O6=D^@:_TSA!=ORJ[>)=]'U-JKM_Q:Y3&AK.NY#6M$-:UC@
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M_=?_ $24JZ(C?7P?_]D .$))300A      !5     0$    / $$ 9 !O &(
M90 @ %  : !O '0 ;P!S &@ ;P!P    $P!! &0 ;P!B &4 ( !0 &@ ;P!T
M &\ <P!H &\ <  @ $, 4P V     0 X0DE-!"(      3I-30 J    "  (
M 0X  @    0*("   1(  P    $  0   1H !0    $   !N 1L !0    $
M  !V 2@  P    $  @   3$  @   !X   !^ 3(  @   !0   "<AVD !
M  $   "P    W  .I@   "<0  ZF    )Q!!9&]B92!0:&]T;W-H;W @0U,V
M("A7:6YD;W=S*0 R,#$U.C T.C(Q(#(Q.C$T.C4R   #H $  P    '__P
MH ( !     $   %!H , !     $   !4          8! P #     0 &   !
M&@ %     0   2H!&P %     0   3(!*  #     0 "   " 0 $     0
M 3H" @ $     0              2     $   !(     3A"24T#_0
M"           _^$!/$U- "H    (  @!#@ "    ! H@(  !$@ #     0
M   !&@ %     0   &X!&P %     0   '8!*  #     0 "   !,0 "
M'@   'X!,@ "    %    )R':0 $     0   +    #<   #P     $   /
M     4%D;V)E(%!H;W1O<VAO<"!#4S8@*%=I;F1O=W,I #(P,34Z,#0Z,C$@
M,C$Z,30Z-3(   .@ 0 #     ?__  "@ @ $     0   4&@ P $     0
M %0         !@$#  ,    !  8   $:  4    !   !*@$;  4    !   !
M,@$H  ,    !  (   (!  0    !   !.@("  0    !              /
M     0   \     !_^%#?VAT=' Z+R]N<RYA9&]B92YC;VTO>&%P+S$N,"\
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M1UASL?$E*31&2%)55F1U=WB"AY*7MM7A_\0 '0$  00# 0$
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M7,U69% I ,RLS[M,;^V;% Q_EUS6:SJYC<#=@3(DU'1+3*;E39OO.Z_(YW
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M_2JT+/>9<S7;';K&.495Y 76.,V@%)6+C(H\2[44&N1O#ALLLJ+7^$@/6<P
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M$G$G(&1%V_730136=+*J$23*8"!'C$%B1P"3ZD_M//XXN7$I2.-&;>RHJEB
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MS/58G'F=NG!V0FSXYFZ$7*V!^C] 9IZDJ0"MW4!?$F,.\<J@D9A$6&P"<Y2
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M$2C)\X(Q=/RNJ"'40J,^8&=.MKDQ6R1)=.I2!@<.IB9=@Y]-YC8BBE-E%^B
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MEB-PY-[G^,CGN>!\?7[3A^0Q>*T$4<,2UJ1Q1K%$G]["JQQJ$11<\!% 50>
M%"C@###Y]Q;XBUJA1R%N>QWO%L5=H$:Y'Z;9OJN79:)IT._>- >"-@N;%9K!
M1CU^+(7/6Z;-%G8MS'Y6$FNBEDH5;IP-M:;N")?U06Y+BWNWN1;Y]N&]J#*]
M=U<"UV>T]3)%1K8S3-16B62544 0D,VZ60;!MX:2RB[G=+W\-ENY-C'<A==J
M5GDP1J6X6)4L=*2<J=*#++%"BW#E5JW$P FD:W49&026$3%,Z>U"#:)E,LNF
M0Z)J>C,D"UO8Q6$E^]G:.->[@$W(L%1B "2>2<2/X#:E6CS>HT[*QV9J U(
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MK<)4ZU%(!PA&P->C6T3$L4@]/WMJP:(($] ^R0-([LSLSL;LQ))XY)^P ?@
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M ,S+)MMN7WMM[\7L;<.2:KR#44E1%D]?[7+2A#41FFJZ=XQ)NV&U53P[P=C
MF/<%(LQ!(!_N_9DQMC%S&L+I9D8N4F2J*1,,U82TW.2**1NE5PTA8%A)RBS9
M(W)5')6G8*8IB"IU )=8RW)<SS?J_1],:@0[3*>K#$J;]VT%II(P2VUK*I)X
M)M;'O.]49%ITP#.*]:,U._H+T*JH>3IA=Y"4L$[!5WJ"S!5N0 2>,?10,M8\
MR@63^@]D;S+B%422F(Y1G)1,O%*+]?8"1AIIE'2K(%P3.*!W#-,BP$,*1C@
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M4IRRC^)T]K%G!/EM>X'-Q;U+/\/I=3KI#)Q24-#)!MKMC25H1S_?*MON40N
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M@$7!N"1A2V.KU^WP$C5;-$LYNO2[7R4E$OT^\T>-0,0X)+$$0,(%.FFH0P&
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K\G"CEE+#14-/2TZLL$*LL:L[R%5ZCM;?(S.0"2!<FPLHX &%-KGQW8__V0$!

end
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
